<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?subarticle pcbi.1009250.r001?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS Comput Biol</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLoS Computational Biology</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1553-734X</issn>
    <issn pub-type="epub">1553-7358</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8437300</article-id>
    <article-id pub-id-type="pmid">34464378</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1009250</article-id>
    <article-id pub-id-type="publisher-id">PCOMPBIOL-D-21-00050</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Cell biology</subject>
          <subj-group>
            <subject>Chromosome biology</subject>
            <subj-group>
              <subject>Chromatin</subject>
              <subj-group>
                <subject>Chromatin modification</subject>
                <subj-group>
                  <subject>DNA methylation</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Epigenetics</subject>
            <subj-group>
              <subject>Chromatin</subject>
              <subj-group>
                <subject>Chromatin modification</subject>
                <subj-group>
                  <subject>DNA methylation</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Gene expression</subject>
            <subj-group>
              <subject>Chromatin</subject>
              <subj-group>
                <subject>Chromatin modification</subject>
                <subj-group>
                  <subject>DNA methylation</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>DNA</subject>
            <subj-group>
              <subject>DNA modification</subject>
              <subj-group>
                <subject>DNA methylation</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Nucleic acids</subject>
            <subj-group>
              <subject>DNA</subject>
              <subj-group>
                <subject>DNA modification</subject>
                <subj-group>
                  <subject>DNA methylation</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Epigenetics</subject>
            <subj-group>
              <subject>DNA modification</subject>
              <subj-group>
                <subject>DNA methylation</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Gene expression</subject>
            <subj-group>
              <subject>DNA modification</subject>
              <subj-group>
                <subject>DNA methylation</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Oncology</subject>
          <subj-group>
            <subject>Cancers and Neoplasms</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Gene Expression</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Epidemiology</subject>
          <subj-group>
            <subject>Medical Risk Factors</subject>
            <subj-group>
              <subject>Cancer Risk Factors</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Oncology</subject>
          <subj-group>
            <subject>Cancer Risk Factors</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Health Care</subject>
          <subj-group>
            <subject>Health Care Policy</subject>
            <subj-group>
              <subject>Treatment Guidelines</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Epidemiology</subject>
          <subj-group>
            <subject>Medical Risk Factors</subject>
            <subj-group>
              <subject>Cancer Risk Factors</subject>
              <subj-group>
                <subject>Genetic Causes of Cancer</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Oncology</subject>
          <subj-group>
            <subject>Cancer Risk Factors</subject>
            <subj-group>
              <subject>Genetic Causes of Cancer</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Gene Expression</subject>
            <subj-group>
              <subject>Gene Regulation</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Chemical Reactions</subject>
            <subj-group>
              <subject>Methylation</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>IUSMMT: Survival mediation analysis of gene expression with multiple DNA methylation exposures and its application to cancers of TCGA</article-title>
      <alt-title alt-title-type="running-head">IUSMMT: Survival mediation analysis</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Shao</surname>
          <given-names>Zhonghe</given-names>
        </name>
        <role content-type="https://casrai.org/credit/">Data curation</role>
        <role content-type="https://casrai.org/credit/">Formal analysis</role>
        <role content-type="https://casrai.org/credit/">Methodology</role>
        <role content-type="https://casrai.org/credit/">Resources</role>
        <role content-type="https://casrai.org/credit/">Software</role>
        <role content-type="https://casrai.org/credit/">Visualization</role>
        <role content-type="https://casrai.org/credit/">Writing – original draft</role>
        <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="econtrib001" ref-type="author-notes">
          <sup>‡</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Ting</given-names>
        </name>
        <role content-type="https://casrai.org/credit/">Data curation</role>
        <role content-type="https://casrai.org/credit/">Formal analysis</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="econtrib001" ref-type="author-notes">
          <sup>‡</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Meng</given-names>
        </name>
        <role content-type="https://casrai.org/credit/">Validation</role>
        <role content-type="https://casrai.org/credit/">Visualization</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4776-429X</contrib-id>
        <name>
          <surname>Jiang</surname>
          <given-names>Zhou</given-names>
        </name>
        <role content-type="https://casrai.org/credit/">Validation</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huang</surname>
          <given-names>Shuiping</given-names>
        </name>
        <role content-type="https://casrai.org/credit/">Supervision</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
        <name>
          <surname>Zeng</surname>
          <given-names>Ping</given-names>
        </name>
        <role content-type="https://casrai.org/credit/">Conceptualization</role>
        <role content-type="https://casrai.org/credit/">Funding acquisition</role>
        <role content-type="https://casrai.org/credit/">Project administration</role>
        <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <label>1</label>
      <addr-line>Department of Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, Jiangsu, China</addr-line>
    </aff>
    <aff id="aff002">
      <label>2</label>
      <addr-line>Center for Medical Statistics and Data Analysis, Xuzhou Medical University, Xuzhou, Jiangsu, China</addr-line>
    </aff>
    <aff id="aff003">
      <label>3</label>
      <addr-line>Key Laboratory of Human Genetics and Environmental Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Rueda</surname>
          <given-names>Oscar</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>University of Cambridge, UNITED KINGDOM</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="other" id="econtrib001">
        <p>‡ These authors are co-first authors on this work.</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>hsp@xzhmu.edu.cn</email> (SH); <email>zpstat@xzhmu.edu.cn</email> (PZ)</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>31</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <volume>17</volume>
    <issue>8</issue>
    <elocation-id>e1009250</elocation-id>
    <history>
      <date date-type="received">
        <day>13</day>
        <month>1</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>6</day>
        <month>7</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 Shao et al</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>Shao et al</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pcbi.1009250.pdf"/>
    <abstract>
      <p>Effective and powerful survival mediation models are currently lacking. To partly fill such knowledge gap, we particularly focus on the mediation analysis that includes multiple DNA methylations acting as exposures, one gene expression as the mediator and one survival time as the outcome. We proposed IUSMMT (intersection-union survival mixture-adjusted mediation test) to effectively examine the existence of mediation effect by fitting an empirical three-component mixture null distribution. With extensive simulation studies, we demonstrated the advantage of IUSMMT over existing methods. We applied IUSMMT to ten TCGA cancers and identified multiple genes that exhibited mediating effects. We further revealed that most of the identified regions, in which genes behaved as active mediators, were cancer type-specific and exhibited a full mediation from DNA methylation CpG sites to the survival risk of various types of cancers. Overall, IUSMMT represents an effective and powerful alternative for survival mediation analysis; our results also provide new insights into the functional role of DNA methylation and gene expression in cancer progression/prognosis and demonstrate potential therapeutic targets for future clinical practice.</p>
    </abstract>
    <abstract abstract-type="summary">
      <title>Author summary</title>
      <p>DNA methylation has a causal effect on tumorigenesis and gene expression may be an important mediator of such influence. However, inferring the existence of mediation effect of gene expression is statistically challenging, especially when multiple and even high-dimensional DNA methylation exposures are collectively analyzed. To solve such challenge, we developed a new mediation approach called IUSMMT, in which mediation effects are determined by two separate tests: one for the association between methylations and the expression, the other for the association between the expression and the survival outcome conditional on methylations. IUSMMT effectively combines the evidence of the two tests and infers the emergence of mediation effect by fitting an empirical three-component mixture null distribution. To evaluate the performance of IUSMMT, we conducted extensive simulation and analyzed ten TCGA cancers. Overall, we demonstrated the robustness, validity, and utility of IUSMMT under a wide variety of scenarios.</p>
    </abstract>
    <funding-group>
      <award-group id="award001">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100002338</institution-id>
            <institution>ministry of education of the people's republic of china</institution>
          </institution-wrap>
        </funding-source>
        <award-id>18YJC910002</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award002">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004608</institution-id>
            <institution>Natural Science Foundation of Jiangsu Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>BK20181472</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award003">
        <funding-source>
          <institution>chinese postdoctoral science foundation</institution>
        </funding-source>
        <award-id>2018M630607, 2019T120465</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award004">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100013088</institution-id>
            <institution>Qinglan Project of Jiangsu Province of China</institution>
          </institution-wrap>
        </funding-source>
        <award-id>WSN-087</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award005">
        <funding-source>
          <institution>training project for youth teams of science and technology innovation at xuzhou medical university</institution>
        </funding-source>
        <award-id>TD202008</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award006">
        <funding-source>
          <institution>postdoctoral science foundation of xuzhou medical university</institution>
        </funding-source>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award007">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
            <institution>national natural science foundation of china</institution>
          </institution-wrap>
        </funding-source>
        <award-id>81402765</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award008">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009376</institution-id>
            <institution>national bureau of statistics of china</institution>
          </institution-wrap>
        </funding-source>
        <award-id>Statistical Science Research Project - 2014LY112</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2710-3440</contrib-id>
          <name>
            <surname>Zeng</surname>
            <given-names>Ping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award009">
        <funding-source>
          <institution>social development project of xuzhou city</institution>
        </funding-source>
        <award-id>KC19017</award-id>
        <principal-award-recipient>
          <name>
            <surname>Huang</surname>
            <given-names>Shuiping</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award010">
        <funding-source>
          <institution>social development project of xuzhou city</institution>
        </funding-source>
        <award-id>KC20062</award-id>
        <principal-award-recipient>
          <name>
            <surname>Wang</surname>
            <given-names>Ting</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <funding-statement>The research of PZ was supported in part by the Youth Foundation of Humanity and Social Science funded by Ministry of Education of China (18YJC910002), the Natural Science Foundation of Jiangsu Province of China (BK20181472), the Chinese Postdoctoral Science Foundation (2018M630607 and 2019T120465), the QingLan Research Project of Jiangsu Province for Outstanding Young Teachers, the Six-Talent Peaks Project in Jiangsu Province of China (WSN-087), the Training Project for Youth Teams of Science and Technology Innovation at Xuzhou Medical University (TD202008), the Postdoctoral Science Foundation of Xuzhou Medical University, the National Natural Science Foundation of China (81402765), and the Statistical Science Research Project from National Bureau of Statistics of China (2014LY112). The research of SH was supported in part by the Social Development Project of Xuzhou City (KC19017). The research of TW was supported in part by the Social Development Project of Xuzhou City (KC20062).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="4"/>
      <table-count count="4"/>
      <page-count count="29"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>PLOS Publication Stage</meta-name>
        <meta-value>vor-update-to-uncorrected-proof</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>Publication Update</meta-name>
        <meta-value>2021-09-13</meta-value>
      </custom-meta>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>All files are available from the TCGA database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://portal.gdc.cancer.gov/legacy-archive/" ext-link-type="uri">https://portal.gdc.cancer.gov/legacy-archive/</ext-link>).</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>All files are available from the TCGA database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://portal.gdc.cancer.gov/legacy-archive/" ext-link-type="uri">https://portal.gdc.cancer.gov/legacy-archive/</ext-link>).</p>
  </notes>
</front>
<body>
  <disp-quote>
    <p>This is a <italic toggle="yes">PLOS Computational Biology</italic> Methods paper.</p>
  </disp-quote>
  <sec sec-type="intro" id="sec001">
    <title>Introduction</title>
    <p>Many recent studies have revealed that epigenetic abnormalities, particularly aberrant changes in methylation, exert an important causative effect on complex diseases [<xref rid="pcbi.1009250.ref001" ref-type="bibr">1</xref>,<xref rid="pcbi.1009250.ref002" ref-type="bibr">2</xref>]. However, the mechanisms regarding how alterations of DNA methylation influence diseases remain largely elusive. Biologically, it has been widely acknowledged that DNA methylation leads to a direct functional modification of the genome by regulating gene expression [<xref rid="pcbi.1009250.ref003" ref-type="bibr">3</xref>–<xref rid="pcbi.1009250.ref013" ref-type="bibr">13</xref>], which reversely affects various diseases [<xref rid="pcbi.1009250.ref014" ref-type="bibr">14</xref>–<xref rid="pcbi.1009250.ref017" ref-type="bibr">17</xref>]. Statistically, this motivates researchers to consider gene expression as a critical causal mediator of DNA methylation on the development of diseases. However, the principal genes that control the pathogenesis of diseases have not yet been identified and the underlying mechanisms of causal genes on diseases are also unclear.</p>
    <p>With respect to statistics, mediation analysis, particularly popular in sociology, epidemiology, and psychology [<xref rid="pcbi.1009250.ref018" ref-type="bibr">18</xref>–<xref rid="pcbi.1009250.ref022" ref-type="bibr">22</xref>], offers a flexible means to interpret the interplay between DNA methylation, gene expression and diseases. The essential requirement of mediation analysis arises when researchers are interested in potential underlying mechanism between an exposure (e.g., DNA methylation) and an outcome (e.g., the survival time and status of cancer patients) and long to acquire an in-depth insight into such understanding. Formally, a mediating variable (or mediator) is defined as an intermediate variable (e.g., gene expression) in the causal sequence that relates the exposure to the outcome [<xref rid="pcbi.1009250.ref018" ref-type="bibr">18</xref>].</p>
    <p>With datasets available from The Cancer Genome Atlas (TCGA) project as an illustrative example [<xref rid="pcbi.1009250.ref023" ref-type="bibr">23</xref>], in this study we aim to utilize appropriate mediation models to investigate the mechanism of gene expression on the signaling pathway from DNA methylation to the survival risk of cancers. In recent years, there have been a lot of methodology extensions of traditional linear mediation analysis to time-to-event outcome with censored data. Tein and MacKinnon (2003) [<xref rid="pcbi.1009250.ref024" ref-type="bibr">24</xref>] studied the estimation and inference of mediated effect for survival outcome under the context of the log-survival and log-hazard time models. Lange and Hansen (2011) [<xref rid="pcbi.1009250.ref025" ref-type="bibr">25</xref>] formulized the natural direct and indirect effects for time-to-event outcome using an additive hazard model within the counterfactual framework and illustrated its application by analyzing socioeconomic status, work environment, and long-term sickness absence. The natural direct and indirect effects were further described using a proportional hazards model with a rare outcome or an accelerated failure time model [<xref rid="pcbi.1009250.ref026" ref-type="bibr">26</xref>]. Wang and Zhang (2011) [<xref rid="pcbi.1009250.ref027" ref-type="bibr">27</xref>] proposed a Bayesian Tobit approach to examine the mediation effect for censored data and applied it to study whether verbal memory ability mediated the relationship between age and everyday functioning. More recently, Luo et al. (2020) [<xref rid="pcbi.1009250.ref028" ref-type="bibr">28</xref>] investigated survival mediation methods with high-dimensional mediators by borrowing the idea of screening-penalization procedure [<xref rid="pcbi.1009250.ref029" ref-type="bibr">29</xref>]. Although great advances have been achieved (see [<xref rid="pcbi.1009250.ref030" ref-type="bibr">30</xref>] for a comprehensive review of statistical methods for high-dimensional mediation analysis in the era of high-throughput genomics), methods for survival mediation analysis are still yet to be developed. These prior methods often consider one or multiple mediators and cannot be readily applied to our setting where multiple exposures, sometimes high-dimensional, would be involved. Specially, we wish to implement a gene-centric mediation analysis to simultaneously model a group of DNA methylation CpG sites as exposures and explore the mediating role of gene expression in the influence of methylations on the survival risk of cancer patients (<xref rid="pcbi.1009250.g001" ref-type="fig">Fig 1</xref>).</p>
    <fig position="float" id="pcbi.1009250.g001">
      <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.g001</object-id>
      <label>Fig 1</label>
      <caption>
        <title>Statistical framework of the survival mediation analysis with multiple exposures, one mediator and one censored outcome.</title>
        <p>The mediation analysis involves in multiple DNA methylations (<bold><italic toggle="yes">M</italic></bold>) as exposures, one gene expression (<italic toggle="yes">G</italic>) as the mediator and one survival time as the outcome (<italic toggle="yes">T</italic>). There are two types of effects from <bold><italic toggle="yes">M</italic></bold> to <italic toggle="yes">T</italic>: the direct effect of <bold><italic toggle="yes">M</italic></bold> on <italic toggle="yes">T</italic> (i.e., <bold>γ</bold><sup><italic toggle="yes">DE</italic></sup>) and the indirect effect of <bold><italic toggle="yes">M</italic></bold> on <italic toggle="yes">T</italic> via the intermediate variable <italic toggle="yes">G</italic>. The indirect effect represents the amount of mediation coming from two sources: the effect from <bold><italic toggle="yes">M</italic></bold> to <italic toggle="yes">G</italic> (i.e., <bold><italic toggle="yes">α</italic></bold>) and the effect from <italic toggle="yes">G</italic> to <italic toggle="yes">T</italic> (i.e., <italic toggle="yes">β</italic>).</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.g001" position="float"/>
    </fig>
    <p>To effectively examine mediation effect in survival studies with multiple exposures, we first employed the variance component-based score test to assess the association between a group of DNA methylation CpG sites and expression level for each gene under the framework of linear mixed-effects model (lmm) [<xref rid="pcbi.1009250.ref031" ref-type="bibr">31</xref>–<xref rid="pcbi.1009250.ref034" ref-type="bibr">34</xref>], and then tested for the effect of gene expression on the overall survival time while adjusting for the direct influence of these methylations within the framework of Cox linear mixed-effects model (coxlmm) [<xref rid="pcbi.1009250.ref035" ref-type="bibr">35</xref>–<xref rid="pcbi.1009250.ref038" ref-type="bibr">38</xref>]. This mediation analysis procedure is displayed in <xref rid="pcbi.1009250.g001" ref-type="fig">Fig 1</xref>, where the methylation-expression effect (i.e., <bold><italic toggle="yes">α</italic></bold>) and the expression-survival effect (i.e., <italic toggle="yes">β</italic>) can be causally interpreted if individual mediation models are correctly constructed and identifiability assumptions are satisfied [<xref rid="pcbi.1009250.ref039" ref-type="bibr">39</xref>–<xref rid="pcbi.1009250.ref041" ref-type="bibr">41</xref>]. Besides the explicit assumption of temporal ordering between methylation, gene expression and survival outcome, the additional assumptions for causal interpretation of these effects include: (i) the confounding between the methylations and the survival outcome is correctly controlled; (ii) the confounding between the gene expression and the survival outcome is correctly controlled; (iii) the confounding between the methylations and the gene expression is correctly controlled; and (iv) there should be no expression-survival confounders which are themselves affected by the methylations. The above assumptions are also known as sequential ignobility assumptions or no unmeasured confounding assumptions [<xref rid="pcbi.1009250.ref020" ref-type="bibr">20</xref>,<xref rid="pcbi.1009250.ref042" ref-type="bibr">42</xref>–<xref rid="pcbi.1009250.ref045" ref-type="bibr">45</xref>]. Note that, our mediation analysis method can still be employed for identifying potential methylation CpG sites or candidate genes for further exploration, even when the above causality conditions are not completely satisfied.</p>
    <p>We subsequently determined the existence of mediation effect to detect candidate genes with potentially mediating roles by adherence to the principle of intersection-union test (IUT) [<xref rid="pcbi.1009250.ref046" ref-type="bibr">46</xref>–<xref rid="pcbi.1009250.ref052" ref-type="bibr">52</xref>], in which the maximum of the two <italic toggle="yes">P</italic>-values (denoted by <italic toggle="yes">P</italic><sub>max</sub>) in the two tests above is taken as the significance measurement. Although it is conceptually straightforward, this naïve IUT-based approach is oftentimes extremely conservative especially in large scale mediation effect tests due to its composite null nature [<xref rid="pcbi.1009250.ref043" ref-type="bibr">43</xref>,<xref rid="pcbi.1009250.ref053" ref-type="bibr">53</xref>], which can be equivalently expressed as a combination of three disjoint component null hypotheses. To correct the intrinsic conservativeness of IUT, we estimated the proportion for each component null hypothesis and constructed a novel null distribution for <italic toggle="yes">P</italic><sub>max</sub> by fitting a three-component mixture null distribution [<xref rid="pcbi.1009250.ref054" ref-type="bibr">54</xref>], which, in contrast to the naïve uniform null distribution of <italic toggle="yes">P</italic><sub>max</sub> assumed in previous literature [<xref rid="pcbi.1009250.ref051" ref-type="bibr">51</xref>,<xref rid="pcbi.1009250.ref052" ref-type="bibr">52</xref>,<xref rid="pcbi.1009250.ref055" ref-type="bibr">55</xref>], can lead to a desirable control of family-wise error rate (FWER) or false discovery rate (FDR). We thus refer to our proposed approach framework as the intersection-union survival mixture-adjusted mediation test (IUSMMT).</p>
    <p>Finally, we applied IUSMMT to ten TCGA cancers and identified multiple genes with mediation effects. We revealed that, although DNA methylation CpG sites across the whole genome showed pleiotropic regularization on gene expressions of various cancers, most of the detected genetic regions, in which gene expressions played key roles as active mediators, were cancer type-specific and exhibited full mediations lying in the signaling pathway from DNA methylation CpG sites to the survival risk of cancers. Overall, IUSMMT represents an effective and powerful statistical tool for survival mediation analysis; our results also provide new insights into the functional role of DNA methylation and gene expression in cancer progression/prognosis and demonstrate potential therapeutic targets for future clinical practice.</p>
  </sec>
  <sec sec-type="results" id="sec002">
    <title>Results</title>
    <sec id="sec003">
      <title>Overview of IUSMMT</title>
      <p>We first offer an overview of the proposed IUSMMT method (<xref rid="pcbi.1009250.g002" ref-type="fig">Fig 2</xref>), with more details illustrated in the <xref rid="pcbi.1009250.s015" ref-type="supplementary-material">S1</xref>–<xref rid="pcbi.1009250.s018" ref-type="supplementary-material">S4 Texts</xref> and the section of Materials and Methods. IUSMMT is a gene-centric mediation method especially for survival data and dedicates to detect candidate genes with potential mediating effects standing on the signaling pathway from DNA methylation CpG sites to cancer survival. It proceeds in the following steps. First, IUSMMT calculates <italic toggle="yes">P</italic>-values of the methylation-expression effect (i.e., <italic toggle="yes">P</italic><sub><bold><italic toggle="yes">α</italic></bold></sub>) and the expression-survival effect (i.e., <italic toggle="yes">P</italic><sub><italic toggle="yes">β</italic></sub>) and takes them as input (<xref rid="pcbi.1009250.g002" ref-type="fig">Fig 2A</xref>); here <italic toggle="yes">P</italic><sub><bold><italic toggle="yes">α</italic></bold></sub> is obtained via a variance component-based score test within lmm by assuming each of <bold><italic toggle="yes">a</italic></bold> following a mean-zero normal distribution with an unknown variance, and <italic toggle="yes">P</italic><sub><italic toggle="yes">β</italic></sub> is yielded through the Wald test within coxlmm. Second, to determine whether a gene of focus has a mediation effect, IUSMMT classifies the joint null hypothesis <italic toggle="yes">H</italic><sub>0</sub>: <bold><italic toggle="yes">α</italic></bold><italic toggle="yes">β</italic> = <bold>0</bold> into three composite null sub-hypotheses and takes the maximum of <italic toggle="yes">P</italic><sub><bold><italic toggle="yes">α</italic></bold></sub> and <italic toggle="yes">P</italic><sub><italic toggle="yes">β</italic></sub> as a significance measurement in terms of the IUT principle (<xref rid="pcbi.1009250.g002" ref-type="fig">Fig 2B</xref>). Finally, to enhance the statistical power, IUSMMT estimates the proportion for each component of the three null hypotheses (<xref rid="pcbi.1009250.g002" ref-type="fig">Fig 2C</xref>) and constructs a newly empirical exact null distribution by fitting a three-component mixture null distribution. Afterwards, an effective control of FWER or FDR is achieved on the basis of the estimated mixture null distribution. As shown below, the power of IUSMMT would improve and the bias in estimated mixture proportions would decrease with the increase of sample sizes.</p>
      <fig position="float" id="pcbi.1009250.g002">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <title>An overview of IUSMMT for examining the mediation effect in survival model.</title>
          <p>Here, <bold><italic toggle="yes">a</italic></bold> = (<italic toggle="yes">α</italic><sub>1</sub>, …, <italic toggle="yes">α</italic><sub><italic toggle="yes">K</italic></sub>) is the vector of effect sizes of a set of DNA methylation CpG sites (i.e., the exposures) on the gene expression level (i.e., the mediator), with <italic toggle="yes">K</italic> the number of CpG sites within that gene; and <italic toggle="yes">β</italic> is the expression-survival effect; <italic toggle="yes">S</italic> indicates the total number of genes; <italic toggle="yes">n</italic> denotes the sample size. (A) IUSMMT first separately evaluates the significance of <bold><italic toggle="yes">a</italic></bold> and <italic toggle="yes">β</italic>, and calculates <italic toggle="yes">P</italic><sub><bold><italic toggle="yes">α</italic></bold></sub> and <italic toggle="yes">P</italic><sub><italic toggle="yes">β</italic></sub>; where <italic toggle="yes">P</italic><sub><bold><italic toggle="yes">α</italic></bold></sub> is obtained by a variance component-based score test within the linear mixed-effects model by assuming each of <bold><italic toggle="yes">a</italic></bold> following a mean-zero normal distribution with an unknown variance τ<sub>2</sub>, while <italic toggle="yes">P</italic><sub><italic toggle="yes">β</italic></sub> is yielded through the Wald test within the Cox linear mixed-effects model. Then, IUSMMT takes the two <italic toggle="yes">P</italic>-values as input. (B) The hypothesis testing of mediation effect is to examine whether the product of <bold><italic toggle="yes">α</italic></bold> and <italic toggle="yes">β</italic> is zero or not (i.e., <italic toggle="yes">H</italic><sub>0</sub>: <bold><italic toggle="yes">α</italic></bold><italic toggle="yes">β</italic> = <bold>0</bold>) and can be divided into three composite null sub-hypotheses. (C) In the three-component mixture null distribution, <italic toggle="yes">κ</italic><sub>10</sub> stands for the probability that the exposures are related to the mediator in the exposure-mediator model but the mediator is not associated with the survival outcome in the mediator-outcome model; <italic toggle="yes">κ</italic><sub>01</sub> stands for the probability that the exposures are not related to the mediator in the exposure-mediator model but the mediator is associated with the survival outcome in the mediator-outcome model; <italic toggle="yes">κ</italic><sub>00</sub> stands for the probability that the exposures are not related to the mediator in the exposure-mediator model and the mediator is not associated with the survival outcome in the mediator-outcome model. The definition of other notations used in B and C can be found in the Materials and Methods section.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.g002" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec004">
    <title>Results for simulation studies</title>
    <sec id="sec005">
      <title>Estimated null proportions</title>
      <p>Following the statistical framework of survival mediation analysis shown in <xref rid="pcbi.1009250.g001" ref-type="fig">Fig 1</xref>, we generated expression and survival outcome based on a set of real methylation values of TCGA under various sample sizes and proportion parameters, with details of simulation described in the Materials and Methods section. We first present the results for simulation studies and display estimated proportion parameters for the three-component mixture null distribution under various simulation scenarios in Tables <xref rid="pcbi.1009250.t001" ref-type="table">1</xref> and <xref rid="pcbi.1009250.s010" ref-type="supplementary-material">S1</xref>. Totally, the estimates of these proportions show slight to moderate biases in the alternative scenarios but are relatively close to the true values in other cases. Nearly in all scenarios, <italic toggle="yes">κ</italic><sub>00</sub> is over-estimated especially when sample size is small. Specifically, in the sparse alternative cases, as can be expected, <italic toggle="yes">κ</italic><sub>10</sub> and <italic toggle="yes">κ</italic><sub>01</sub> are also over-estimated because they are non-negatively estimated but their true values are actually zero, which necessarily results in the underestimation for <italic toggle="yes">κ</italic><sub>11</sub>. In contrast, in the dense alternative cases, the opposite patterns are observed, with <italic toggle="yes">κ</italic><sub>00</sub> is over-estimated but <italic toggle="yes">κ</italic><sub>01</sub> is under-estimated, which is certainly a direct consequence of limited power when testing the effect of the exposure on the mediator (i.e., τ<sub>2</sub>) and the effect of the mediator on the survival outcome (i.e., <italic toggle="yes">β</italic>) (<xref rid="pcbi.1009250.s001" ref-type="supplementary-material">S1 Fig</xref>). Particularly, in all the simulation scenarios, <italic toggle="yes">κ</italic><sub>11</sub> is always underestimated or approximately unbiased, implying that we can minimize the false discovery when examining the mediation effect. In addition, we find that the estimates of some proportion parameters (e.g., <italic toggle="yes">κ</italic><sub>00</sub>) have greater bias under the dense null compared to these under the sparse null. The reason is primarily due to relatively more sufficient information that can be available for estimating these non-zero proportion parameters under the sparse null compared to the dense null (e.g., 90% vs. 10%).</p>
      <table-wrap position="float" id="pcbi.1009250.t001">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.t001</object-id>
        <label>Table 1</label>
        <caption>
          <title>Estimated and true proportion parameters (mean and standard deviation) in the three-component mixture null distribution under the five simulation scenarios with different sample sizes and numbers of mediation tests.</title>
        </caption>
        <alternatives>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.t001" id="pcbi.1009250.t001g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>dense null</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>00</bold>
                  </sub>
                  <bold>= 0.1</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>01</bold>
                  </sub>
                  <bold>= 0.85</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>10</bold>
                  </sub>
                  <bold>= 0.05</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>11</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 250</td>
                <td align="right" rowspan="1" colspan="1">0.441 (0.175)</td>
                <td align="right" rowspan="1" colspan="1">0.536 (0.174)</td>
                <td align="right" rowspan="1" colspan="1">0.022 (0.012)</td>
                <td align="right" rowspan="1" colspan="1">0.001 (0.001)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 400</td>
                <td align="right" rowspan="1" colspan="1">0.293 (0.155)</td>
                <td align="right" rowspan="1" colspan="1">0.675 (0.154)</td>
                <td align="right" rowspan="1" colspan="1">0.031 (0.012)</td>
                <td align="right" rowspan="1" colspan="1">0.001 (0.001)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 548</td>
                <td align="right" rowspan="1" colspan="1">0.215 (0.116)</td>
                <td align="right" rowspan="1" colspan="1">0.750 (0.116)</td>
                <td align="right" rowspan="1" colspan="1">0.034 (0.012)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.002)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>sparse null</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>00</bold>
                  </sub>
                  <bold>= 0.99</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>01</bold>
                  </sub>
                  <bold>= 0.01</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>10</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>11</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 250</td>
                <td align="right" rowspan="1" colspan="1">0.977 (0.017)</td>
                <td align="right" rowspan="1" colspan="1">0.022 (0.017)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.001)</td>
                <td align="right" rowspan="1" colspan="1">0.001 (0.003)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 400</td>
                <td align="right" rowspan="1" colspan="1">0.986 (0.011)</td>
                <td align="right" rowspan="1" colspan="1">0.013 (0.011)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.001)</td>
                <td align="right" rowspan="1" colspan="1">0.001 (0.001)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 548</td>
                <td align="right" rowspan="1" colspan="1">0.977 (0.018)</td>
                <td align="right" rowspan="1" colspan="1">0.023 (0.019)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.001)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.000)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>complete null</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>00</bold>
                  </sub>
                  <bold>= 1</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>01</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>10</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>11</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 250</td>
                <td align="right" rowspan="1" colspan="1">0.993 (0.011)</td>
                <td align="right" rowspan="1" colspan="1">0.005 (0.010)</td>
                <td align="right" rowspan="1" colspan="1">0.002 (0.006)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.000)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 400</td>
                <td align="right" rowspan="1" colspan="1">0.998 (0.003)</td>
                <td align="right" rowspan="1" colspan="1">0.001 (0.003)</td>
                <td align="right" rowspan="1" colspan="1">0.001 (0.002)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.000)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 548</td>
                <td align="right" rowspan="1" colspan="1">0.994 (0.013)</td>
                <td align="right" rowspan="1" colspan="1">0.004 (0.012)</td>
                <td align="right" rowspan="1" colspan="1">0.003 (0.008)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.000)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>dense alternative</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>00</bold>
                  </sub>
                  <bold>= 0.1</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>01</bold>
                  </sub>
                  <bold>= 0.75</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>10</bold>
                  </sub>
                  <bold>= 0.05</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>11</bold>
                  </sub>
                  <bold>= 0.1</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 250</td>
                <td align="right" rowspan="1" colspan="1">0.394 (0.179)</td>
                <td align="right" rowspan="1" colspan="1">0.537 (0.174)</td>
                <td align="right" rowspan="1" colspan="1">0.070 (0.036)</td>
                <td align="right" rowspan="1" colspan="1">0.000 (0.000)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 400</td>
                <td align="right" rowspan="1" colspan="1">0.241 (0.145)</td>
                <td align="right" rowspan="1" colspan="1">0.667 (0.143)</td>
                <td align="right" rowspan="1" colspan="1">0.081 (0.035)</td>
                <td align="right" rowspan="1" colspan="1">0.011 (0.022)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 548</td>
                <td align="right" rowspan="1" colspan="1">0.172 (0.098)</td>
                <td align="right" rowspan="1" colspan="1">0.725 (0.097)</td>
                <td align="right" rowspan="1" colspan="1">0.077 (0.037)</td>
                <td align="right" rowspan="1" colspan="1">0.027 (0.034)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>sparse alternative</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>00</bold>
                  </sub>
                  <bold>= 0.9</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>01</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>10</bold>
                  </sub>
                  <bold>= 0</bold>
                </td>
                <td align="right" rowspan="1" colspan="1">
                  <bold>
                    <italic toggle="yes">κ</italic>
                  </bold>
                  <sub>
                    <bold>11</bold>
                  </sub>
                  <bold>= 0.1</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 250</td>
                <td align="right" rowspan="1" colspan="1">0.900 (0.021)</td>
                <td align="right" rowspan="1" colspan="1">0.055 (0.020)</td>
                <td align="right" rowspan="1" colspan="1">0.033 (0.018)</td>
                <td align="right" rowspan="1" colspan="1">0.013 (0.018)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 400</td>
                <td align="right" rowspan="1" colspan="1">0.892 (0.017)</td>
                <td align="right" rowspan="1" colspan="1">0.047 (0.026)</td>
                <td align="right" rowspan="1" colspan="1">0.025 (0.018)</td>
                <td align="right" rowspan="1" colspan="1">0.036 (0.028)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">n = 548</td>
                <td align="right" rowspan="1" colspan="1">0.870 (0.029)</td>
                <td align="right" rowspan="1" colspan="1">0.061 (0.031)</td>
                <td align="right" rowspan="1" colspan="1">0.040 (0.026)</td>
                <td align="right" rowspan="1" colspan="1">0.028 (0.028)</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="t001fn001">
            <p>Note: <italic toggle="yes">κ</italic><sub>10</sub> stands for the probability that the exposures are related to the mediator in the exposure-mediator model but the mediator is not associated with the survival outcome in the mediator-outcome model; <italic toggle="yes">κ</italic><sub>01</sub> stands for the probability that the exposures are not related to the mediator in the exposure-mediator model but the mediator is associated with the survival outcome in the mediator-outcome model; <italic toggle="yes">κ</italic><sub>00</sub> stands for the probability that the exposures are not related to the mediator in the exposure-mediator model and the mediator is not associated with the survival outcome in the mediator-outcome model; <italic toggle="yes">κ</italic><sub>11</sub> stands for the probability of the existence of mediation effects. The number of genes (i.e., the mediators) was set to 10<sup>4</sup>. Note that, here we only present the estimates of one simulation scenario, with more results shown in <xref rid="pcbi.1009250.s010" ref-type="supplementary-material">S1 Table</xref>.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Moreover, to evaluate the impact of various numbers of mediators on the estimators of proportions, we implemented an additional simulation with 10<sup>3</sup> genes (i.e., mediators) with <italic toggle="yes">κ</italic><sub>11</sub> = 0.10, <italic toggle="yes">κ</italic><sub>10</sub> = 0.75, <italic toggle="yes">κ</italic><sub>01</sub> = 0.05, and <italic toggle="yes">κ</italic><sub>00</sub> = 0.10 (a case that was very close to proportions obtained from our real applications). As can be anticipated, due to more information available (e.g., more genes), it turns out that increasing the number of mediators from 10<sup>3</sup> to 10<sup>4</sup> can generally improve the accuracy in estimating these proportion parameters (<xref rid="pcbi.1009250.s011" ref-type="supplementary-material">S2 Table</xref>).</p>
      <sec id="sec006">
        <title>Type I error and power</title>
        <p>Based on these estimated proportion parameters, the mixture null distribution is constructed, and the mediation effect test is implemented. First, when assessing the performance of type I error control, we demonstrate that IUSMMT, which is based on the estimated mixture null distribution, can maintain the type I error correctly across these simulation scenarios (Figs <xref rid="pcbi.1009250.g003" ref-type="fig">3</xref> and <xref rid="pcbi.1009250.s002" ref-type="supplementary-material">S2</xref>); however, IUT, which utilizes the uniform distribution as its null distribution, is conservative. This conservativeness of IUT indicates it would be underpowered in the detection of significant mediation effect. In the power assessment, due to the adjustment of the mixture null distribution, IUSMMT is much more powerful compared to IUT (Figs <xref rid="pcbi.1009250.g003" ref-type="fig">3</xref> and <xref rid="pcbi.1009250.s003" ref-type="supplementary-material">S3</xref>). For instance, when n = 400 and <italic toggle="yes">β</italic> = 0.05, compared with IUT, IUSMMT has a 0.06, 0.12, 0.07 or 0.11 higher power under the sparse alternative and 0.25, 0.49, 0.45 or 0.30 higher power under the dense alternative when τ<sub>2</sub> = 0.02, 0.04, 0.05 or 0.10, clearly indicating the benefit of estimating the empirical power function in the mixture null distribution. Moreover, it is clearly shown that IUSMMT has a much more pronounced advantage in power over IUT under the dense alternative (Figs <xref rid="pcbi.1009250.g003" ref-type="fig">3</xref> and <xref rid="pcbi.1009250.s003" ref-type="supplementary-material">S3</xref>). For example, IUSMMT is on average 29.8% more powerful than IUT under the dense alternative, while is on average only 7.3% more powerful under the sparse alternative.</p>
        <fig position="float" id="pcbi.1009250.g003">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.g003</object-id>
          <label>Fig 3</label>
          <caption>
            <p><bold>The QQ plot (</bold>A<bold>) and the average power curve (</bold>B<bold>-</bold>C<bold>) for IUSMMT and IUT.</bold> The QQ plot (A) is under the scenario of sparse nulls. The average power curve is calculated when the mediation strength parameter τ<sub>2</sub> increases under the sparse alternative (B) and the dense alternative (C). Here, n = 400, <italic toggle="yes">β</italic> = 0.3, and τ<sub>2</sub> = 0.01, 0.02, 0.04, 0.05 or 0.10 at the x-axis. The magnitude of τ<sub>2</sub> quantifies the strength of association between DNA methylation CpG sites and gene expression. In B and C, the number of genes (i.e., mediators) was set to 10<sup>4</sup>.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.g003" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="sec007">
      <title>DNA methylations are significantly associated with the survival risk of cancers</title>
      <p>We now applied IUSMMT to ten types of cancers available from TCGA [<xref rid="pcbi.1009250.ref023" ref-type="bibr">23</xref>]; summary information of these cancers is shown in <xref rid="pcbi.1009250.s012" ref-type="supplementary-material">S3</xref> and <xref rid="pcbi.1009250.s013" ref-type="supplementary-material">S4</xref> Tables. We first examine the association between a group of DNA methylation CpG sites and the survival risk of cancers for each gene (i.e., <italic toggle="yes">H</italic><sub>0</sub>: <bold>γ</bold><sup><italic toggle="yes">TE</italic></sup> = 0). A total of 57 (30 unique) regions of DNA methylation CpG sites are identified to be associated with the overall survival of these cancers (FDR &lt; 0.05) except BLCA and HNSC (<xref rid="pcbi.1009250.t002" ref-type="table">Table 2</xref>), including 8 methylation regions for BRCA, 7 for CESC, 7 for COAD, 17 for KIRP, 4 for LUAD, 1 for LUSC, 9 for SARC and 4 for STAD. Approximately 23.3 (= 7/30) of these regions of DNA methylation CpG sites exhibit pleiotropic effects (<xref rid="pcbi.1009250.g004" ref-type="fig">Fig 4A</xref>). For example, methylation CpG sites located in <italic toggle="yes">ACAA2</italic>, <italic toggle="yes">NUSAP1</italic>, <italic toggle="yes">OGFOD1</italic>, <italic toggle="yes">PSMD5</italic>, <italic toggle="yes">SNRNP40</italic> and <italic toggle="yes">XRCC6</italic> are simultaneously associated with five cancers including BRCA, CESC, COAD, KIRP and SARC; methylation CpG sites located in <italic toggle="yes">USP37</italic> are simultaneously related to four cancers (i.e., BRCA, CESC, COAD and SARC). Moreover, we recognize some cancer type-specific methylation CpG sites, including all the associated methylation sites identified for LUAD, STAD or LUSC, and partly for KIRP (11 out of 17), SARC (2 out of 9), or BRCA (1 out 8).</p>
      <fig position="float" id="pcbi.1009250.g004">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.g004</object-id>
        <label>Fig 4</label>
        <caption>
          <p><bold>Upset plot and heatmap plot of the <italic toggle="yes">P</italic>-values (</bold>A<bold>-</bold>F<bold>).</bold> In the heatmaps of γ<sup>TE</sup> (A) and γ<sup>DE</sup> (C), the color of each box indicates the magnitude of the <italic toggle="yes">P</italic>-value. The number in the comment part represents the <italic toggle="yes">P</italic>-value processed by the negative logarithmic transformation. The darker the color, the smaller the <italic toggle="yes">P</italic>-value. In the Upset plots of γ<sup>TE</sup>, β, γ<sup>DE</sup>, IUT, and IUSMMT, each bar shows the number of shared genes. In these Upset plots, the blue part represents cancer type-specific genes, and the red, green, orange, and purple parts represent genes shared in two, three, four and five types of cancers. (F) The heatmap of the <italic toggle="yes">P</italic>-values of the 14 overlapped genes across all the cancers. The color of each box indicates the magnitude of the <italic toggle="yes">P</italic>-value. The number in the comment part represents the <italic toggle="yes">P</italic>-value processed by the negative log transformation, the darker the color, the smaller the <italic toggle="yes">P</italic>-value.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.g004" position="float"/>
      </fig>
      <table-wrap position="float" id="pcbi.1009250.t002">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.t002</object-id>
        <label>Table 2</label>
        <caption>
          <title>Number of associated regions of DNA methylation CpG sites and genes identified in the survival mediation analysis.</title>
        </caption>
        <alternatives>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.t002" id="pcbi.1009250.t002g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1">cancers</th>
                <th align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1">γ<sup><italic toggle="yes">TE</italic></sup></th>
                <th align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><italic toggle="yes">α</italic> (%<xref rid="t002fn002" ref-type="table-fn"><sup>#</sup></xref>)</th>
                <th align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><italic toggle="yes">β</italic> (%<xref rid="t002fn002" ref-type="table-fn"><sup>#</sup></xref>)</th>
                <th align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1">γ<sup><italic toggle="yes">DE</italic></sup> (%<xref rid="t002fn002" ref-type="table-fn"><sup>#</sup></xref>)</th>
                <th align="center" colspan="3" style="background-color:#FFFFFF" rowspan="1">Mediation effect test</th>
              </tr>
              <tr>
                <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">IUT (%<xref rid="t002fn003" ref-type="table-fn"><sup>$</sup></xref>)</th>
                <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">IUSMMT (%<xref rid="t002fn003" ref-type="table-fn"><sup>$</sup></xref>)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>BLCA</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11,325 (86.29)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">76 (0.58)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41 (0.31)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">61 (0.46)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (13.1)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>BRCA</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11,872 (89.46)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">56 (0.42)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (0.05)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">30 (0.23)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">46 (0.35)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">14 (30.4)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>CESC</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10,059 (76.19)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">9 (0.07)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (0.06)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.01)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.01)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>COAD</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8,963 (68.25)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (0.05)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>HNSC</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11,284 (84.73)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">42 (0.32)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">23 (0.17)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">49 (0.37)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (16.7)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>KIRP</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">17</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8182 (62.80)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">170 (1.30)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">32 (0.22)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">34 (0.26)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">34 (0.26)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (2.9)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>LUAD</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10,342 (77.80)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">17 (0.13)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.01)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">176 (1.32)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">188 (1.41)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">39 (20.9)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>LUSC</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11,427 (84.73)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (0.02)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (0.02)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (0.02)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>SARC</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">9</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10,653 (81.73)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">204 (1.57)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (0.07)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">88 (0.68)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">156 (1.2)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">18 (11.5)</td>
              </tr>
              <tr>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>STAD</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10,879 (80.84)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (0.06)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (0.02)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (0.03)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (0.04)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>total</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">57</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">104,986</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">585</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">69</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">400</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">543</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">88 (16.3)</td>
              </tr>
              <tr>
                <td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>unique</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">30</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13,801</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">570</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">392</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">529</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                  <bold>pleiotropy (%)</bold>
                </td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (23.3)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13,553 (98.2)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">15 (2.6)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (17.1)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (2.0)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">14 (2.6)</td>
                <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="t002fn001">
            <p>Note</p>
          </fn>
          <fn id="t002fn002">
            <p># denotes the proportion among the total genes under investigation</p>
          </fn>
          <fn id="t002fn003">
            <p>$ denotes the proportion among the genes that are associated with the survival risk of cancers; the proportion of pleiotropy is computed by the ratio between the number of associations with pleiotropic effects and the number of unique associations. The last second column shows the number and proportion of genes with mediating effects, and the last column shows the number and proportion of potential passenger methylation events among genes with mediating roles.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec008">
      <title>Identified associations between methylation and expression</title>
      <p>We here evaluate the association between a group of DNA methylation CpG sites and gene expression (i.e., <italic toggle="yes">H</italic><sub>0</sub>: <bold><italic toggle="yes">α</italic></bold> = 0) through SKAT with the linear kernel. As a result, a particularly large number of associations are detected (FDR &lt; 0.05) (<xref rid="pcbi.1009250.t002" ref-type="table">Table 2</xref>), with the number of methylation-regulated genes ranging from 8,182 (62.8% = 8,182/13,029) for KIRP to 11,872 (89.5% = 11,872/13,270) for BRCA and an average of 79.3% across these cancers. There are approximately 98.2% methylation-regulated genes shared by at least two types of cancers, including 3,801 genes (e.g., <italic toggle="yes">HIST1H4F</italic>, <italic toggle="yes">FBP1</italic> and <italic toggle="yes">CPEB4</italic>) shared across all cancers.</p>
      <p>We also performed the similar methylation-expression analysis in 193 normal tissues combined across the ten cancers and find that 43.9% (= 6075/13840) of genes are methylation-regulated (FDR &lt; 0.05). This proportion is relatively smaller than that obtained from the tumor tissues, which may be a direct consequence of low power due to smaller sample size of normal tissues compared tumor tissues and the distinction mechanism in gene regulation between normal and tumor tissues. On average, 81.0% of methylation-regulated genes discovered in normal tissues are overlapped with these detected in tumor tissues across the cancers (<xref rid="pcbi.1009250.s005" ref-type="supplementary-material">S5A Fig</xref>). Interestingly, we observe that the effect of methylation on expression is much stronger in tumor tissues compared with that in the normal tissue. For example, the median value of τ<sub>2</sub>, which can be employed to quantify the magnitude of the methylation effect on expression, is 3.7 times higher in the BRCA tissue than that in the normal tissue (<xref rid="pcbi.1009250.s005" ref-type="supplementary-material">S5B Fig</xref>).</p>
    </sec>
    <sec id="sec009">
      <title>Identified associations between expression and survival risk</title>
      <p>We next explore the association between the expression level and the survival risk of cancers for each gene (i.e., <italic toggle="yes">H</italic><sub>0</sub>: <italic toggle="yes">β</italic> = 0) while adjusting for the direct effects of methylation alterations within the framework of coxlmm. The number of associated genes varies from zero for COAD to 204 for SARC (FDR &lt; 0.05). Approximately 2.6% of these associated genes are simultaneously shared by at least two cancers (<xref rid="pcbi.1009250.g004" ref-type="fig">Fig 4B</xref>), while most of the associated genes (~97.4%) are cancer type-specific. In addition, a total of 69 (41 unique) regions of methylation CpG sites also exhibit direct influence (i.e., γ<sup><italic toggle="yes">DE</italic></sup>≠0) on the overall survival of some cancers (except BLCA, HNSC and LUSC) (<xref rid="pcbi.1009250.t002" ref-type="table">Table 2</xref> and <xref rid="pcbi.1009250.g004" ref-type="fig">Fig 4C</xref>); and approximately 17.1% of significant regions of methylation CpG sites show direct pleiotropic effects. For example, the methylation regions located in <italic toggle="yes">ACAA2</italic>, <italic toggle="yes">NUSAP1</italic>, <italic toggle="yes">OGFOD1</italic>, <italic toggle="yes">PSMD5</italic>, <italic toggle="yes">SNRNP40</italic>, <italic toggle="yes">USP37</italic> and <italic toggle="yes">XRCC6</italic> are shared by five cancers (i.e., BRCA, CESC, COAD, KIRP and SARC). Moreover, we find that there are 12 methylation regions (i.e., located within <italic toggle="yes">ACAA2</italic>, <italic toggle="yes">NUSAP1</italic>, <italic toggle="yes">OGFOD1</italic>, <italic toggle="yes">PSMD5</italic>, <italic toggle="yes">SNRNP40</italic>, <italic toggle="yes">USP37</italic>, <italic toggle="yes">XRCC6</italic>, <italic toggle="yes">CCL18</italic>, <italic toggle="yes">DPP6</italic>, <italic toggle="yes">GRIK3</italic>, <italic toggle="yes">LZTFL1</italic>, and <italic toggle="yes">LACTB</italic>) that not only have non-zero total effect on the survival risk, but also have substantial direct influence on the survival risk of cancers.</p>
    </sec>
    <sec id="sec010">
      <title>Associated genes with mediating effects</title>
      <p>We now utilize IUT and IUSMMT to assess whether the expression level of a gene has substantial mediating effect on the pathway from methylation CpG sites to the survival risk of cancers. The estimated proportion parameters for the three-component mixture null distribution for each cancer are shown in <xref rid="pcbi.1009250.t003" ref-type="table">Table 3</xref>. These proportions also reflect the probability of the association between the methylations and the gene expression (i.e., <italic toggle="yes">κ</italic><sub>10</sub>), and between the gene expression and the survival time (i.e., <italic toggle="yes">κ</italic><sub>01</sub>), in line with the results described above. The QQ-plot of <italic toggle="yes">P</italic><sub>max</sub> for each cancer is demonstrated in <xref rid="pcbi.1009250.s004" ref-type="supplementary-material">S4 Fig</xref>. An observable upward deviation of <italic toggle="yes">P</italic><sub>max</sub> from the diagonal line implies the presence of mediating genes for most of these cancers except COAD. Specifically, IUSMMT detects 35.8% more genes with mediating effects compared to IUT, and all genes having mediation effects identified by IUT (a total of 400 genes) are also discovered by IUSMMT. Therefore, in the following we focus on the results of IUSMMT. As suggested by the association results described above and in terms of the principle of IUSMMT, except COAD (consistent with the pattern of the distribution of its <italic toggle="yes">P</italic><sub>max</sub> shown in <xref rid="pcbi.1009250.s004" ref-type="supplementary-material">S4 Fig</xref>), we identify multiple genes mediating the impact of methylation CpG sites on the survival risk of various cancers (<xref rid="pcbi.1009250.t002" ref-type="table">Table 2</xref> and <xref rid="pcbi.1009250.g004" ref-type="fig">Fig 4E</xref>). Specifically, there are a total of 543 (529 unique) significant methylation-expression mediation associations, with the number of genes exhibiting mediating effects ranging from 1 for CESC, to 156 for SARC and 188 for LUAD. It is very interesting that these mediating genes are more likely cancer type-specific as approximately 97.4% of genes are identified for a single cancer while only 2.6% (i.e., a total of 14 genes, including <italic toggle="yes">CD79A</italic>, <italic toggle="yes">HPN</italic>, <italic toggle="yes">CBFA2T3</italic>, <italic toggle="yes">TACC3</italic>, <italic toggle="yes">KIF18B</italic>, <italic toggle="yes">RRM2</italic>, <italic toggle="yes">CIDEC</italic>, <italic toggle="yes">GNG7</italic>, <italic toggle="yes">B3GNT8</italic>, <italic toggle="yes">APOL2</italic>, <italic toggle="yes">CBX7</italic>, <italic toggle="yes">APOBEC3G</italic>, <italic toggle="yes">APOL1</italic>, and <italic toggle="yes">PEX11G</italic>) are shared across distinct cancers (<xref rid="pcbi.1009250.g004" ref-type="fig">Fig 4F</xref>).</p>
      <table-wrap position="float" id="pcbi.1009250.t003">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.t003</object-id>
        <label>Table 3</label>
        <caption>
          <title>Estimated proportion parameters in the three-component mixture null distribution for 10 TCGA cancers.</title>
        </caption>
        <alternatives>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.t003" id="pcbi.1009250.t003g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">cancers</th>
                <th align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">κ</italic>
                  <sub>10</sub>
                </th>
                <th align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">κ</italic>
                  <sub>01</sub>
                </th>
                <th align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">κ</italic>
                  <sub>00</sub>
                </th>
                <th align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">κ</italic>
                  <sub>11</sub>
                </th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>BLCA</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.858</td>
                <td align="center" rowspan="1" colspan="1">0.001</td>
                <td align="center" rowspan="1" colspan="1">0.136</td>
                <td align="center" rowspan="1" colspan="1">0.005</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>BRCA</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.891</td>
                <td align="center" rowspan="1" colspan="1">0.001</td>
                <td align="center" rowspan="1" colspan="1">0.105</td>
                <td align="center" rowspan="1" colspan="1">0.004</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>CESC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.761</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
                <td align="center" rowspan="1" colspan="1">0.238</td>
                <td align="center" rowspan="1" colspan="1">0.001</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>COAD</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.683</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
                <td align="center" rowspan="1" colspan="1">0.317</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>HNSC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.844</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
                <td align="center" rowspan="1" colspan="1">0.152</td>
                <td align="center" rowspan="1" colspan="1">0.003</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>KIRP</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.621</td>
                <td align="center" rowspan="1" colspan="1">0.006</td>
                <td align="center" rowspan="1" colspan="1">0.366</td>
                <td align="center" rowspan="1" colspan="1">0.007</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>LUAD</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.777</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
                <td align="center" rowspan="1" colspan="1">0.222</td>
                <td align="center" rowspan="1" colspan="1">0.001</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>LUSC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.847</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
                <td align="center" rowspan="1" colspan="1">0.153</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>SARC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.803</td>
                <td align="center" rowspan="1" colspan="1">0.002</td>
                <td align="center" rowspan="1" colspan="1">0.181</td>
                <td align="center" rowspan="1" colspan="1">0.014</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>STAD</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.808</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
                <td align="center" rowspan="1" colspan="1">0.191</td>
                <td align="center" rowspan="1" colspan="1">0.000</td>
              </tr>
              <tr>
                <td align="right" rowspan="1" colspan="1">
                  <bold>average</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">0.789</td>
                <td align="center" rowspan="1" colspan="1">0.001</td>
                <td align="center" rowspan="1" colspan="1">0.206</td>
                <td align="center" rowspan="1" colspan="1">0.004</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="t003fn001">
            <p>Note: <italic toggle="yes">κ</italic><sub>10</sub> stands for the probability that the methylations are related to the gene expression in the exposure-mediator model but the gene expression is not associated with the survival outcome in the mediator-outcome model; <italic toggle="yes">κ</italic><sub>01</sub> stands for the probability that the methylations are not related to the gene expression in the exposure-mediator model but the gene expression is associated with the survival outcome in the mediator-outcome model; <italic toggle="yes">κ</italic><sub>00</sub> stands for the probability that the methylations are not related to the gene expression in the exposure-mediator model and the gene expression is not associated with the survival outcome in the mediator-outcome model.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec011">
      <title>Functional role of selective DNA methylation and gene expression on TCGA cancers</title>
      <p>It first needs to emphasize that among these methylation-expression mediation associations, nearly all are full mediations, with only one being partial mediation (i.e., <italic toggle="yes">ZNF763</italic> for CESC) (<xref rid="pcbi.1009250.s006" ref-type="supplementary-material">S6 Fig</xref>). <italic toggle="yes">ZNF763</italic> is a typical zinc finger protein containing Krüppel-associated box (KRAB), which is reportedly related to the development of cervical cancer. In addition, KRAB activates NF-κB by participating in the assembly of the IκB kinase (IKK) complex and promoting phosphorylation of IKK [<xref rid="pcbi.1009250.ref056" ref-type="bibr">56</xref>], while NF-κB is a multifunctional transcription factor and is related to the occurrence and development of cervical cancer [<xref rid="pcbi.1009250.ref057" ref-type="bibr">57</xref>]. Taken together, it is suggested that <italic toggle="yes">ZNF763</italic> may contribute to the occurrence of cervical cancer by enhancing NF-κB signaling and changing cell growth. In addition, among the 3,801 methylation-regulated genes that are shared by all analyzed cancers, 39 are histone genes. It has been revealed that histone gene loci are abnormally hypermethylated in a wide range of solid tumors [<xref rid="pcbi.1009250.ref058" ref-type="bibr">58</xref>,<xref rid="pcbi.1009250.ref059" ref-type="bibr">59</xref>]. For example, <italic toggle="yes">HIST1H4F</italic>, one of the identified histone genes with mediating effect, was abnormally hypermethylated in 17 types of cancers, acting as a potential universal-cancer-only methylation (UCOM) marker [<xref rid="pcbi.1009250.ref059" ref-type="bibr">59</xref>].</p>
      <p>Prior studies also offered empirical evidence for these identified mediating genes, three of which are described in detail as follows, with all the mediating genes shown at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/biostatpzeng/IUSMMT" ext-link-type="uri">https://github.com/biostatpzeng/IUSMMT</ext-link>. First, <italic toggle="yes">TRIM26</italic>, as a mediating gene associated with BLCA, was proved to play a key role in several types of cancers. For example, it was demonstrated that <italic toggle="yes">TRIM26</italic> had an oncogene impact on bladder cancer through regulating cell proliferation, migration and invasion via the Akt/GSK 3 β/β-catenin pathway [<xref rid="pcbi.1009250.ref060" ref-type="bibr">60</xref>], and methylation CpG sites had a significant effect on the regulation of <italic toggle="yes">TRIM26</italic> [<xref rid="pcbi.1009250.ref061" ref-type="bibr">61</xref>]. Second, <italic toggle="yes">ZNF496</italic>, as a mediating gene related to BRCA, was shown to significantly suppress ERα transactivation through over-expression, reduce the expression of estrogen receptor-alpha specific target genes, and inhibit the growth of breast cancer cells via ERα in an E2-dependent manner [<xref rid="pcbi.1009250.ref062" ref-type="bibr">62</xref>]. On the other hand, ERα is a key transcription factor involved in the proliferation and differentiation of mammary epithelia and has been demonstrated as an important predictor of breast cancer prognosis and a therapeutic target [<xref rid="pcbi.1009250.ref063" ref-type="bibr">63</xref>,<xref rid="pcbi.1009250.ref064" ref-type="bibr">64</xref>]. Moreover, the ZNF family, to which <italic toggle="yes">ZNF496</italic> belongs, has been shown to be mechanically linked to DNA methylation variability [<xref rid="pcbi.1009250.ref065" ref-type="bibr">65</xref>]. Third, <italic toggle="yes">TMBIM6</italic>, as a mediating gene discovered for HNSC, played an important role in the progression of laryngeal squamous cell carcinoma as a downstream target of <italic toggle="yes">RBM15</italic>-mediated N6-methyladenosine modification [<xref rid="pcbi.1009250.ref066" ref-type="bibr">66</xref>]. In addition, N6-methyladenosine methylation modification involved by <italic toggle="yes">RBM15</italic> regulates gene expression of <italic toggle="yes">TMBIM</italic>.</p>
    </sec>
    <sec id="sec012">
      <title>Enrichment pathway analysis for mediating genes</title>
      <p>We performed the gene ontology (GO) and KEGG pathway enrichment analysis for all identified mediating genes using the DAVID database [<xref rid="pcbi.1009250.ref067" ref-type="bibr">67</xref>] and showed results in <xref rid="pcbi.1009250.s007" ref-type="supplementary-material">S7 Fig</xref>. In brief, the GO analysis demonstrates that the biological processes of these genes are concentrated in DNA template, immune response and cell-cell adhesion, the cellular components of these genes mainly involve cytoplasm, cytosol and perinuclear region of cytoplasm, and the molecular functions of these genes are primarily manifested in protein binding, cadherin binding and microtubule binding. The KEGG analysis of these genes also reveals multiple signaling pathways which are related to PI3K-Akt, Ras and histidine metabolism.</p>
    </sec>
    <sec id="sec013">
      <title>Direction of mediation effects</title>
      <p>We further examined the direction of the effect of methylation CpG sites on expression and the effect of expression on the survival risk for these mediating genes (<xref rid="pcbi.1009250.t004" ref-type="table">Table 4</xref>). It is found that the expression level of most of the genes (68.7% = 373/543) were inhibited by methylation alterations, while the expression level of some genes (~31.3%) was also upregulated by methylation alterations, in line with prior observations of the dual function of methylations on gene expression [<xref rid="pcbi.1009250.ref068" ref-type="bibr">68</xref>, <xref rid="pcbi.1009250.ref069" ref-type="bibr">69</xref>]. The downregulated expressions may lead to higher (43.4% = 162/373) or lower (56.6% = 211/373) survival risk of cancers, and the upregulated expressions can also likely result in higher (30.6% = 52/170) or lower (68.8% = 118/170) survival risk of cancers. Totally, 48.4% of (= 263/543) genes have the methylation-expression effect and the expression-survival effect in the same direction and 51.6% (= 280/543) of genes have opposite directions.</p>
      <table-wrap position="float" id="pcbi.1009250.t004">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1009250.t004</object-id>
        <label>Table 4</label>
        <caption>
          <title>Direction of the effect of methylations on expression and the effect of expression on the survival risk of cancers for identified genes with mediating influence.</title>
        </caption>
        <alternatives>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.t004" id="pcbi.1009250.t004g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="2" colspan="1">cancers</th>
                <th align="center" rowspan="2" colspan="1">
                  <italic toggle="yes">N</italic>
                </th>
                <th align="center" colspan="4" rowspan="1">Direction (<italic toggle="yes">α</italic> &amp; <italic toggle="yes">β</italic>)</th>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">+ +</th>
                <th align="center" rowspan="1" colspan="1">- -</th>
                <th align="center" rowspan="1" colspan="1">- +</th>
                <th align="center" rowspan="1" colspan="1">+ -</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>BLCA</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">61</td>
                <td align="center" rowspan="1" colspan="1">12</td>
                <td align="center" rowspan="1" colspan="1">24</td>
                <td align="center" rowspan="1" colspan="1">12</td>
                <td align="center" rowspan="1" colspan="1">13</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>BRCA</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">46</td>
                <td align="center" rowspan="1" colspan="1">2</td>
                <td align="center" rowspan="1" colspan="1">28</td>
                <td align="center" rowspan="1" colspan="1">4</td>
                <td align="center" rowspan="1" colspan="1">12</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>CESC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">0</td>
                <td align="center" rowspan="1" colspan="1">0</td>
                <td align="center" rowspan="1" colspan="1">0</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>HNSC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">49</td>
                <td align="center" rowspan="1" colspan="1">2</td>
                <td align="center" rowspan="1" colspan="1">18</td>
                <td align="center" rowspan="1" colspan="1">3</td>
                <td align="center" rowspan="1" colspan="1">26</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>KIRP</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">34</td>
                <td align="center" rowspan="1" colspan="1">5</td>
                <td align="center" rowspan="1" colspan="1">11</td>
                <td align="center" rowspan="1" colspan="1">16</td>
                <td align="center" rowspan="1" colspan="1">2</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>LUAD</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">188</td>
                <td align="center" rowspan="1" colspan="1">19</td>
                <td align="center" rowspan="1" colspan="1">70</td>
                <td align="center" rowspan="1" colspan="1">59</td>
                <td align="center" rowspan="1" colspan="1">40</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>LUSC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">3</td>
                <td align="center" rowspan="1" colspan="1">2</td>
                <td align="center" rowspan="1" colspan="1">0</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">0</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>SARC</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">156</td>
                <td align="center" rowspan="1" colspan="1">8</td>
                <td align="center" rowspan="1" colspan="1">59</td>
                <td align="center" rowspan="1" colspan="1">64</td>
                <td align="center" rowspan="1" colspan="1">25</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>STAD</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">5</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">3</td>
                <td align="center" rowspan="1" colspan="1">0</td>
              </tr>
              <tr>
                <td align="right" rowspan="1" colspan="1">
                  <bold>total</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">543</td>
                <td align="center" rowspan="1" colspan="1">52</td>
                <td align="center" rowspan="1" colspan="1">211</td>
                <td align="center" rowspan="1" colspan="1">162</td>
                <td align="center" rowspan="1" colspan="1">118</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="t004fn001">
            <p>Note: <italic toggle="yes">N</italic> denotes the number of genes with mediating effect; + or—refers to the positive or negative direction in the effect of methylations on expression (i.e., <bold><italic toggle="yes">α</italic></bold>) or in the effect of expression on the survival risk of cancers (<italic toggle="yes">β</italic>).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec014">
      <title>Distinguish passenger methylation events from mediation methylation events</title>
      <p>Finally, we highlight that the effect pathway in our mediation analysis depends on a critical assumption that DNA methylation CpG sites regulate gene expression rather than conversely. However, such assumption may not fully hold as recent methylation studies in large cancer datasets have revealed that a bulk of methylation alterations observed in cancers might be a consequence of global epigenetic remodeling mechanism including (i) global loss via replication related errors; and (ii) CpG island/shore methylation gain associated with tumor proliferation [<xref rid="pcbi.1009250.ref070" ref-type="bibr">70</xref>,<xref rid="pcbi.1009250.ref071" ref-type="bibr">71</xref>]. Under this case, altered expression of a handful of key genes would have a reverse influence on DNA methylation CpG sites over the cancer epigenome. Namely, the expression of a gene can affect the survival risk of cancers while impacting DNA methylations, leading to the biological consequence that changed DNA methylations are just passenger events.</p>
      <p>Therefore, distinguishing passenger methylation events from mediation methylation events that are likely to have a direct or indirect (via expression mediation) influence on the survival risk of cancers is necessary for the biological interpretation of results in our mediation analysis. In terms of the result of multivariate variance-component score test conducted via MultiSKAT [<xref rid="pcbi.1009250.ref072" ref-type="bibr">72</xref>], we find that approximately 16.3% (= 88/543) of the discovered mediation methylation events might be passenger methylation events across these cancers after the adjustment with Bonferroni’s method (<italic toggle="yes">P</italic> &lt; 0.05) (<xref rid="pcbi.1009250.t002" ref-type="table">Table 2</xref>).</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec015">
    <title>Discussions</title>
    <p>In the present study we have proposed a novel statistical approach, called IUSMMT, for examining high-dimensional mediation effects in survival models with multiple exposures and one mediator. We have applied IUSMMT to ten TCGA cancers to identify genes that likely exhibited mediation effects of gene expression on the signaling pathway from DNA methylation CpG sites to the survival risk of cancers and observed some interesting results which provide supplementary insights on the biological mechanism from DNA methylation to gene expression and to survival outcome. First, only a few of DNA methylation CpG sites showed a total impact on the survival risk of cancers, although we cannot completely rule out the possibility of low statistical power due to small sample sizes and high censoring rates of these analyzed cancers. Second, we found that DNA methylation CpG sites can influence expression level directly for a wide range of genes and that most of these methylation-regulated genes were shared across distinct cancers, authenticating the prior finding that DNA methylation is a pervasive epigenomic mechanism of gene regulation [<xref rid="pcbi.1009250.ref073" ref-type="bibr">73</xref>,<xref rid="pcbi.1009250.ref074" ref-type="bibr">74</xref>].</p>
    <p>Third, many genes were related to the survival risk of cancers, whereas most of them (~84.6%) were cancer type-specific, with only a few simultaneously shared between various cancers. As a result, although a wealth of genes mediated the influence of DNA methylation CpG sites on the overall survival time of cancers, the majority of the mediations associations were also cancer type-specific. This specificity largely reflects the inter-tumor heterogeneity of the transcriptomic influence on cancers and the tissue distinction in cancer prognosis [<xref rid="pcbi.1009250.ref075" ref-type="bibr">75</xref>], implying that mediated pathways of the epigenomic impact vary cancer by cancer although DNA methylation pervasively regulates gene expression. It also has important implication on targeted therapies of precision cancers medicine by intervening DNA methylations [<xref rid="pcbi.1009250.ref076" ref-type="bibr">76</xref>–<xref rid="pcbi.1009250.ref078" ref-type="bibr">78</xref>].</p>
    <p>Fourth, besides the indirect impact mediated by genes, multiple regions of DNA methylation CpG sites also have direct effects on these cancers. Fifth, we found that almost all the associations were full mediations, with only few partial mediations. Besides the truly biological mechanism, other possible explanations also include low power in examining the direct effects (i.e., <bold>γ</bold><sup>DE</sup>) of DNA methylation CpG sites for these TCGA cancers. Note that, potentially due to the lack of coverage of distal regulatory elements in the TCGA 450K chip, our analysis cannot include distal enhancer when defining methylation loci for every gene although we can consider methylation alterations around the promoter. It has been shown that the distal enhancers of CpG sites are unmethylated in normal cells but often gain methylations in cancer cells and tissues [<xref rid="pcbi.1009250.ref079" ref-type="bibr">79</xref>,<xref rid="pcbi.1009250.ref080" ref-type="bibr">80</xref>]. With the growing increase in the use of whole genome bisulfite whole genome sequencing (WGBS) and Illumina’s newly released methylated EPIC BeadChip [<xref rid="pcbi.1009250.ref081" ref-type="bibr">81</xref>], including methylation loci around the enhancer would become feasible and important in epigenetic mediation analysis from both the biological and statistical perspectives. For instance, a mediation event, which was identified as partial mediation using only promoter CpG sites, may be tagged as fully mediated if enhancers/transcription factor binding would be considered as well. This is certainly an interesting topic for future work. It also needs to emphasize that our analysis cannot directly indicate these mediating genes include in proliferation or cell cycle related genes. Further experimental studies are warranted to elucidate the biological function of these genes.</p>
    <p>In addition, although many studies have demonstrated that the variability in DNA methylation level can be largely attributable to diverse cell types and that cellular composition can be an important factor for elucidating biological processes [<xref rid="pcbi.1009250.ref082" ref-type="bibr">82</xref>] (e.g., the ratio of infiltrating neutrophils to plasma cells has important prognostic significance in cancer survival [<xref rid="pcbi.1009250.ref083" ref-type="bibr">83</xref>]), in the present analysis we followed prior work (e.g., [<xref rid="pcbi.1009250.ref043" ref-type="bibr">43</xref>,<xref rid="pcbi.1009250.ref084" ref-type="bibr">84</xref>]) and did not consider cell types as covariates due to two main reasons listed below. First, because cell types are often inferred directly from gene expressions or methylations [<xref rid="pcbi.1009250.ref085" ref-type="bibr">85</xref>–<xref rid="pcbi.1009250.ref087" ref-type="bibr">87</xref>], we did not incorporate them in the mediation model to avoid using data twice. Second, to our knowledge, adjusting cell types is primarily for DNA in the blood sample, and is very rare in the tumor tissue. Nevertheless, we recognize the critical role of cell types in the high-dimensional mediation analysis [<xref rid="pcbi.1009250.ref088" ref-type="bibr">88</xref>] and would pursue this issue in our future work.</p>
    <p>It needs to highlight that IUSMMT adopted the principle of intersection-union test and is conceptually straightforward [<xref rid="pcbi.1009250.ref047" ref-type="bibr">47</xref>,<xref rid="pcbi.1009250.ref049" ref-type="bibr">49</xref>,<xref rid="pcbi.1009250.ref050" ref-type="bibr">50</xref>]. Like many previous mediation analyses, we implemented IUSMMT in two stages. Specifically, in the first step, the influence of DNA methylation CpG sites on the gene expression was examined and in the second step the association between the expression levels was investigated. Note that, although there are two null hypotheses involved in IUSMMT, no adjustment for multiplicity is needed because the overall null hypothesis of no mediation effect is rejected if and only if each of individual null hypotheses (rather than any of individual null hypotheses) is rejected. It is evident that the power of IUSMMT depends on the individual power in each stage.</p>
    <p>Our analysis relies on an implicit assumption that DNA methylation CpG sites can regulate gene expression [<xref rid="pcbi.1009250.ref089" ref-type="bibr">89</xref>–<xref rid="pcbi.1009250.ref092" ref-type="bibr">92</xref>]. This assumption is largely supported by prior finding that epigenetic modification is closely relevant to the gene expression level which in turn has a direct function consequence on complex human diseases including malignant tumors [<xref rid="pcbi.1009250.ref093" ref-type="bibr">93</xref>,<xref rid="pcbi.1009250.ref094" ref-type="bibr">94</xref>]. Previous studies also showed that genes often exhibited cancer type-specific methylation changes and contributed to a higher incidence in cancer patients [<xref rid="pcbi.1009250.ref095" ref-type="bibr">95</xref>]. In addition, methylation CpG sites not only affect the survival through the expression of its located genes but also work via a variety of other mechanisms, including splice variants and enhancer regions [<xref rid="pcbi.1009250.ref096" ref-type="bibr">96</xref>–<xref rid="pcbi.1009250.ref098" ref-type="bibr">98</xref>]. Recent work discovered that the methylation profiles of patients of four cancer subtypes played an important role in regulating gene expression during many biological processes and identified some functional genes with different methylation status in different subtypes [<xref rid="pcbi.1009250.ref099" ref-type="bibr">99</xref>].</p>
    <p>However, the regulation assumption from DNA methylations to gene expression may not fully hold as revealed in terms of recent studies which found that methylation alterations can be reversely regulated by gene expression under the global epigenetic remodeling mechanism [<xref rid="pcbi.1009250.ref070" ref-type="bibr">70</xref>,<xref rid="pcbi.1009250.ref071" ref-type="bibr">71</xref>]. As a consequence, altered DNA methylation may simply represent a passenger event rather than a mediation event. To distinguish passenger methylation events from mediation methylation events, using the reverse regression analysis we found statistically supportive evidence that a small fraction of mediation associations may be passenger methylation events. However, this reverse analysis strategy is an <italic toggle="yes">ad-hoc</italic> approach which has no clear theoretical basis and which only considered the <italic toggle="yes">cis</italic> influence of gene expression regulation on methylation. It also demonstrates an important limitation of mediation analysis; namely, although it is useful for uncovering evidence of causal association, mediation analysis <italic toggle="yes">per se</italic> can be inadequate for completely determining the direction of the identified causal relationship. Therefore, addressing passenger methylation event in our epigenetic mediation analysis comprehensively is a promising but challenging direction for future investigation.</p>
    <p>We finally highlight that there is still some room for further enhancement of the power in the first stage where the relationship between a set of DNA methylation CpG sites and gene expression level was examined with the variance-component test with a linear kernel function in the present study. As well-documented in previous studies, other more complicated kernels or a composite optimal kernel may have the potential to improve the power [<xref rid="pcbi.1009250.ref100" ref-type="bibr">100</xref>–<xref rid="pcbi.1009250.ref106" ref-type="bibr">106</xref>]. In addition, herein we implicitly suppose that all DNA methylation CpG sites had an influence on the gene expression, which may not hold in the real-life dataset. Instead, there may be only a few DNA methylation CpG sites regulating the expression level of a gene. Under this circumstance, a sparse relationship between DNA methylation CpG sites and the expression level should be modeled [<xref rid="pcbi.1009250.ref051" ref-type="bibr">51</xref>,<xref rid="pcbi.1009250.ref107" ref-type="bibr">107</xref>]. Furthermore, IUSMMT may be sub-optimal if the effect sizes of DNA methylation CpG sites located within the gene have the same direction (e.g., all are positive or negative). In this scenario, the burden test with a weighted score across these methylation CpG sites often leads to more powerful mediation approaches [<xref rid="pcbi.1009250.ref033" ref-type="bibr">33</xref>,<xref rid="pcbi.1009250.ref101" ref-type="bibr">101</xref>,<xref rid="pcbi.1009250.ref108" ref-type="bibr">108</xref>]. However, it seems very challenging to select a test that is consistently optimal across various settings because of the true relationship is unknown. Alternatively, it is hence desirable to construct a feasible omnibus mediation effect test that can aggregate all these strengths stated above. Nevertheless, in the present study we offer a very general framework for the assessment of mediation effect and we leave these issues mentioned above as an important and promising research avenue in our further work.</p>
  </sec>
  <sec sec-type="materials|methods" id="sec016">
    <title>Materials and methods</title>
    <sec id="sec017">
      <title>Modeling framework for survival mediation analysis with multiple exposures</title>
      <p>IUSMMT is a gene-centric high-dimensional survival mediation approach and considers one gene at each time. Assume there are multiple exposures (<bold><italic toggle="yes">M</italic></bold>; e.g., a set of DNA methylation values for CpG sites located within a given gene), one mediator (<italic toggle="yes">G</italic>; e.g., expression level of that gene) and one survival outcome (<italic toggle="yes">T</italic>; including the survival time <italic toggle="yes">t</italic> and the survival status <italic toggle="yes">d</italic>) for <italic toggle="yes">n</italic> individuals. In the conventional mediation analysis [<xref rid="pcbi.1009250.ref018" ref-type="bibr">18</xref>–<xref rid="pcbi.1009250.ref022" ref-type="bibr">22</xref>], the impact of <bold><italic toggle="yes">M</italic></bold> on <italic toggle="yes">T</italic> stands for the direct effect, and the influence of <bold><italic toggle="yes">M</italic></bold> on <italic toggle="yes">G</italic> and subsequently <italic toggle="yes">G</italic> on <italic toggle="yes">T</italic> for the indirect effect. Our objective is to evaluate the causal effect of <bold><italic toggle="yes">M</italic></bold> on <italic toggle="yes">T</italic> that is mediated via <italic toggle="yes">G</italic>. If <bold><italic toggle="yes">M</italic></bold> affects <italic toggle="yes">T</italic> only through <italic toggle="yes">G</italic> (i.e., <bold>γ</bold><sup>DE</sup> = 0), it is called full mediation; otherwise, it is referred to as partial mediation if <bold>γ</bold><sup>DE</sup> ≠ 0 [<xref rid="pcbi.1009250.ref109" ref-type="bibr">109</xref>]. For a gene under investigation, the associations between DNA methylations, expression, or clinical covariates (<bold><italic toggle="yes">X</italic></bold>) and the survival outcome can be determined within the framework of mediation analysis through the following procedures.</p>
    </sec>
    <sec id="sec018">
      <title>Step 1: Cox linear mixed-effects model testing for the total effect of methylations on the survival outcome</title>
      <p>Following previous work [<xref rid="pcbi.1009250.ref028" ref-type="bibr">28</xref>,<xref rid="pcbi.1009250.ref038" ref-type="bibr">38</xref>], we first fit an exposure-outcome Cox model (i.e., methylation-survival model) to examine the association between a group of DNA methylation CpG sites (<bold><italic toggle="yes">M</italic></bold>) of a gene of focus and the survival outcome (<italic toggle="yes">T</italic>) (i.e., <bold><italic toggle="yes">M</italic></bold> → <italic toggle="yes">T</italic>) while adjusting for the impact of existing covariates (<bold><italic toggle="yes">X</italic></bold>)
<disp-formula id="pcbi.1009250.e001"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e001.jpg" id="pcbi.1009250.e001g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="normal">log</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>h</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>|</mml:mo><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msubsup><mml:mi mathvariant="normal">γ</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mstyle><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">M</mml:mi><mml:msup><mml:mi mathvariant="bold">γ</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
where <italic toggle="yes">h</italic>(<italic toggle="yes">t</italic>|<bold><italic toggle="yes">M</italic></bold>,<bold><italic toggle="yes">X</italic></bold>) is the hazard risk at time <italic toggle="yes">t</italic> given <bold><italic toggle="yes">M</italic></bold> and <bold><italic toggle="yes">X</italic></bold>; <inline-formula id="pcbi.1009250.e002"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e002.jpg" id="pcbi.1009250.e002g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">γ</mml:mi></mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msubsup><mml:mi mathvariant="normal">γ</mml:mi><mml:mi>K</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> is the vector of total effect sizes of exposures on the survival outcome; <bold><italic toggle="yes">w</italic></bold><sub>1</sub> = (<italic toggle="yes">w</italic><sub>11</sub>,…,<italic toggle="yes">w</italic><sub>1<italic toggle="yes">L</italic></sub>) denotes the vector of effect sizes of <italic toggle="yes">L</italic> covariates in the exposure-outcome model; <italic toggle="yes">h</italic><sub>0</sub>(<italic toggle="yes">t</italic>) is an arbitrary baseline hazard function, and <italic toggle="yes">K</italic> is the number of methylations. Nota bene, <italic toggle="yes">K</italic> varies gene by gene. In terms of the weighted residual method proposed in [<xref rid="pcbi.1009250.ref110" ref-type="bibr">110</xref>], we find that the proportional hazards assumption required by the utilization of the Cox model (here only covariates are considered; see below) is satisfied across all the ten TCGA cancers (<italic toggle="yes">P</italic>&gt;0.05) (<xref rid="pcbi.1009250.s014" ref-type="supplementary-material">S5 Table</xref>).</p>
      <p>To assess the relationship between <bold><italic toggle="yes">M</italic></bold> and <italic toggle="yes">T</italic> (<italic toggle="yes">H</italic><sub>0</sub>: <bold>γ</bold><sup><italic toggle="yes">TE</italic></sup> = 0), one may treat <bold>γ</bold><sup><italic toggle="yes">TE</italic></sup> to be fixed effects and apply the classical score test (or multivariate Wald test) for hypothesis testing. However, as the number of methylations (i.e., <italic toggle="yes">K</italic>) in a gene might be very large up to several hundred and highly correlated with each other (<xref rid="pcbi.1009250.s008" ref-type="supplementary-material">S8 Fig</xref>), the fixed-effects test methods would have a large degree of freedom and are thus underpowered [<xref rid="pcbi.1009250.ref031" ref-type="bibr">31</xref>–<xref rid="pcbi.1009250.ref033" ref-type="bibr">33</xref>,<xref rid="pcbi.1009250.ref111" ref-type="bibr">111</xref>]. Alternatively, we assume <inline-formula id="pcbi.1009250.e003"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e003.jpg" id="pcbi.1009250.e003g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">γ</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>K</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> follows a normal distribution <italic toggle="yes">N</italic>(0, τ<sub>1</sub>) in terms of previous relevant studies [<xref rid="pcbi.1009250.ref032" ref-type="bibr">32</xref>–<xref rid="pcbi.1009250.ref034" ref-type="bibr">34</xref>], leading to the so-called coxlmm [<xref rid="pcbi.1009250.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1009250.ref038" ref-type="bibr">38</xref>]. Based on this effect assumption, we estimate and test the direct path within the framework of kernel-machine (KM) based Cox model relying on another equivalent null hypothesis <italic toggle="yes">H</italic><sub>0</sub>: τ<sub>1</sub> = 0 via the coxKM package [<xref rid="pcbi.1009250.ref112" ref-type="bibr">112</xref>].</p>
      <p>Traditionally, the presence of a significant total effect (i.e., <bold>γ</bold><sup><italic toggle="yes">TE</italic></sup> ≠ 0) is the prerequisite for the subsequent mediation test [<xref rid="pcbi.1009250.ref022" ref-type="bibr">22</xref>]. However, in practice it is not uncommon for the situation where the total effect is nonsignificant (i.e., <bold>γ</bold><sup><italic toggle="yes">TE</italic></sup> = 0) but a substantial mediation effect remains [<xref rid="pcbi.1009250.ref113" ref-type="bibr">113</xref>]. Therefore, we always further investigate the existence of mediation effect irrespective of the significance or insignificance of <bold>γ</bold><sup><italic toggle="yes">TE</italic></sup>.</p>
    </sec>
    <sec id="sec019">
      <title>Step 2: Linear mixed-effects model testing for the effect of methylations on gene expression</title>
      <p>Next, in the exposure-mediator model (i.e., methylation-expression model) we evaluate the association path from methylation CpG sites to expression while controlling the influences of other covariates (i.e., <bold><italic toggle="yes">M</italic></bold> → G). With the similar reason described in the first step, like <bold>γ</bold><sup><italic toggle="yes">TE</italic></sup> we also suppose the effects of methylations <bold><italic toggle="yes">α</italic></bold> have a normal distribution with variance τ<sub>2</sub>
<disp-formula id="pcbi.1009250.e004"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e004.jpg" id="pcbi.1009250.e004g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4" display="block" overflow="scroll"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mspace width="0.25em"/><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mi>α</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mi mathvariant="bold">α</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>α</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="normal">τ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="0.25em"/><mml:mi>ε</mml:mi><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi mathvariant="normal">σ</mml:mi><mml:mi>ε</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(2)</label></disp-formula>
where <bold><italic toggle="yes">α</italic></bold> = (<italic toggle="yes">α</italic><sub>1</sub>,…,<italic toggle="yes">α</italic><sub><italic toggle="yes">K</italic></sub>) is the vector of effect sizes of exposures on the mediator; <bold><italic toggle="yes">w</italic></bold><sub>2</sub> = (<italic toggle="yes">w</italic><sub>21</sub>,…,<italic toggle="yes">w</italic><sub>2<italic toggle="yes">L</italic></sub>) denotes the vector of the effect sizes of covariates in the exposure-mediator model; and <italic toggle="yes">ε</italic> is a mean-zero normal residual with variance <inline-formula id="pcbi.1009250.e005"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e005.jpg" id="pcbi.1009250.e005g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">σ</mml:mi><mml:mi>ε</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. We examine the null hypothesis <italic toggle="yes">H</italic><sub>0</sub>: <bold><italic toggle="yes">α</italic></bold> = 0 (or equivalently τ<sub>2</sub> = 0) by utilizing the variance component-based score test within the framework of lmm [<xref rid="pcbi.1009250.ref031" ref-type="bibr">31</xref>,<xref rid="pcbi.1009250.ref032" ref-type="bibr">32</xref>,<xref rid="pcbi.1009250.ref114" ref-type="bibr">114</xref>–<xref rid="pcbi.1009250.ref116" ref-type="bibr">116</xref>] albeit the likelihood ratio-based test is also applicable [<xref rid="pcbi.1009250.ref033" ref-type="bibr">33</xref>,<xref rid="pcbi.1009250.ref117" ref-type="bibr">117</xref>,<xref rid="pcbi.1009250.ref118" ref-type="bibr">118</xref>]
<disp-formula id="pcbi.1009250.e006"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e006.jpg" id="pcbi.1009250.e006g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6" display="block" overflow="scroll"><mml:mrow><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mover accent="true"><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula>
where <inline-formula id="pcbi.1009250.e007"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e007.jpg" id="pcbi.1009250.e007g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> is the estimate of <bold><italic toggle="yes">w</italic></bold><sub>2</sub> under the null model (i.e., <italic toggle="yes">G</italic> = <bold><italic toggle="yes">Xw</italic></bold><sub>2</sub>+<italic toggle="yes">ε</italic>). Under <italic toggle="yes">H</italic><sub>0</sub>, the score statistic <italic toggle="yes">Q</italic> follows a mixture of chi-square distribution and the <italic toggle="yes">P</italic>-value is approximately obtained by Davies’ method [<xref rid="pcbi.1009250.ref032" ref-type="bibr">32</xref>,<xref rid="pcbi.1009250.ref119" ref-type="bibr">119</xref>]. We implement this test via the SKAT package [<xref rid="pcbi.1009250.ref032" ref-type="bibr">32</xref>].</p>
    </sec>
    <sec id="sec020">
      <title>Step 3: Cox linear mixed-effects model testing for the effect of gene expression on the survival outcome</title>
      <p>In the third step under the mediator-outcome model (i.e., expression-survival model), we examine the path from gene expression (<italic toggle="yes">G</italic>) to the survival outcome (<italic toggle="yes">T</italic>) conditional on methylation CpG sites (i.e., <italic toggle="yes">G</italic> → <italic toggle="yes">T</italic>) through coxlmm
<disp-formula id="pcbi.1009250.e008"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e008.jpg" id="pcbi.1009250.e008g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M8" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="normal">log</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>h</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>|</mml:mo><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mo>,</mml:mo><mml:mi>G</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msubsup><mml:mi mathvariant="normal">γ</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mi>G</mml:mi><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">M</mml:mi><mml:msup><mml:mi mathvariant="bold">γ</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>G</mml:mi><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula>
where <inline-formula id="pcbi.1009250.e009"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e009.jpg" id="pcbi.1009250.e009g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M9" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">γ</mml:mi></mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msubsup><mml:mi mathvariant="normal">γ</mml:mi><mml:mi>K</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> is the vector of the direct effects of methylations, <italic toggle="yes">β</italic> is the effect size of gene expression, and <bold><italic toggle="yes">w</italic></bold><sub>3</sub> = (<italic toggle="yes">w</italic><sub>31</sub>,…,<italic toggle="yes">w</italic><sub>3<italic toggle="yes">L</italic></sub>) denotes the vector of the effect sizes of covariates in the mediator-outcome model. In the same principle, we suppose <inline-formula id="pcbi.1009250.e010"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e010.jpg" id="pcbi.1009250.e010g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M10" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">γ</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>K</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> follows a normal distribution <italic toggle="yes">N</italic>(0, τ<sub>3</sub>). Herein, we are interested in testing <italic toggle="yes">H</italic><sub>0</sub>: <italic toggle="yes">β</italic> = 0. We estimate <italic toggle="yes">β</italic> and implement a Wald test via the coxme package [<xref rid="pcbi.1009250.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1009250.ref120" ref-type="bibr">120</xref>].</p>
      <p>Based on these models described above, the average nature direct effect and nature indirect effect can then be derived (<xref rid="pcbi.1009250.s015" ref-type="supplementary-material">S1 Text</xref>) [<xref rid="pcbi.1009250.ref026" ref-type="bibr">26</xref>,<xref rid="pcbi.1009250.ref121" ref-type="bibr">121</xref>]; the modeling assumptions required for estimation identifiability and causal interpretation of these effects are also given (<xref rid="pcbi.1009250.s015" ref-type="supplementary-material">S1 Text</xref>).</p>
    </sec>
    <sec id="sec021">
      <title>Intersection-union survival mixture-adjusted mediation test (IUSMMT)</title>
      <p>Finally, to verify whether a given gene has mediation effect on the path from methylation CpG sites to the survival risk, we test the joint null hypothesis in which both effects have to be zero: <italic toggle="yes">H</italic><sub>0</sub>: <bold><italic toggle="yes">α</italic></bold> = <italic toggle="yes">β</italic> = 0 (or equivalently, <italic toggle="yes">H</italic><sub>0</sub>: τ<sub>2</sub> = <italic toggle="yes">β</italic> = 0). As mentioned before, we need to implement the similar hypothesis testing across the whole genome. Therefore, this is a high-dimensional problem of mediation effect test. That is, we have <italic toggle="yes">H</italic><sub>0<italic toggle="yes">j</italic></sub> (<italic toggle="yes">j</italic> = 1, …, <italic toggle="yes">S</italic>) for all <italic toggle="yes">S</italic> genes. For simplicity, in the following we here ignore the subscript <italic toggle="yes">j</italic>. The individual mediation effect test is also equivalent to the hypothesis testing whether the mediation effect exists or not (<italic toggle="yes">H</italic><sub>0</sub>: <bold><italic toggle="yes">α</italic></bold><italic toggle="yes">β</italic> = <bold>0</bold> versus <italic toggle="yes">H</italic><sub>1</sub>: <bold><italic toggle="yes">α</italic></bold><italic toggle="yes">β ≠</italic>
<bold>0</bold>) in the absence of interactions between the exposures and the mediator and can be divided into three composite null sub-hypotheses
<disp-formula id="pcbi.1009250.e011"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e011.jpg" id="pcbi.1009250.e011g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M11" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mo>≠</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">τ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>≠</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">and</mml:mi><mml:mspace width="0.25em"/><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">τ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">and</mml:mi><mml:mspace width="0.25em"/><mml:mi>β</mml:mi><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>00</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">τ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">and</mml:mi><mml:mspace width="0.25em"/><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></alternatives><label>(5)</label></disp-formula></p>
      <p>The hypothesis in (5) can be formulated within the framework of the intersection-union test (IUT) (<xref rid="pcbi.1009250.s016" ref-type="supplementary-material">S2 Text</xref>) [<xref rid="pcbi.1009250.ref046" ref-type="bibr">46</xref>–<xref rid="pcbi.1009250.ref050" ref-type="bibr">50</xref>]
<disp-formula id="pcbi.1009250.e012"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e012.jpg" id="pcbi.1009250.e012g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M12" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>∪</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>∪</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>00</mml:mn></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">versus</mml:mi><mml:mspace width="0.25em"/><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>H</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mi>c</mml:mi></mml:msubsup><mml:mo>∩</mml:mo><mml:msubsup><mml:mi>H</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow><mml:mi>c</mml:mi></mml:msubsup><mml:mo>∩</mml:mo><mml:msubsup><mml:mi>H</mml:mi><mml:mrow><mml:mn>00</mml:mn></mml:mrow><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives><label>(6)</label></disp-formula>
with <italic toggle="yes">A</italic> denoting the complement of set <italic toggle="yes">A</italic>.</p>
      <p>To conduct IUT, we additionally define <inline-formula id="pcbi.1009250.e013"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e013.jpg" id="pcbi.1009250.e013g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M13" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>0</mml:mn><mml:mi mathvariant="bold-italic">α</mml:mi></mml:msubsup><mml:mo>:</mml:mo><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> versus <inline-formula id="pcbi.1009250.e014"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e014.jpg" id="pcbi.1009250.e014g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M14" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>1</mml:mn><mml:mi mathvariant="bold-italic">α</mml:mi></mml:msubsup><mml:mo>:</mml:mo><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1009250.e015"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e015.jpg" id="pcbi.1009250.e015g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M15" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>0</mml:mn><mml:mi mathvariant="bold-italic">β</mml:mi></mml:msubsup><mml:mo>:</mml:mo><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> versus <inline-formula id="pcbi.1009250.e016"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e016.jpg" id="pcbi.1009250.e016g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M16" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>1</mml:mn><mml:mi mathvariant="bold-italic">β</mml:mi></mml:msubsup><mml:mo>:</mml:mo><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, and suppose the <italic toggle="yes">P</italic>-value obtained from <inline-formula id="pcbi.1009250.e017"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e017.jpg" id="pcbi.1009250.e017g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M17" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>0</mml:mn><mml:mi mathvariant="bold-italic">α</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is <italic toggle="yes">P</italic><sub><bold><italic toggle="yes">α</italic></bold></sub> and the <italic toggle="yes">P</italic>-value obtained from <inline-formula id="pcbi.1009250.e018"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e018.jpg" id="pcbi.1009250.e018g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M18" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>0</mml:mn><mml:mi>β</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is <italic toggle="yes">P</italic><sub><italic toggle="yes">β</italic></sub>. To ensure the desirable type I error control of IUT, we exploit <italic toggle="yes">P</italic><sub>max</sub> = max(<italic toggle="yes">P</italic><sub><bold><italic toggle="yes">α</italic></bold></sub>, <italic toggle="yes">P</italic><sub><italic toggle="yes">β</italic></sub>) to evaluate the overall significance of the mediation effect. IUT is advantageous in that the resulting mediation effect test has conceptual simplicity and feasibility of maneuver, and <italic toggle="yes">P</italic><sub>max</sub>
<italic toggle="yes">per se</italic> can be employed as the <italic toggle="yes">P-</italic>value for assessing the significance of mediation [<xref rid="pcbi.1009250.ref051" ref-type="bibr">51</xref>,<xref rid="pcbi.1009250.ref052" ref-type="bibr">52</xref>,<xref rid="pcbi.1009250.ref055" ref-type="bibr">55</xref>,<xref rid="pcbi.1009250.ref122" ref-type="bibr">122</xref>]. Obviously, when rejecting <italic toggle="yes">H</italic><sub>0</sub> if <italic toggle="yes">P</italic><sub>max</sub> is less than the given significance level of <italic toggle="yes">α</italic>, IUT is indeed a level-<italic toggle="yes">α</italic> test, representing that the type I error of IUT is guaranteed at most <italic toggle="yes">α</italic> once the rejection decision for <italic toggle="yes">H</italic><sub>0</sub> is made [<xref rid="pcbi.1009250.ref047" ref-type="bibr">47</xref>,<xref rid="pcbi.1009250.ref049" ref-type="bibr">49</xref>].</p>
      <p>However, IUT is oftentimes extremely conservative especially when both <inline-formula id="pcbi.1009250.e019"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e019.jpg" id="pcbi.1009250.e019g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M19" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>0</mml:mn><mml:mi mathvariant="bold-italic">α</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1009250.e020"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e020.jpg" id="pcbi.1009250.e020g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M20" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mn>0</mml:mn><mml:mi>β</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (i.e., <italic toggle="yes">H</italic><sub>00</sub>) hold [<xref rid="pcbi.1009250.ref043" ref-type="bibr">43</xref>,<xref rid="pcbi.1009250.ref053" ref-type="bibr">53</xref>], which is particularly true in genome-wide mediation studies where most of molecular markers such as gene expression or DNA methylation may be not expected to be related to the outcome of interest. To our knowledge, the commonly-used Sobel test [<xref rid="pcbi.1009250.ref123" ref-type="bibr">123</xref>,<xref rid="pcbi.1009250.ref124" ref-type="bibr">124</xref>], which is also often overly conservative [<xref rid="pcbi.1009250.ref053" ref-type="bibr">53</xref>,<xref rid="pcbi.1009250.ref125" ref-type="bibr">125</xref>], cannot be directly applicable for examining gene-centric high-dimensional mediation effects. Alternatively, to efficiently correct this conservativeness of IUT, we estimate the proportion for each component of the three null hypotheses and construct a new empirical null distribution for <italic toggle="yes">P</italic><sub>max</sub> by fitting a three-component mixture null distribution (<xref rid="pcbi.1009250.s017" ref-type="supplementary-material">S3 Text</xref>) [<xref rid="pcbi.1009250.ref054" ref-type="bibr">54</xref>]
<disp-formula id="pcbi.1009250.e021"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e021.jpg" id="pcbi.1009250.e021g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M21" display="block" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>u</mml:mi><mml:mo>|</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mi>u</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mi>u</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mn>00</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>u</mml:mi><mml:mo>|</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>β</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>u</mml:mi><mml:mo>|</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(7)</label></disp-formula>
where <italic toggle="yes">κ</italic><sub>10</sub>, <italic toggle="yes">κ</italic><sub>01</sub> and <italic toggle="yes">κ</italic><sub>00</sub> are the proportions corresponding to the three null hypotheses illustrated in (5), <italic toggle="yes">u</italic> is a given threshold value for the significance evaluation, while <italic toggle="yes">p</italic><sub>10</sub> and <italic toggle="yes">p</italic><sub>01</sub> are actually the power of rejecting <bold><italic toggle="yes">a</italic></bold> = 0 under <italic toggle="yes">H</italic><sub>10</sub> or <italic toggle="yes">β</italic> = 0 under <italic toggle="yes">H</italic><sub>01</sub> respectively; and can be estimated via the Grenander method [<xref rid="pcbi.1009250.ref126" ref-type="bibr">126</xref>]. The estimation of these proportion parameters required in (7) can be easily implemented with methods that were well-established in the FDR literature (<xref rid="pcbi.1009250.s018" ref-type="supplementary-material">S4 Text</xref>) [<xref rid="pcbi.1009250.ref029" ref-type="bibr">29</xref>,<xref rid="pcbi.1009250.ref127" ref-type="bibr">127</xref>–<xref rid="pcbi.1009250.ref135" ref-type="bibr">135</xref>]. Once the estimates of these proportions are obtained, the estimated mixture null distribution for <italic toggle="yes">P</italic><sub>max</sub> can be built to control FWER or FDR. A comprehensive theoretical derivation with regards to the control of FWER or FDR can be conferred in [<xref rid="pcbi.1009250.ref054" ref-type="bibr">54</xref>].</p>
      <p>To distinguish from the naïve IUT-based mediation test which takes <italic toggle="yes">P</italic><sub>max</sub> as the statistic and the uniform as the null distribution, we refer to the proposed approach as IUSMMT (intersection-union survival mixture-adjusted mediation test) which exploits the estimated mixture as the null distribution. IUSMMT is freely available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/biostatpzeng/IUSMMT" ext-link-type="uri">https://github.com/biostatpzeng/IUSMMT</ext-link>.</p>
    </sec>
    <sec id="sec022">
      <title>Simulation studies for type I error control and power evaluation</title>
      <p>To evaluate the performance of IUSMMT, we undertake extensive simulations to investigate the type I error control and power. To simulate the truth in practice, we generated the gene expression level (<italic toggle="yes">G</italic>) and the survival outcome with 50 methylation CpG sites (<bold><italic toggle="yes">M</italic></bold>) of <italic toggle="yes">B3GALT4</italic> on 548 BRCA individuals in TCGA [<xref rid="pcbi.1009250.ref023" ref-type="bibr">23</xref>]. Of note, the selection of this gene and this cancer was primarily because the number of methylation CpG sites and the sample size satisfied our simulation settings. Specifically, we first simulated <italic toggle="yes">G</italic> via a linear mixed-effect model with the number of methylation CpG sites varying in terms of a uniform distribution (ranging from 10 to 30, with an average of 20). Two covariates <italic toggle="yes">x</italic><sub>1</sub> (based on the age of the BRCA patients) and <italic toggle="yes">x</italic><sub>2</sub> (based on the cancer stage of the BRCA patients) (<bold><italic toggle="yes">X</italic></bold>) were also included, both having an effect size of 0.5 in the exposure-mediator model
<disp-formula id="pcbi.1009250.e022"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e022.jpg" id="pcbi.1009250.e022g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M22" display="block" overflow="scroll"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mi>α</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mi mathvariant="bold">α</mml:mi><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>α</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="normal">τ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>ε</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(8)</label></disp-formula></p>
      <p>Thereafter, we employed the inverse probability method to create the survival time (i.e. <italic toggle="yes">t</italic>) in terms of the Weibull distribution with a fixed shape parameter λ = 1 and a fixed scale parameter <italic toggle="yes">ρ</italic> = 0.01 [<xref rid="pcbi.1009250.ref136" ref-type="bibr">136</xref>]. The location parameter of the Weibull distribution was determined by <bold><italic toggle="yes">M</italic></bold>, <italic toggle="yes">G</italic> and <bold><italic toggle="yes">X</italic></bold> in the mediator-outcome model
<disp-formula id="pcbi.1009250.e023"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e023.jpg" id="pcbi.1009250.e023g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M23" display="block" overflow="scroll"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi mathvariant="normal">log</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>ρ</mml:mi></mml:mfrac><mml:mi mathvariant="normal">log</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">log</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">λ</mml:mi><mml:mi mathvariant="normal">exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>η</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="0.50em"/><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msubsup><mml:mi mathvariant="normal">γ</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mi>G</mml:mi><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">M</mml:mi><mml:msup><mml:mi mathvariant="bold">γ</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>G</mml:mi><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="0.50em"/><mml:mi>u</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi mathvariant="bold">γ</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msup><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="normal">τ</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(9)</label></disp-formula>
where <italic toggle="yes">u</italic> was a 0–1 uniform variable and τ<sub>3</sub> = 0.02. The censored rate was fixed to be 50% in a random manner (the high censored rate corresponded to the similar situation observed in TCGA cancer dataset; see below).</p>
      <p>To balance the statistical power, we set τ<sub>2</sub> = 0, 0.01, 0.02, 0.04, 0.05 or 0.10 and <italic toggle="yes">β</italic> = 0, 0.15, 0.2, 0.25 or 0.30, and considered various configurations of the two parameters. For each configuration, we set the sample size n = 250, 400 or 548, and generated 10<sup>4</sup> datasets with <bold><italic toggle="yes">M</italic></bold>, G, <italic toggle="yes">X</italic>, and <italic toggle="yes">T</italic>; that is, we had <italic toggle="yes">S</italic> = 10<sup>4</sup> genes (i.e., mediators). Because there were too many possibilities for the effect sizes and the mixture proportions, in the present study we were primarily interested in several cases that matched closely to our context application. Following the previous study [<xref rid="pcbi.1009250.ref054" ref-type="bibr">54</xref>], five scenarios for proportion parameters were designed (<xref rid="pcbi.1009250.s010" ref-type="supplementary-material">S1 Table</xref>), including the dense null under which <italic toggle="yes">κ</italic><sub>11</sub> was set to zero but <italic toggle="yes">κ</italic><sub>10</sub> or (and) <italic toggle="yes">κ</italic><sub>10</sub> had a small value, the sparse null under which<italic toggle="yes">κ</italic><sub>11</sub> was set to zero, but in contrast to the sparse nulls, <italic toggle="yes">κ</italic><sub>00</sub> had a small value, and both <italic toggle="yes">κ</italic><sub>10</sub> and <italic toggle="yes">κ</italic><sub>10</sub> had a relatively large value, the complete null under which<italic toggle="yes">κ</italic><sub>00</sub> was set to one, the sparse alternative under which<italic toggle="yes">κ</italic><sub>11</sub> was not equal to zero, <italic toggle="yes">κ</italic><sub>00</sub> had a large value, and <italic toggle="yes">κ</italic><sub>10</sub> and <italic toggle="yes">κ</italic><sub>10</sub> were set to zero, and the dense alternative under which<italic toggle="yes">κ</italic><sub>11</sub> was not equal to zero, but in contrast to the sparse alternative. The control of type I error was assessed with QQ plot and the power was calculated by the proportion of true positive discoveries among the true mediation effects. We repeated the simulations 100 times and took the average across the replications.</p>
    </sec>
    <sec id="sec023">
      <title>Application to ten TCGA cancer datasets</title>
      <p>We finally applied IUSMMT to ten cancer datasets (<xref rid="pcbi.1009250.s012" ref-type="supplementary-material">S3 Table</xref>) publicly available from TCGA [<xref rid="pcbi.1009250.ref023" ref-type="bibr">23</xref>]. For these cancers, we downloaded their clinical information, RNAseq expressions as well as DNA methylations from UCSC Xena (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://xenabrowser.net/" ext-link-type="uri">https://xenabrowser.net/</ext-link>). DNA methylation levels were determined by Illumina Infinium HumanMethylation 450K platform and gene expression profiles were measured via the Illumina HiSeq 2000 RNA Sequencing platform. For methylation measurements, we removed non-CpG sites (i.e., these probes with <italic toggle="yes">ch</italic> labels) and CpG sites located on sex chromosomes; we also excluded cross-reactive probes as suggested in [<xref rid="pcbi.1009250.ref137" ref-type="bibr">137</xref>]. The beta values of methylation levels were logit-transformed to obtain the M-value for each CpG locus as the M-value is not bounded between zero and one and is thus more valid for our subsequent statistical analysis [<xref rid="pcbi.1009250.ref138" ref-type="bibr">138</xref>]. For each cancer, we focused on patients of self-report European ancestry while excluding patients whose tissues were formalin-fixed and paraffin-embedded. For gene expression measurements, we only considered protein coding genes and removed genes with over 50% zero expressions and variances smaller than 20% quantile of expression values. Then, we yielded methylation-expression pair for each gene in terms of the position annotation file provided by UCSC Xena. In each gene pair, we standardized both DNA methylation and expression level so that methylation and expression have a mean zero and variance one. According to TCGA gene annotation mapping file, we defined in our analysis methylations as those located within the entire gene body and a 500 bps upstream of the transcription start site (TSS) so that the promoter can be included. The distance of 500 bps is to some extent arbitrary and experience-based. In fact, the optimal extension distance upstream of TSS is not clear and various choices were applied in prior literature [<xref rid="pcbi.1009250.ref139" ref-type="bibr">139</xref>]. To examine the robustness of various extension distances, we performed a sensitivity analysis by incorporating methylation CpG sites within distinct extended regions, and found that the extension of the distance upstream of TSS in defining methylation loci seems to be very robust and has little influence on our final identification of mediating genes for methylation levels measured with the 450K platform (<xref rid="pcbi.1009250.s009" ref-type="supplementary-material">S9 Fig</xref>).</p>
      <p>In addition, some clinical covariates available with only a few missing values, such as gender (coded as 0 or 1), age (treated as continuous variable), stage (coded from 1 to 5 and treated as continuous variable), estrogen receptor status (ER) (coded as 0 or 1) and progesterone receptor status (PR) (coded as 0 or 1), were also considered. We had to ignore other common covariates (e.g., alcohol consumption) that had too many missing values although they may be also greatly important. For the remaining datasets, the missing values were simply imputed by the mean if any. Notably, some of these covariates were cancer type-specific (e.g., ER and PR). Following previous studies [<xref rid="pcbi.1009250.ref038" ref-type="bibr">38</xref>,<xref rid="pcbi.1009250.ref140" ref-type="bibr">140</xref>–<xref rid="pcbi.1009250.ref143" ref-type="bibr">143</xref>], we employed the overall survival time and the corresponding survival status as the outcome as there was minimal ambiguity in defining an overall survival event [<xref rid="pcbi.1009250.ref144" ref-type="bibr">144</xref>]. In brief, overall survival in TCGA was the duration from the diagnosis of cancer to the death of patients. The employed TCGA cancer datasets and data process are summarized in <xref rid="pcbi.1009250.s011" ref-type="supplementary-material">S2</xref> and <xref rid="pcbi.1009250.s013" ref-type="supplementary-material">S4</xref> Tables.</p>
    </sec>
    <sec id="sec024">
      <title>Identify passenger methylation event via MultiSKAT</title>
      <p>To distinguish passenger methylation events from mediation methylation events that are likely to have a direct or indirect (via expression mediation) influence on the survival risk of cancers, we here assume the gene expression may affect a set of DNA methylations and perform a reverse analysis by regressing methylation measurements on expression for all the identified mediating genes based on a multivariate model
<disp-formula id="pcbi.1009250.e024"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e024.jpg" id="pcbi.1009250.e024g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M24" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mrow><mml:mi>G</mml:mi><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mover accent="true"><mml:mi mathvariant="bold">W</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mover accent="true"><mml:mi mathvariant="bold">ε</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mi>G</mml:mi><mml:mover accent="true"><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:msub><mml:mover accent="true"><mml:mi mathvariant="bold">W</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mover accent="true"><mml:mi mathvariant="bold">ε</mml:mi><mml:mo>˜</mml:mo></mml:mover></mml:mrow></mml:math></alternatives><label>(10)</label></disp-formula>
where <inline-formula id="pcbi.1009250.e025"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e025.jpg" id="pcbi.1009250.e025g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M25" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>˜</mml:mo></mml:mover></mml:math></alternatives></inline-formula> = <inline-formula id="pcbi.1009250.e026"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e026.jpg" id="pcbi.1009250.e026g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M26" display="inline" overflow="scroll"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mi>K</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> denotes the vector of effect sizes of gene expression on DNA methylation sites, <inline-formula id="pcbi.1009250.e027"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e027.jpg" id="pcbi.1009250.e027g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M27" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi mathvariant="bold">W</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> is the matrix of effect sizes for covariates, and <inline-formula id="pcbi.1009250.e028"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e028.jpg" id="pcbi.1009250.e028g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M28" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi mathvariant="bold">ε</mml:mi><mml:mo>˜</mml:mo></mml:mover></mml:math></alternatives></inline-formula> is the matrix of residual error terms. We further suppose that each <inline-formula id="pcbi.1009250.e029"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e029.jpg" id="pcbi.1009250.e029g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M29" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>˜</mml:mo></mml:mover><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (<italic toggle="yes">k</italic> = 1, …, <italic toggle="yes">K</italic>) follows a normal distribution with mean zero and variance <italic toggle="yes">τ</italic>. Then, our objective is to test for the null hypothesis <italic toggle="yes">H</italic><sub>0</sub>: <inline-formula id="pcbi.1009250.e030"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e030.jpg" id="pcbi.1009250.e030g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M30" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>˜</mml:mo></mml:mover></mml:math></alternatives></inline-formula> = 0, which is equivalent to examining <italic toggle="yes">H</italic><sub>0</sub>: <italic toggle="yes">τ</italic> = 0. The corresponding variance component score test statistic is given as
<disp-formula id="pcbi.1009250.e031"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e031.jpg" id="pcbi.1009250.e031g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M31" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msup><mml:mi>G</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mo>−</mml:mo><mml:mover accent="true"><mml:mi mathvariant="bold-italic">μ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo><mml:msup><mml:mover accent="true"><mml:mi mathvariant="bold">V</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mo>{</mml:mo><mml:mrow><mml:msup><mml:mi>G</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mo>−</mml:mo><mml:mover accent="true"><mml:mi mathvariant="bold-italic">μ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo><mml:msup><mml:mover accent="true"><mml:mi mathvariant="bold">V</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:math></alternatives><label>(11)</label></disp-formula>
where <inline-formula id="pcbi.1009250.e032"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e032.jpg" id="pcbi.1009250.e032g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M32" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi mathvariant="bold-italic">μ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1009250.e033"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.e033.jpg" id="pcbi.1009250.e033g" position="anchor"/><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M33" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi mathvariant="bold">V</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></alternatives></inline-formula> are the estimated mean and covariance of <bold><italic toggle="yes">M</italic></bold> under the null hypothesis. Then, the test statistic <italic toggle="yes">Q</italic><sub><italic toggle="yes">M</italic></sub> follows a mixture of chi-square distribution and this test can be implemented via MultiSKAT [<xref rid="pcbi.1009250.ref072" ref-type="bibr">72</xref>].</p>
    </sec>
  </sec>
  <sec id="sec025" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pcbi.1009250.s001" position="float" content-type="local-data">
      <label>S1 Fig</label>
      <caption>
        <title>Estimated power for <italic toggle="yes">α</italic> and <italic toggle="yes">β</italic>.</title>
        <p>These powers are estimated under six alternative simulation scenarios from A to I with various mixture proportions. The graph in the left column is the power of <italic toggle="yes">β</italic>, and the x-axis is the value of <italic toggle="yes">β</italic> = 0.15, 0.20, 0.25 or 0.30; The graph in the left column is the power of <italic toggle="yes">α</italic>, and the x-axis is the value of τ<sub>2</sub> = 0.01, 0.02, 0.04, 0.05 or 0.10. These powers are estimated by the average across the 100 replications.</p>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s001.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s002" position="float" content-type="local-data">
      <label>S2 Fig</label>
      <caption>
        <title>QQ plot for IUSMMT and IUT under various the scenarios of nulls and sample sizes.</title>
        <p>Here (A), (B) and (C) represent the sample size n = 250, 400 and 548, respectively.</p>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s002.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s003" position="float" content-type="local-data">
      <label>S3 Fig</label>
      <caption>
        <title>Estimated power for IUSMMT and the IUT method.</title>
        <p>Here, τ<sub>2</sub> = 0.01, 0.02, 0.04, 0.05 or 0.10 at the x-axis, β = 0.15, 0.20, 0.25 or 0.30 on the top. These powers are estimated for the nine alternative simulation scenarios from A to I with various values for the mixture proportions by the average across the 100 replications. (A), (B) and (C) represent the sample size n = 250, 400 and 548, respectively.</p>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s003.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s004" position="float" content-type="local-data">
      <label>S4 Fig</label>
      <caption>
        <title>QQ plot for the mediation effect test statistic <italic toggle="yes">P</italic><sub>max</sub> for 10 TCGA cancers.</title>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s004.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s005" position="float" content-type="local-data">
      <label>S5 Fig</label>
      <caption>
        <p><bold>(</bold>A<bold>) Proportion of overlapped methylation-regulated genes discovered in various cancer tumor tissues and these discovered in normal tissue. (</bold>B<bold>) Estimated values of τ</bold><sub><bold>2</bold></sub><bold>in the BRCA tissue and in the normal tissue.</bold> Here, τ<sub>2</sub> can be employed to quantify the magnitude of the methylation effect on expression, the sample size for the normal tissue is combined and analyzed across all the 10 cancers.</p>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s005.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s006" position="float" content-type="local-data">
      <label>S6 Fig</label>
      <caption>
        <title>Partial mediation framework of <italic toggle="yes">ZNF763</italic> for CESC.</title>
        <p>Please refer to <xref rid="pcbi.1009250.g001" ref-type="fig">Fig 1</xref> for the interpretation of these parameters shown herein.</p>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s006.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s007" position="float" content-type="local-data">
      <label>S7 Fig</label>
      <caption>
        <title>Results of KEGG pathway enrichment analysis and the significant terms identified by GO enrichment analysis for the genes.</title>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s007.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s008" position="float" content-type="local-data">
      <label>S8 Fig</label>
      <caption>
        <title>Number of methylation markers belonging to each gene across the while genome in TCGA cancer in terms of the annotation mapping file provided by UCSC Xena.</title>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s008.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s009" position="float" content-type="local-data">
      <label>S9 Fig</label>
      <caption>
        <title>Correlation between <italic toggle="yes">P</italic>-values (in–log10 scale) of the methylation-expression association for all genes with meditation effects with various distances before the transcription start site (TSS) so that the promoter can be included.</title>
        <p>Here, various distances before the TSS were extended, ranging from 500bp to 5000bp with an increment of 500bp. For each extension, the methylations within that extended region and gene body were included to examine their relationship with gene expression using the variance-component score test. The <italic toggle="yes">P</italic>-values calculated with methylations within a 500bp upstream of the TSS were treated as the reference.</p>
        <p>(TIF)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s009.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s010" position="float" content-type="local-data">
      <label>S1 Table</label>
      <caption>
        <title>Estimated and true proportion parameters (mean and standard deviation) in the three-component mixture null distribution under the five simulation scenarios and different sample sizes and different numbers of mediators.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s010.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s011" position="float" content-type="local-data">
      <label>S2 Table</label>
      <caption>
        <title>Comparison of the effect of different numbers of mediators on the bias of the estimators for these proportion parameters.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s011.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s012" position="float" content-type="local-data">
      <label>S3 Table</label>
      <caption>
        <title>Data process of the ten TCGA cancers used in our mediation analysis.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s012.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s013" position="float" content-type="local-data">
      <label>S4 Table</label>
      <caption>
        <title>Basic characteristics of the ten TCGA cancer datasets.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s013.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s014" position="float" content-type="local-data">
      <label>S5 Table</label>
      <caption>
        <title>Results for testing for the proportional hazards assumption in the used Cox model.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s014.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s015" position="float" content-type="local-data">
      <label>S1 Text</label>
      <caption>
        <title>Effects in survival mediation analysis with multiple exposures, and identifiability assumptions.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s015.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s016" position="float" content-type="local-data">
      <label>S2 Text</label>
      <caption>
        <title>Intersection-union test.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s016.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s017" position="float" content-type="local-data">
      <label>S3 Text</label>
      <caption>
        <title>Three-component mixture null distribution.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s017.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s018" position="float" content-type="local-data">
      <label>S4 Text</label>
      <caption>
        <title>Estimation of proportion parameters.</title>
        <p>(DOCX)</p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s018.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>We would like to express our gratitude to TCGA for making genomic datasets publicly available and are indebted to all the investigators and participants contributed to this project. Data analyses and simulations in the present study were carried out with the high-performance computing cluster that was supported by the special central finance project of local universities for Xuzhou Medical University.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="pcbi.1009250.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Xiong</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Huang</surname><given-names>K</given-names></name>, <name><surname>Lu</surname><given-names>M</given-names></name>, <name><surname>Shi</surname><given-names>H</given-names></name>, <name><surname>Ma</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Association between DAPK1 promoter methylation and cervical cancer: a meta-analysis</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>9</issue>):<fpage>e107272</fpage>–e. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0107272</pub-id> .<?supplied-pmid 25268905?><pub-id pub-id-type="pmid">25268905</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Baylin</surname><given-names>SB</given-names></name>. <article-title>The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications</article-title>. <source>Proc Am Thorac Soc</source>. <year>2012</year>;<volume>9</volume>(<issue>2</issue>):<fpage>64</fpage>–<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1513/pats.201201-001MS</pub-id> .<?supplied-pmid 22550245?><pub-id pub-id-type="pmid">22550245</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Momparler</surname><given-names>RL</given-names></name>, <name><surname>Bovenzi</surname><given-names>V</given-names></name>. <article-title>DNA methylation and cancer</article-title>. <source>J Cell Physiol</source>. <year>2000</year>;<volume>183</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>54</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/(SICI)1097-4652(200005)183:2&amp;lt;145::AID-JCP1&amp;gt;3.0.CO;2-V</pub-id><?supplied-pmid 10737890?><pub-id pub-id-type="pmid">10737890</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><name><surname>Busslinger</surname><given-names>M</given-names></name>, <name><surname>Hurst</surname><given-names>J</given-names></name>, <name><surname>Flavell</surname><given-names>RA</given-names></name>. <article-title>DNA methylation and the regulation of globin gene expression</article-title>. <source>Cell</source>. <year>1983</year>;<volume>34</volume>(<issue>1</issue>):<fpage>197</fpage>–<lpage>206</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0092-8674(83)90150-2</pub-id> .<?supplied-pmid 6883509?><pub-id pub-id-type="pmid">6883509</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Deaton</surname><given-names>AM</given-names></name>, <name><surname>Bird</surname><given-names>A</given-names></name>. <article-title>CpG islands and the regulation of transcription</article-title>. <source>Genes Dev</source>. <year>2011</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1010</fpage>–<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/gad.2037511</pub-id> .<?supplied-pmid 21576262?><pub-id pub-id-type="pmid">21576262</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>LD</given-names></name>, <name><surname>Le</surname><given-names>T</given-names></name>, <name><surname>Fan</surname><given-names>G</given-names></name>. <article-title>DNA methylation and its basic function</article-title>. <source>Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology</source>. <year>2013</year>;<volume>38</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>38</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/npp.2012.112</pub-id> .<?supplied-pmid 22781841?><pub-id pub-id-type="pmid">22781841</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>JR</given-names></name>, <name><surname>Busche</surname><given-names>S</given-names></name>, <name><surname>Ge</surname><given-names>B</given-names></name>, <name><surname>Kwan</surname><given-names>T</given-names></name>, <name><surname>Pastinen</surname><given-names>T</given-names></name>, <name><surname>Blanchette</surname><given-names>M</given-names></name>. <article-title>The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts</article-title>. <source>Genome Biol</source>. <year>2014</year>;<volume>15</volume>(<issue>2</issue>):<fpage>R37</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/gb-2014-15-2-r37</pub-id><?supplied-pmid 24555846?><pub-id pub-id-type="pmid">24555846</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref008">
      <label>8</label>
      <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>WY</given-names></name>, <name><surname>Hsu</surname><given-names>SD</given-names></name>, <name><surname>Huang</surname><given-names>HY</given-names></name>, <name><surname>Sun</surname><given-names>YM</given-names></name>, <name><surname>Chou</surname><given-names>CH</given-names></name>, <name><surname>Weng</surname><given-names>SL</given-names></name>, <etal>et al</etal>. <article-title>MethHC: a database of DNA methylation and gene expression in human cancer</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>;<volume>43</volume>(Database issue):<fpage>D856</fpage>–<lpage>61</lpage>. Epub 2014/11/16. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gku1151</pub-id> ; PubMed Central PMCID: PMC4383953.<?supplied-pmid 25398901?><pub-id pub-id-type="pmid">25398901</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref009">
      <label>9</label>
      <mixed-citation publication-type="journal"><name><surname>Schübeler</surname><given-names>D</given-names></name>. <article-title>Function and information content of DNA methylation.</article-title><source>Nature</source>. <year>2015</year>;<volume>517</volume>(<issue>7534</issue>):<fpage>321</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature14192</pub-id><?supplied-pmid 25592537?><pub-id pub-id-type="pmid">25592537</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref010">
      <label>10</label>
      <mixed-citation publication-type="journal"><name><surname>Das</surname><given-names>PM</given-names></name>, <name><surname>Singal</surname><given-names>R</given-names></name>. <article-title>DNA Methylation and Cancer.</article-title><source>J Clin Oncol</source>. <year>2004</year>;<volume>22</volume>(<issue>22</issue>):<fpage>4632</fpage>–<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1200/JCO.2004.07.151</pub-id> .<?supplied-pmid 15542813?><pub-id pub-id-type="pmid">15542813</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref011">
      <label>11</label>
      <mixed-citation publication-type="journal"><name><surname>Blake</surname><given-names>LE</given-names></name>, <name><surname>Roux</surname><given-names>J</given-names></name>, <name><surname>Hernando-Herraez</surname><given-names>I</given-names></name>, <name><surname>Banovich</surname><given-names>NE</given-names></name>, <name><surname>Perez</surname><given-names>RG</given-names></name>, <name><surname>Hsiao</surname><given-names>CJ</given-names></name>, <etal>et al</etal>. <article-title>A comparison of gene expression and DNA methylation patterns across tissues and species</article-title>. <source>Genome Res</source>. <year>2020</year>;<volume>30</volume>(<issue>2</issue>):<fpage>250</fpage>–<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/gr.254904.119</pub-id><?supplied-pmid 31953346?><pub-id pub-id-type="pmid">31953346</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref012">
      <label>12</label>
      <mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>DL</given-names></name>, <name><surname>Jackson</surname><given-names>AU</given-names></name>, <name><surname>Narisu</surname><given-names>N</given-names></name>, <name><surname>Hemani</surname><given-names>G</given-names></name>, <name><surname>Erdos</surname><given-names>MR</given-names></name>, <name><surname>Chines</surname><given-names>PS</given-names></name>, <etal>et al</etal>. <article-title>Integrative analysis of gene expression, DNA methylation, physiological traits, and genetic variation in human skeletal muscle</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2019</year>;<volume>116</volume>(<issue>22</issue>):<fpage>10883</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1814263116</pub-id><?supplied-pmid 31076557?><pub-id pub-id-type="pmid">31076557</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref013">
      <label>13</label>
      <mixed-citation publication-type="journal"><name><surname>Gong</surname><given-names>J</given-names></name>, <name><surname>Wan</surname><given-names>H</given-names></name>, <name><surname>Mei</surname><given-names>S</given-names></name>, <name><surname>Ruan</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Liu</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Pancan-meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer</article-title>. <source>Nucleic Acids Res</source>. <year>2019</year>;<volume>47</volume>(<issue>D1</issue>):<fpage>D1066</fpage>–<lpage>D72</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gky814</pub-id> .<?supplied-pmid 30203047?><pub-id pub-id-type="pmid">30203047</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref014">
      <label>14</label>
      <mixed-citation publication-type="journal"><name><surname>Dermitzakis</surname><given-names>ET</given-names></name>. <article-title>From gene expression to disease risk</article-title>. <source>Nat Genet</source>. <year>2008</year>;<volume>40</volume>(<issue>5</issue>):<fpage>492</fpage>–<lpage>3</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ng0508-492</pub-id><?supplied-pmid 18443581?><pub-id pub-id-type="pmid">18443581</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref015">
      <label>15</label>
      <mixed-citation publication-type="journal"><collab>GTEx Consortium</collab>. <article-title>Genetic effects on gene expression across human tissues</article-title>. <source>Nature</source>. <year>2017</year>;<volume>550</volume>(<issue>7675</issue>):<fpage>204</fpage>–<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature24277</pub-id><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nature.com/nature/journal/v550/n7675/abs/nature24277.html#supplementary-information" ext-link-type="uri">http://www.nature.com/nature/journal/v550/n7675/abs/nature24277.html#supplementary-information</ext-link>. <?supplied-pmid 29022597?><pub-id pub-id-type="pmid">29022597</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref016">
      <label>16</label>
      <mixed-citation publication-type="journal"><collab>GTEx Consortium</collab>. <article-title>The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans.</article-title><source>Science</source>. <year>2015</year>;<volume>348</volume>(<issue>6235</issue>):<fpage>648</fpage>–<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1262110</pub-id><?supplied-pmid 25954001?><pub-id pub-id-type="pmid">25954001</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref017">
      <label>17</label>
      <mixed-citation publication-type="journal"><name><surname>Emilsson</surname><given-names>V</given-names></name>, <name><surname>Thorleifsson</surname><given-names>G</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <name><surname>Leonardson</surname><given-names>AS</given-names></name>, <name><surname>Zink</surname><given-names>F</given-names></name>, <name><surname>Zhu</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Genetics of gene expression and its effect on disease</article-title>. <source>Nature</source>. <year>2008</year>;<volume>452</volume>(<issue>7186</issue>):<fpage>423</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature06758</pub-id><?supplied-pmid 18344981?><pub-id pub-id-type="pmid">18344981</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref018">
      <label>18</label>
      <mixed-citation publication-type="book"><name><surname>MacKinnon</surname><given-names>DP</given-names></name>. <source>Introduction to statistical mediation analysis:</source><publisher-name>Routledge</publisher-name>; <year>2008</year>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref019">
      <label>19</label>
      <mixed-citation publication-type="book"><name><surname>VanderWeele</surname><given-names>T.</given-names></name><source>Explanation in causal inference: methods for mediation and interaction:</source><publisher-name>Oxford University Press</publisher-name>; <year>2015</year>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref020">
      <label>20</label>
      <mixed-citation publication-type="journal"><name><surname>Imai</surname><given-names>K</given-names></name>, <name><surname>Keele</surname><given-names>L</given-names></name>, <name><surname>Tingley</surname><given-names>D</given-names></name>. <article-title>A general approach to causal mediation analysis.</article-title><source>Psychol Methods</source>. <year>2010</year>;<volume>15</volume>(<issue>4</issue>):<fpage>309</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/a0020761</pub-id><?supplied-pmid 20954780?><pub-id pub-id-type="pmid">20954780</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref021">
      <label>21</label>
      <mixed-citation publication-type="journal"><name><surname>Hicks</surname><given-names>R</given-names></name>, <name><surname>Tingley</surname><given-names>D</given-names></name>. <article-title>Causal mediation analysis</article-title>. <source>The Stata Journal</source>. <year>2011</year>;<volume>11</volume>(<issue>4</issue>):<fpage>605</fpage>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref022">
      <label>22</label>
      <mixed-citation publication-type="journal"><name><surname>Baron</surname><given-names>RM</given-names></name>, <name><surname>Kenny</surname><given-names>DA</given-names></name>. <article-title>The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.</article-title><source>J Pers Soc Psychol</source>. <year>1986</year>;<volume>51</volume>(<issue>6</issue>):<fpage>1173</fpage>–<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037//0022-3514.51.6.1173</pub-id><?supplied-pmid 3806354?><pub-id pub-id-type="pmid">3806354</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref023">
      <label>23</label>
      <mixed-citation publication-type="journal"><name><surname>Hoadley</surname><given-names>KA</given-names></name>, <name><surname>Yau</surname><given-names>C</given-names></name>, <name><surname>Hinoue</surname><given-names>T</given-names></name>, <name><surname>Wolf</surname><given-names>DM</given-names></name>, <name><surname>Lazar</surname><given-names>AJ</given-names></name>, <name><surname>Drill</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer</article-title>. <source>Cell</source>. <year>2018</year>;<volume>173</volume>(<issue>2</issue>):<fpage>291</fpage>–<lpage>304</lpage>.e6. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.022</pub-id> .<?supplied-pmid 29625048?><pub-id pub-id-type="pmid">29625048</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref024">
      <label>24</label>
      <mixed-citation publication-type="book"><name><surname>Tein</surname><given-names>J-Y</given-names></name>, <name><surname>MacKinnon</surname><given-names>DP</given-names></name>, editors. <source>Estimating Mediated Effects with Survival Data. New Developments in Psychometrics</source>; <year>2003</year> 2003//; <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Springer Japan</publisher-name>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref025">
      <label>25</label>
      <mixed-citation publication-type="journal"><name><surname>Lange</surname><given-names>T</given-names></name>, <name><surname>Hansen</surname><given-names>JV</given-names></name>. <article-title>Direct and Indirect Effects in a Survival Context.</article-title><source>Epidemiology.</source><year>2011</year>;<volume>22</volume>(<issue>4</issue>):<fpage>575</fpage>–<lpage>81</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/EDE.0b013e31821c680c</pub-id> 00001648-201107000-00024. <?supplied-pmid 21552129?><pub-id pub-id-type="pmid">21552129</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref026">
      <label>26</label>
      <mixed-citation publication-type="journal"><name><surname>VanderWeele</surname><given-names>TJ</given-names></name>. <article-title>Causal mediation analysis with survival data.</article-title><source>Epidemiology</source>. <year>2011</year>;<volume>22</volume>(<issue>4</issue>):<fpage>582</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/EDE.0b013e31821db37e</pub-id><?supplied-pmid 21642779?><pub-id pub-id-type="pmid">21642779</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref027">
      <label>27</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>. <article-title>Estimating and Testing Mediation Effects with Censored Data.</article-title><source>Structural Equation Modeling: A Multidisciplinary Journal.</source><year>2011</year>;<volume>18</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/10705511.2011.534324</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref028">
      <label>28</label>
      <mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>C</given-names></name>, <name><surname>Fa</surname><given-names>B</given-names></name>, <name><surname>Yan</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>High-dimensional mediation analysis in survival models.</article-title><source>PLoS Comput Biol</source>. <year>2020</year>;<volume>16</volume>(<issue>4</issue>):<fpage>e1007768</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007768</pub-id><?supplied-pmid 32302299?><pub-id pub-id-type="pmid">32302299</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref029">
      <label>29</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Zheng</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Gao</surname><given-names>T</given-names></name>, <name><surname>Joyce</surname><given-names>B</given-names></name>, <name><surname>Yoon</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Estimating and testing high-dimensional mediation effects in epigenetic studies</article-title>. <source>Bioinformatics</source>. <year>2016</year>;<volume>32</volume>(<issue>20</issue>):<fpage>3150</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btw351</pub-id><?supplied-pmid 27357171?><pub-id pub-id-type="pmid">27357171</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref030">
      <label>30</label>
      <mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>P</given-names></name>, <name><surname>Shao</surname><given-names>Z</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>. <article-title>Statistical methods for mediation analysis in the era of high-throughput genomics: current successes and future challenges.</article-title><source>Computational and Structural Biotechnology Journal</source>. <year>2021</year>;in press. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.csbj.2021.05.042</pub-id>.<?supplied-pmid 34141140?><pub-id pub-id-type="pmid">34141140</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref031">
      <label>31</label>
      <mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>MC</given-names></name>, <name><surname>Kraft</surname><given-names>P</given-names></name>, <name><surname>Epstein</surname><given-names>MP</given-names></name>, <name><surname>Taylor</surname><given-names>DM</given-names></name>, <name><surname>Chanock</surname><given-names>SJ</given-names></name>, <name><surname>Hunter</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. <article-title>Powerful SNP-Set Analysis for Case-Control Genome-wide Association Studies</article-title>. <source>Am J Hum Genet</source>. <year>2010</year>;<volume>86</volume>(<issue>6</issue>):<fpage>929</fpage>–<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajhg.2010.05.002</pub-id><?supplied-pmid 20560208?><pub-id pub-id-type="pmid">20560208</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref032">
      <label>32</label>
      <mixed-citation publication-type="journal"><name><surname>Wu Michael</surname><given-names>C</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Cai</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Boehnke</surname><given-names>M</given-names></name>, <name><surname>Lin</surname><given-names>X</given-names></name>. <article-title>Rare-Variant Association Testing for Sequencing Data with the Sequence Kernel Association Test</article-title>. <source>Am J Hum Genet</source>. <year>2011</year>;<volume>89</volume>(<issue>1</issue>):<fpage>82</fpage>–<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.05.029</pub-id><?supplied-pmid 21737059?><pub-id pub-id-type="pmid">21737059</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref033">
      <label>33</label>
      <mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>P</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Likelihood Ratio Tests in Rare Variant Detection for Continuous Phenotypes</article-title>. <source>Ann Hum Genet</source>. <year>2014</year>;<volume>78</volume>(<issue>5</issue>):<fpage>320</fpage>–<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/ahg.12071</pub-id><?supplied-pmid 25117149?><pub-id pub-id-type="pmid">25117149</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref034">
      <label>34</label>
      <mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>P</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>. <article-title>Permutation-based variance component test in generalized linear mixed model with application to multilocus genetic association study.</article-title><source>BMC Med Res Methodol</source>. <year>2015</year>;<volume>15</volume>:<fpage>37</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12874-015-0030-1</pub-id><?supplied-pmid 25897803?><pub-id pub-id-type="pmid">25897803</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref035">
      <label>35</label>
      <mixed-citation publication-type="journal"><name><surname>Therneau</surname><given-names>TM</given-names></name>, <name><surname>Grambsch</surname><given-names>PM</given-names></name>, <name><surname>Pankratz</surname><given-names>VS</given-names></name>. <article-title>Penalized survival models and frailty</article-title>. <source>J Comput Graph Statist</source>. <year>2003</year>;<volume>12</volume>:<fpage>156</fpage>–<lpage>75</lpage>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref036">
      <label>36</label>
      <mixed-citation publication-type="journal"><name><surname>Ripatti</surname><given-names>S</given-names></name>, <name><surname>Palmgren</surname><given-names>J</given-names></name>. <article-title>Estimation of Multivariate Frailty Models Using Penalized Partial Likelihood</article-title>. <source>Biometrics</source>. <year>2000</year>;<volume>56</volume>(<issue>4</issue>):<fpage>1016</fpage>–<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.0006-341x.2000.01016.x</pub-id><?supplied-pmid 11129456?><pub-id pub-id-type="pmid">11129456</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref037">
      <label>37</label>
      <mixed-citation publication-type="book"><name><surname>Therneau</surname><given-names>TM</given-names></name>, <name><surname>Grambsch</surname><given-names>PM</given-names></name>. <source>Modelling Survival Data: Extending the Cox Model</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2000</year>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref038">
      <label>38</label>
      <mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Huang</surname><given-names>S</given-names></name>, <name><surname>Zeng</surname><given-names>P</given-names></name>. <article-title>How can gene expression information improve prognostic prediction in TCGA cancers: an empirical comparison study on regularization and mixed-effect survival models.</article-title><source>Frontiers in Genetics</source>. <year>2020</year>;<volume>11</volume>(<issue>920</issue>). <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fgene.2020.00920</pub-id><?supplied-pmid 32973875?><pub-id pub-id-type="pmid">32973875</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref039">
      <label>39</label>
      <mixed-citation publication-type="journal"><name><surname>VanderWeele</surname><given-names>TJ</given-names></name>. <article-title>Mediation analysis: a practitioner’s guide.</article-title><source>Annu Rev Public Health</source>. <year>2016</year>;<volume>37</volume>:<fpage>17</fpage>–<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev-publhealth-032315-021402</pub-id><?supplied-pmid 26653405?><pub-id pub-id-type="pmid">26653405</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref040">
      <label>40</label>
      <mixed-citation publication-type="journal"><name><surname>Robins</surname><given-names>JM</given-names></name>, <name><surname>Greenland</surname><given-names>S</given-names></name>. <article-title>Identifiability and exchangeability for direct and indirect effects.</article-title><source>Epidemiology</source>. <year>1992</year>:<fpage>143</fpage>–<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/00001648-199203000-00013</pub-id><?supplied-pmid 1576220?><pub-id pub-id-type="pmid">1576220</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref041">
      <label>41</label>
      <mixed-citation publication-type="journal"><name><surname>MacKinnon</surname><given-names>DP</given-names></name>, <name><surname>Fairchild</surname><given-names>AJ</given-names></name>, <name><surname>Fritz</surname><given-names>MS</given-names></name>. <article-title>Mediation analysis.</article-title><source>Annu Rev Psychol</source>. <year>2007</year>;<volume>58</volume>:<fpage>593</fpage>–<lpage>614</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev.psych.58.110405.085542</pub-id><?supplied-pmid 16968208?><pub-id pub-id-type="pmid">16968208</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref042">
      <label>42</label>
      <mixed-citation publication-type="journal"><name><surname>Imai</surname><given-names>K</given-names></name>, <name><surname>Keele</surname><given-names>L</given-names></name>, <name><surname>Yamamoto</surname><given-names>T</given-names></name>. <article-title>Identification, inference and sensitivity analysis for causal mediation effects.</article-title><source>Stat Sci</source>. <year>2010</year>;<volume>25</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>71</lpage>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref043">
      <label>43</label>
      <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>Y-T</given-names></name>. <article-title>Genome-wide analyses of sparse mediation effects under composite null hypotheses.</article-title><source>The Annals of Applied Statistics</source>. <year>2019</year>;<volume>13</volume>(<issue>1</issue>):<fpage>60</fpage>–<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1214/18-aoas1181</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref044">
      <label>44</label>
      <mixed-citation publication-type="journal"><name><surname>Pearl</surname><given-names>J.</given-names></name><article-title>The causal mediation formula—a guide to the assessment of pathways and mechanisms.</article-title><source>Prev Sci</source>. <year>2012</year>;<volume>13</volume>(<issue>4</issue>):<fpage>426</fpage>–<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11121-011-0270-1</pub-id><?supplied-pmid 22419385?><pub-id pub-id-type="pmid">22419385</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref045">
      <label>45</label>
      <mixed-citation publication-type="journal"><name><surname>Pearl</surname><given-names>J</given-names></name>. <article-title>Interpretation and identification of causal mediation.</article-title><source>Psychol Methods</source>. <year>2014</year>;<volume>19</volume>(<issue>4</issue>):<fpage>459</fpage>–<lpage>81</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/a0036434</pub-id> .<?supplied-pmid 24885338?><pub-id pub-id-type="pmid">24885338</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref046">
      <label>46</label>
      <mixed-citation publication-type="journal"><name><surname>Berger</surname><given-names>RL</given-names></name>. <article-title>Uniformly More Powerful Tests for Hypotheses concerning Linear Inequalities and Normal Means</article-title>. <source>J Am Stat Assoc</source>. <year>1989</year>;<volume>84</volume>(<issue>405</issue>):<fpage>192</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/01621459.1989.10478755</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref047">
      <label>47</label>
      <mixed-citation publication-type="journal"><name><surname>Berger</surname><given-names>RL</given-names></name>. <article-title>Multiparameter Hypothesis Testing and Acceptance Sampling.</article-title><source>Technometrics</source>. <year>1982</year>;<volume>24</volume>(<issue>4</issue>):<fpage>295</fpage>–<lpage>300</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00401706.1982.10487790</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref048">
      <label>48</label>
      <mixed-citation publication-type="journal"><name><surname>Sen</surname><given-names>PK</given-names></name>, <name><surname>Tsai</surname><given-names>M-T</given-names></name>. <article-title>Two-Stage Likelihood Ratio and Union–Intersection Tests for One-Sided Alternatives Multivariate Mean with Nuisance Dispersion Matrix</article-title>. <source>J Multivariate Anal</source>. <year>1999</year>;<volume>68</volume>(<issue>2</issue>):<fpage>264</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1006/jmva.1998.1791</pub-id>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref049">
      <label>49</label>
      <mixed-citation publication-type="journal"><name><surname>Berger</surname><given-names>RL</given-names></name>, <name><surname>Hsu</surname><given-names>JC</given-names></name>. <article-title>Bioequivalence trials, intersection-union tests and equivalence confidence sets.</article-title><source>Stat Sci</source>. <year>1996</year>;<volume>11</volume>(<issue>4</issue>):<fpage>283</fpage>–<lpage>319</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1214/ss/1032280304</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref050">
      <label>50</label>
      <mixed-citation publication-type="book"><name><surname>Berger</surname><given-names>RL</given-names></name>. <source>Likelihood Ratio Tests and Intersection-Union Tests.</source> In: <name><surname>Panchapakesan</surname><given-names>S</given-names></name>, <name><surname>Balakrishnan</surname><given-names>N</given-names></name>, editors. <part-title>Advances in Statistical Decision Theory and Applications.</part-title>
<publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Birkhäuser Boston</publisher-name>; <year>1997</year>. p. <fpage>225</fpage>–<lpage>37</lpage>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref051">
      <label>51</label>
      <mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Fang</surname><given-names>R</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Goode</surname><given-names>EL</given-names></name>, <name><surname>Cui</surname><given-names>Y</given-names></name>. <article-title>Testing Mediation Effects in High-Dimensional Epigenetic Studies.</article-title><source>Frontiers in Genetics</source>. <year>2019</year>;<volume>10</volume>:<fpage>1195</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fgene.2019.01195</pub-id>.<?supplied-pmid 31824577?><pub-id pub-id-type="pmid">31824577</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref052">
      <label>52</label>
      <mixed-citation publication-type="journal"><name><surname>Zhong</surname><given-names>W</given-names></name>, <name><surname>Spracklen</surname><given-names>CN</given-names></name>, <name><surname>Mohlke</surname><given-names>KL</given-names></name>, <name><surname>Zheng</surname><given-names>X</given-names></name>, <name><surname>Fine</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>. <article-title>SMUT: Multi-SNP mediation intersection-union test</article-title>. <source>Bioinformatics</source>. <year>2019</year>;<volume>35</volume>(<issue>22</issue>):<fpage>4724</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btz285</pub-id><?supplied-pmid 31099385?><pub-id pub-id-type="pmid">31099385</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref053">
      <label>53</label>
      <mixed-citation publication-type="journal"><name><surname>Barfield</surname><given-names>R</given-names></name>, <name><surname>Shen</surname><given-names>J</given-names></name>, <name><surname>Just</surname><given-names>AC</given-names></name>, <name><surname>Vokonas</surname><given-names>PS</given-names></name>, <name><surname>Schwartz</surname><given-names>J</given-names></name>, <name><surname>Baccarelli</surname><given-names>AA</given-names></name>, <etal>et al</etal>. <article-title>Testing for the indirect effect under the null for genome-wide mediation analyses</article-title>. <source>Genet Epidemiol</source>. <year>2017</year>;<volume>41</volume>(<issue>8</issue>):<fpage>824</fpage>–<lpage>33</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/gepi.22084</pub-id><?supplied-pmid 29082545?><pub-id pub-id-type="pmid">29082545</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref054">
      <label>54</label>
      <mixed-citation publication-type="journal"><name><surname>Dai</surname><given-names>JY</given-names></name>, <name><surname>Stanford</surname><given-names>JL</given-names></name>, <name><surname>LeBlanc</surname><given-names>M</given-names></name>. <article-title>A Multiple-Testing Procedure for High-Dimensional Mediation Hypotheses</article-title>. <source>J Am Stat Assoc</source>. <year>2020</year>:<fpage>1</fpage>–<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/01621459.2020.1765785</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref055">
      <label>55</label>
      <mixed-citation publication-type="journal"><name><surname>Zhong</surname><given-names>W</given-names></name>, <name><surname>Darville</surname><given-names>T</given-names></name>, <name><surname>Zheng</surname><given-names>X</given-names></name>, <name><surname>Fine</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>. <article-title>Generalized Multi-SNP Mediation Intersection-Union Test.</article-title><source>bioRxiv</source>. <year>2019</year>:<fpage>780767</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/780767</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref056">
      <label>56</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Guo</surname><given-names>M</given-names></name>, <name><surname>Hu</surname><given-names>L</given-names></name>, <name><surname>Cai</surname><given-names>J</given-names></name>, <name><surname>Zeng</surname><given-names>Y</given-names></name>, <name><surname>Luo</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>The zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-κB signaling</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>51</issue>):<fpage>42856</fpage>–<lpage>66</lpage>. Epub 2012/10/22. <comment>doi: </comment><pub-id pub-id-type="doi">10.1074/jbc.M112.399923</pub-id> .<?supplied-pmid 23091055?><pub-id pub-id-type="pmid">23091055</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref057">
      <label>57</label>
      <mixed-citation publication-type="journal"><name><surname>Nair</surname><given-names>A</given-names></name>, <name><surname>Venkatraman</surname><given-names>M</given-names></name>, <name><surname>Maliekal</surname><given-names>TT</given-names></name>, <name><surname>Nair</surname><given-names>B</given-names></name>, <name><surname>Karunagaran</surname><given-names>D</given-names></name>. <article-title>NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix</article-title>. <source>Oncogene</source>. <year>2003</year>;<volume>22</volume>(<issue>1</issue>):<fpage>50</fpage>–<lpage>8</lpage>. Epub 2003/01/16. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.onc.1206043</pub-id> .<?supplied-pmid 12527907?><pub-id pub-id-type="pmid">12527907</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref058">
      <label>58</label>
      <mixed-citation publication-type="journal"><name><surname>Fritz</surname><given-names>AJ</given-names></name>, <name><surname>Ghule</surname><given-names>PN</given-names></name>, <name><surname>Boyd</surname><given-names>JR</given-names></name>, <name><surname>Tye</surname><given-names>CE</given-names></name>, <name><surname>Page</surname><given-names>NA</given-names></name>, <name><surname>Hong</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Intranuclear and higher-order chromatin organization of the major histone gene cluster in breast cancer</article-title>. <source>Journal of Cellular Physiology</source>. <year>2018</year>;<volume>233</volume>(<issue>2</issue>):<fpage>1278</fpage>–<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcp.25996</pub-id><?supplied-pmid 28504305?><pub-id pub-id-type="pmid">28504305</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref059">
      <label>59</label>
      <mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Hu</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated HIST1H4F Could Serve as a Pan-Cancer Biomarker</article-title>. <source>Cancer Research</source>. <year>2019</year>;<volume>79</volume>(<issue>24</issue>):<fpage>6101</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-1019</pub-id><?supplied-pmid 31575549?><pub-id pub-id-type="pmid">31575549</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref060">
      <label>60</label>
      <mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Pan</surname><given-names>J</given-names></name>, <name><surname>Han</surname><given-names>X</given-names></name>. <article-title>Knockdown of TRIM26 inhibits the proliferation, migration and invasion of bladder cancer cells through the Akt/GSK3β/β-catenin pathway</article-title>. <source>Chemico-Biological Interactions</source>. <year>2021</year>;<volume>337</volume>:<fpage>109366</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cbi.2021.109366</pub-id><?supplied-pmid 33549581?><pub-id pub-id-type="pmid">33549581</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref061">
      <label>61</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Pei</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Spina bifida in fetus is associated with an altered pattern of DNA methylation in placenta</article-title>. <source>J Hum Genet</source>. <year>2015</year>;<volume>60</volume>(<issue>10</issue>):<fpage>605</fpage>–<lpage>11</lpage>. Epub 2015/07/17. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/jhg.2015.80</pub-id> .<?supplied-pmid 26178427?><pub-id pub-id-type="pmid">26178427</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref062">
      <label>62</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Ling</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>KRAB-containing zinc finger protein ZNF496 inhibits breast cancer cell proliferation by selectively repressing ERα activity</article-title>. <source>Biochim Biophys Acta Gene Regul Mech</source>. <year>2018</year>. Epub 2018/07/18. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.bbagrm.2018.07.003</pub-id>.<?supplied-pmid 30012466?><pub-id pub-id-type="pmid">30012466</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref063">
      <label>63</label>
      <mixed-citation publication-type="journal"><name><surname>Burns</surname><given-names>KA</given-names></name>, <name><surname>Korach</surname><given-names>KS</given-names></name>. <article-title>Estrogen receptors and human disease: an update</article-title>. <source>Archives of Toxicology</source>. <year>2012</year>;<volume>86</volume>(<issue>10</issue>):<fpage>1491</fpage>–<lpage>504</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00204-012-0868-5</pub-id><?supplied-pmid 22648069?><pub-id pub-id-type="pmid">22648069</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref064">
      <label>64</label>
      <mixed-citation publication-type="journal"><name><surname>Arnal</surname><given-names>J-F</given-names></name>, <name><surname>Lenfant</surname><given-names>F</given-names></name>, <name><surname>Metivier</surname><given-names>R</given-names></name>, <name><surname>Flouriot</surname><given-names>G</given-names></name>, <name><surname>Henrion</surname><given-names>D</given-names></name>, <name><surname>Adlanmerini</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications</article-title>. <source>Physiological Reviews</source>. <year>2017</year>;<volume>97</volume>(<issue>3</issue>):<fpage>1045</fpage>–<lpage>87</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1152/physrev.00024.2016</pub-id><?supplied-pmid 28539435?><pub-id pub-id-type="pmid">28539435</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref065">
      <label>65</label>
      <mixed-citation publication-type="journal"><name><surname>Bertozzi</surname><given-names>TM</given-names></name>, <name><surname>Elmer</surname><given-names>JL</given-names></name>, <name><surname>Macfarlan</surname><given-names>TS</given-names></name>, <name><surname>Ferguson-Smith</surname><given-names>AC</given-names></name>. <article-title>KRAB zinc finger protein diversification drives mammalian interindividual methylation variability</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2020</year>;<volume>117</volume>(<issue>49</issue>):<fpage>31290</fpage>–<lpage>300</lpage>. Epub 2020/11/25. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.2017053117</pub-id> .<?supplied-pmid 33239447?><pub-id pub-id-type="pmid">33239447</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref066">
      <label>66</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Tian</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Yan</surname><given-names>B</given-names></name>, <name><surname>Yang</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2021</year>;<volume>40</volume>(<issue>1</issue>):<fpage>80</fpage>–. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13046-021-01871-4</pub-id> .<?supplied-pmid 33637103?><pub-id pub-id-type="pmid">33637103</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref067">
      <label>67</label>
      <mixed-citation publication-type="journal"><collab>The Medicaid Outcomes Distributed Research N</collab>. <article-title>Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014–2018.</article-title><source>JAMA</source>. <year>2021</year>;<volume>326</volume>(<issue>2</issue>):<fpage>154</fpage>–<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2021.7374</pub-id><?supplied-pmid 34255008?><pub-id pub-id-type="pmid">34255008</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref068">
      <label>68</label>
      <mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PA</given-names></name>. <article-title>The DNA methylation paradox</article-title>. <source>Trends Genet</source>. <year>1999</year>;<volume>15</volume>(<issue>1</issue>):<fpage>34</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0168-9525(98)01636-9</pub-id> .<?supplied-pmid 10087932?><pub-id pub-id-type="pmid">10087932</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref069">
      <label>69</label>
      <mixed-citation publication-type="journal"><name><surname>Kass</surname><given-names>S</given-names></name>, <name><surname>Landsberger</surname><given-names>N</given-names></name>, <name><surname>Wolffe</surname><given-names>A</given-names></name>. <article-title>DNA methylation directs a time-dependent repression of transcription initiation</article-title>. <source>Curr Biol</source>. <year>1997</year>;<volume>7</volume>:<fpage>157</fpage>–<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0960-9822(97)70086-1</pub-id><?supplied-pmid 9395433?><pub-id pub-id-type="pmid">9395433</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref070">
      <label>70</label>
      <mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>W</given-names></name>, <name><surname>Dinh</surname><given-names>HQ</given-names></name>, <name><surname>Ramjan</surname><given-names>Z</given-names></name>, <name><surname>Weisenberger</surname><given-names>DJ</given-names></name>, <name><surname>Nicolet</surname><given-names>CM</given-names></name>, <name><surname>Shen</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>DNA methylation loss in late-replicating domains is linked to mitotic cell division</article-title>. <source>Nat Genet</source>. <year>2018</year>;<volume>50</volume>(<issue>4</issue>):<fpage>591</fpage>–<lpage>602</lpage>. Epub 2018/04/04. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41588-018-0073-4</pub-id> ; PubMed Central PMCID: PMC5893360.<?supplied-pmid 29610480?><pub-id pub-id-type="pmid">29610480</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref071">
      <label>71</label>
      <mixed-citation publication-type="journal"><name><surname>Meir</surname><given-names>Z</given-names></name>, <name><surname>Mukamel</surname><given-names>Z</given-names></name>, <name><surname>Chomsky</surname><given-names>E</given-names></name>, <name><surname>Lifshitz</surname><given-names>A</given-names></name>, <name><surname>Tanay</surname><given-names>A</given-names></name>. <article-title>Single-cell analysis of clonal maintenance of transcriptional and epigenetic states in cancer cells</article-title>. <source>Nat Genet</source>. <year>2020</year>;<volume>52</volume>(<issue>7</issue>):<fpage>709</fpage>–<lpage>18</lpage>. Epub 2020/07/01. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41588-020-0645-y</pub-id> ; PubMed Central PMCID: PMC7610382.<?supplied-pmid 32601473?><pub-id pub-id-type="pmid">32601473</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref072">
      <label>72</label>
      <mixed-citation publication-type="journal"><name><surname>Dutta</surname><given-names>D</given-names></name>, <name><surname>Scott</surname><given-names>L</given-names></name>, <name><surname>Boehnke</surname><given-names>M</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>. <article-title>Multi-SKAT: General framework to test for rare-variant association with multiple phenotypes</article-title>. <source>Genet Epidemiol</source>. <year>2019</year>;<volume>43</volume>(<issue>1</issue>). <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/gepi.22156</pub-id>.<?supplied-pmid 30298564?><pub-id pub-id-type="pmid">30298564</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref073">
      <label>73</label>
      <mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PA</given-names></name>, <name><surname>Baylin</surname><given-names>SB</given-names></name>. <article-title>The fundamental role of epigenetic events in cancer</article-title>. <source>Nat Rev Genet</source>. <year>2002</year>;<volume>3</volume>(<issue>6</issue>):<fpage>415</fpage>–<lpage>28</lpage>. Epub 2002/06/04. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrg816</pub-id> .<?supplied-pmid 12042769?><pub-id pub-id-type="pmid">12042769</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref074">
      <label>74</label>
      <mixed-citation publication-type="journal"><name><surname>Feinberg</surname><given-names>AP</given-names></name>, <name><surname>Koldobskiy</surname><given-names>MA</given-names></name>, <name><surname>Göndör</surname><given-names>A</given-names></name>. <article-title>Epigenetic modulators, modifiers and mediators in cancer aetiology and progression</article-title>. <source>Nat Rev Genet</source>. <year>2016</year>;<volume>17</volume>(<issue>5</issue>):<fpage>284</fpage>–<lpage>99</lpage>. Epub 2016/03/15. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrg.2016.13</pub-id> ; PubMed Central PMCID: PMC4888057.<?supplied-pmid 26972587?><pub-id pub-id-type="pmid">26972587</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref075">
      <label>75</label>
      <mixed-citation publication-type="journal"><name><surname>Prasetyanti</surname><given-names>PR</given-names></name>, <name><surname>Medema</surname><given-names>JP</given-names></name>. <article-title>Intra-tumor heterogeneity from a cancer stem cell perspective</article-title>. <source>Mol Cancer</source>. <year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>41</fpage>–. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12943-017-0600-4</pub-id> .<?supplied-pmid 28209166?><pub-id pub-id-type="pmid">28209166</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref076">
      <label>76</label>
      <mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>Y</given-names></name>, <name><surname>He</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Ma</surname><given-names>X</given-names></name>, <name><surname>Mo</surname><given-names>F</given-names></name>, <name><surname>Yang</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials</article-title>. <source>Signal Transduction and Targeted Therapy</source>. <year>2019</year>;<volume>4</volume>(<issue>1</issue>):<fpage>62</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41392-019-0095-0</pub-id><?supplied-pmid 31871779?><pub-id pub-id-type="pmid">31871779</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref077">
      <label>77</label>
      <mixed-citation publication-type="journal"><name><surname>Issa</surname><given-names>J-PJ</given-names></name>. <article-title>DNA methylation as a therapeutic target in cancer.</article-title><source>Clinical cancer research: an official journal of the American Association for Cancer Research.</source><year>2007</year>;<volume>13</volume>(<issue>6</issue>):<fpage>1634</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2076</pub-id> .<?supplied-pmid 17363514?><pub-id pub-id-type="pmid">17363514</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref078">
      <label>78</label>
      <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Su</surname><given-names>X</given-names></name>, <name><surname>Dai</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>N</given-names></name>, <name><surname>Fang</surname><given-names>C</given-names></name>, <name><surname>Dong</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer</article-title>. <source>Carcinogenesis</source>. <year>2019</year>;<volume>41</volume>(<issue>2</issue>):<fpage>235</fpage>–<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/carcin/bgz199</pub-id><?supplied-pmid 31802101?><pub-id pub-id-type="pmid">31802101</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref079">
      <label>79</label>
      <mixed-citation publication-type="journal"><name><surname>Pidsley</surname><given-names>R</given-names></name>, <name><surname>Zotenko</surname><given-names>E</given-names></name>, <name><surname>Peters</surname><given-names>TJ</given-names></name>, <name><surname>Lawrence</surname><given-names>MG</given-names></name>, <name><surname>Risbridger</surname><given-names>GP</given-names></name>, <name><surname>Molloy</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling</article-title>. <source>Genome Biol</source>. <year>2016</year>;<volume>17</volume>(<issue>1</issue>):<fpage>208</fpage>. Epub 2016/10/09. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13059-016-1066-1</pub-id>; PubMed Central PMCID: PMC5055731.<?supplied-pmid 27717381?><pub-id pub-id-type="pmid">27717381</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref080">
      <label>80</label>
      <mixed-citation publication-type="journal"><name><surname>Akhtar-Zaidi</surname><given-names>B</given-names></name>, <name><surname>Cowper-Sal-lari</surname><given-names>R</given-names></name>, <name><surname>Corradin</surname><given-names>O</given-names></name>, <name><surname>Saiakhova</surname><given-names>A</given-names></name>, <name><surname>Bartels</surname><given-names>CF</given-names></name>, <name><surname>Balasubramanian</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Epigenomic enhancer profiling defines a signature of colon cancer</article-title>. <source>Science</source>. <year>2012</year>;<volume>336</volume>(<issue>6082</issue>):<fpage>736</fpage>–<lpage>9</lpage>. Epub 2012/04/14. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1217277</pub-id> ; PubMed Central PMCID: PMC3711120.<?supplied-pmid 22499810?><pub-id pub-id-type="pmid">22499810</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref081">
      <label>81</label>
      <mixed-citation publication-type="journal"><name><surname>Stirzaker</surname><given-names>C</given-names></name>, <name><surname>Taberlay</surname><given-names>PC</given-names></name>, <name><surname>Statham</surname><given-names>AL</given-names></name>, <name><surname>Clark</surname><given-names>SJ</given-names></name>. <article-title>Mining cancer methylomes: prospects and challenges</article-title>. <source>Trends Genet</source>. <year>2014</year>;<volume>30</volume>(<issue>2</issue>):<fpage>75</fpage>–<lpage>84</lpage>. Epub 2013/12/26. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.tig.2013.11.004</pub-id> .<?supplied-pmid 24368016?><pub-id pub-id-type="pmid">24368016</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref082">
      <label>82</label>
      <mixed-citation publication-type="journal"><name><surname>Jaffe</surname><given-names>AE</given-names></name>, <name><surname>Irizarry</surname><given-names>RA</given-names></name>. <article-title>Accounting for cellular heterogeneity is critical in epigenome-wide association studies</article-title>. <source>Genome Biol</source>. <year>2014</year>;<volume>15</volume>(<issue>2</issue>):<fpage>R31</fpage>. Epub 2014/02/06. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/gb-2014-15-2-r31</pub-id>; PubMed Central PMCID: PMC4053810.<?supplied-pmid 24495553?><pub-id pub-id-type="pmid">24495553</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref083">
      <label>83</label>
      <mixed-citation publication-type="journal"><name><surname>Gentles</surname><given-names>AJ</given-names></name>, <name><surname>Newman</surname><given-names>AM</given-names></name>, <name><surname>Liu</surname><given-names>CL</given-names></name>, <name><surname>Bratman</surname><given-names>SV</given-names></name>, <name><surname>Feng</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>The prognostic landscape of genes and infiltrating immune cells across human cancers</article-title>. <source>Nat Med</source>. <year>2015</year>;<volume>21</volume>(<issue>8</issue>):<fpage>938</fpage>–<lpage>45</lpage>. Epub 2015/07/21. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nm.3909</pub-id> ; PubMed Central PMCID: PMC4852857.<?supplied-pmid 26193342?><pub-id pub-id-type="pmid">26193342</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref084">
      <label>84</label>
      <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>YT</given-names></name>. <article-title>Variance component tests of multivariate mediation effects under composite null hypotheses</article-title>. <source>Biometrics</source>. <year>2019</year>;<volume>75</volume>(<issue>4</issue>):<fpage>1191</fpage>–<lpage>204</lpage>. Epub 2019/04/23. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/biom.13073</pub-id> .<?supplied-pmid 31009061?><pub-id pub-id-type="pmid">31009061</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref085">
      <label>85</label>
      <mixed-citation publication-type="journal"><name><surname>Arneson</surname><given-names>D</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>K</given-names></name>. <article-title>MethylResolver—a method for deconvoluting bulk DNA methylation profiles into known and unknown cell contents</article-title>. <source>Communications Biology</source>. <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<fpage>422</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s42003-020-01146-2</pub-id><?supplied-pmid 32747663?><pub-id pub-id-type="pmid">32747663</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref086">
      <label>86</label>
      <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>T</given-names></name>, <name><surname>Fu</surname><given-names>J</given-names></name>, <name><surname>Zeng</surname><given-names>Z</given-names></name>, <name><surname>Cohen</surname><given-names>D</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>TIMER2.0 for analysis of tumor-infiltrating immune cells</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>;<volume>48</volume>(<issue>W1</issue>):<fpage>W509</fpage>–<lpage>W14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkaa407</pub-id> .<?supplied-pmid 32442275?><pub-id pub-id-type="pmid">32442275</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref087">
      <label>87</label>
      <mixed-citation publication-type="journal"><name><surname>Jaakkola</surname><given-names>MK</given-names></name>, <name><surname>Elo</surname><given-names>LL</given-names></name>. <article-title>Computational deconvolution to estimate cell type-specific gene expression from bulk data</article-title>. <source>NAR Genom Bioinform</source>. <year>2021</year>;<volume>3</volume>(<issue>1</issue>):<fpage>lqaa110</fpage>. Epub 2021/02/13. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nargab/lqaa110</pub-id>; PubMed Central PMCID: PMC7803005.<?supplied-pmid 33575652?><pub-id pub-id-type="pmid">33575652</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref088">
      <label>88</label>
      <mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>X</given-names></name>, <name><surname>Schwartz</surname><given-names>J</given-names></name>, <name><surname>Baccarelli</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>Z</given-names></name>. <article-title>Testing cell-type-specific mediation effects in genome-wide epigenetic studies</article-title>. <source>Brief Bioinform</source>. <year>2021</year>;<volume>22</volume>(<issue>3</issue>). Epub 2020/07/08. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bib/bbaa131</pub-id>; PubMed Central PMCID: PMC8138838.<?supplied-pmid 32632436?><pub-id pub-id-type="pmid">32632436</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref089">
      <label>89</label>
      <mixed-citation publication-type="journal"><name><surname>Glinsky</surname><given-names>GV</given-names></name>. <article-title>Integration of HapMap-Based SNP Pattern Analysis and Gene Expression Profiling Reveals Common SNP Profiles for Cancer Therapy Outcome Predictor Genes*</article-title>. <source>Cell Cycle</source>. <year>2006</year>;<volume>5</volume>(<issue>22</issue>):<fpage>2613</fpage>–<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4161/cc.5.22.3498</pub-id><?supplied-pmid 17172834?><pub-id pub-id-type="pmid">17172834</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref090">
      <label>90</label>
      <mixed-citation publication-type="journal"><name><surname>Fabiani</surname><given-names>E</given-names></name>, <name><surname>Leone</surname><given-names>G</given-names></name>, <name><surname>Giachelia</surname><given-names>M</given-names></name>, <name><surname>D’Alo</surname><given-names>F</given-names></name>, <name><surname>Greco</surname><given-names>M</given-names></name>, <name><surname>Criscuolo</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Analysis of genome-wide methylation and gene expression induced by 5-aza-2’-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia</article-title>. <source>Leuk Lymphoma</source>. <year>2010</year>;<volume>51</volume>(<issue>12</issue>):<fpage>2275</fpage>–<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3109/10428194.2010.528093</pub-id> .<?supplied-pmid 21077739?><pub-id pub-id-type="pmid">21077739</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref091">
      <label>91</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Baladandayuthapani</surname><given-names>V</given-names></name>, <name><surname>Morris</surname><given-names>JS</given-names></name>, <name><surname>Broom</surname><given-names>BM</given-names></name>, <name><surname>Manyam</surname><given-names>G</given-names></name>, <name><surname>Do</surname><given-names>K-A</given-names></name>. <article-title>iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data</article-title>. <source>Bioinformatics</source>. <year>2013</year>;<volume>29</volume>(<issue>2</issue>):<fpage>149</fpage>–<lpage>59</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/bts655</pub-id><?supplied-pmid 23142963?><pub-id pub-id-type="pmid">23142963</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref092">
      <label>92</label>
      <mixed-citation publication-type="journal"><name><surname>de Tayrac</surname><given-names>M</given-names></name>, <name><surname>Lê</surname><given-names>S</given-names></name>, <name><surname>Aubry</surname><given-names>M</given-names></name>, <name><surname>Mosser</surname><given-names>J</given-names></name>, <name><surname>Husson</surname><given-names>F</given-names></name>. <article-title>Simultaneous analysis of distinct Omics data sets with integration of biological knowledge: Multiple Factor Analysis approach</article-title>. <source>BMC Genomics</source>. <year>2009</year>;<volume>10</volume>(<issue>1</issue>):<fpage>32</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2164-10-32</pub-id><?supplied-pmid 19154582?><pub-id pub-id-type="pmid">19154582</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref093">
      <label>93</label>
      <mixed-citation publication-type="journal"><name><surname>Bernstein</surname><given-names>BE</given-names></name>, <name><surname>Meissner</surname><given-names>A</given-names></name>, <name><surname>Lander</surname><given-names>ES</given-names></name>. <article-title>The mammalian epigenome</article-title>. <source>Cell</source>. <year>2007</year>;<volume>128</volume>(<issue>4</issue>):<fpage>669</fpage>–<lpage>81</lpage>. Epub 2007/02/27. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2007.01.033</pub-id> .<?supplied-pmid 17320505?><pub-id pub-id-type="pmid">17320505</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref094">
      <label>94</label>
      <mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>G</given-names></name>, <name><surname>Weisenberger</surname><given-names>DJ</given-names></name>. <article-title>DNA methylation aberrancies as a guide for surveillance and treatment of human cancers</article-title>. <source>Epigenetics</source>. <year>2017</year>;<volume>12</volume>(<issue>6</issue>):<fpage>416</fpage>–<lpage>32</lpage>. Epub 2017/03/30. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/15592294.2017.1311434</pub-id> .<?supplied-pmid 28358281?><pub-id pub-id-type="pmid">28358281</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref095">
      <label>95</label>
      <mixed-citation publication-type="journal"><name><surname>Tsai</surname><given-names>H</given-names></name>, <name><surname>Baylin</surname><given-names>S</given-names></name>. <article-title>Cancer epigenetics: linking basic biology to clinical medicine</article-title>. <source>Cell research</source>. <year>2011</year>;<volume>21</volume>(<issue>3</issue>):<fpage>502</fpage>–<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/cr.2011.24</pub-id> .<?supplied-pmid 21321605?><pub-id pub-id-type="pmid">21321605</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref096">
      <label>96</label>
      <mixed-citation publication-type="journal"><name><surname>Ehrlich</surname><given-names>M.</given-names></name><article-title>DNA hypomethylation in cancer cells</article-title>. <source>Epigenomics</source>. <year>2009</year>;<volume>1</volume>(<issue>2</issue>):<fpage>239</fpage>–<lpage>59</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2217/epi.09.33</pub-id> .<?supplied-pmid 20495664?><pub-id pub-id-type="pmid">20495664</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref097">
      <label>97</label>
      <mixed-citation publication-type="journal"><name><surname>Lopez-Serra</surname><given-names>P</given-names></name>, <name><surname>Esteller</surname><given-names>M</given-names></name>. <article-title>DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer</article-title>. <source>Oncogene</source>. <year>2012</year>;<volume>31</volume>(<issue>13</issue>):<fpage>1609</fpage>–<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/onc.2011.354</pub-id><?supplied-pmid 21860412?><pub-id pub-id-type="pmid">21860412</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref098">
      <label>98</label>
      <mixed-citation publication-type="journal"><name><surname>Wan</surname><given-names>J</given-names></name>, <name><surname>Oliver</surname><given-names>VF</given-names></name>, <name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Zhu</surname><given-names>H</given-names></name>, <name><surname>Zack</surname><given-names>DJ</given-names></name>, <name><surname>Merbs</surname><given-names>SL</given-names></name>, <etal>et al</etal>. <article-title>Characterization of tissue-specific differential DNA methylation suggests distinct modes of positive and negative gene expression regulation</article-title>. <source>BMC Genomics</source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>49</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12864-015-1271-4</pub-id><?supplied-pmid 25652663?><pub-id pub-id-type="pmid">25652663</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref099">
      <label>99</label>
      <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>T</surname><given-names>Z</given-names></name>, <name><surname>X</surname><given-names>P</given-names></name>, <name><surname>YH</surname><given-names>Z</given-names></name>, <name><surname>T</surname><given-names>H</given-names></name>, <name><surname>YD</surname><given-names>C</given-names></name>. <article-title>Identifying Methylation Pattern and Genes Associated with Breast Cancer Subtypes</article-title>. <source>International journal of molecular sciences</source>. <year>2019</year>;<volume>20</volume>(<issue>17</issue>). <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms20174269</pub-id>.<?supplied-pmid 31480430?><pub-id pub-id-type="pmid">31480430</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref100">
      <label>100</label>
      <mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>R</given-names></name>, <name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Gao</surname><given-names>Y</given-names></name>, <name><surname>Cao</surname><given-names>H</given-names></name>, <name><surname>Goode</surname><given-names>EL</given-names></name>, <name><surname>Cui</surname><given-names>Y</given-names></name>. <article-title>Gene-based mediation analysis in epigenetic studies</article-title>. <source>Brief Bioinform</source>. <year>2020</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bib/bbaa113</pub-id><?supplied-pmid 32608480?><pub-id pub-id-type="pmid">32608480</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref101">
      <label>101</label>
      <mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>MC</given-names></name>, <name><surname>Maity</surname><given-names>A</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Simmons</surname><given-names>EM</given-names></name>, <name><surname>Harmon</surname><given-names>QE</given-names></name>, <name><surname>Lin</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Kernel Machine SNP-Set Testing Under Multiple Candidate Kernels</article-title>. <source>Genet Epidemiol</source>. <year>2013</year>;<volume>37</volume>(<issue>3</issue>):<fpage>267</fpage>–<lpage>75</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/gepi.21715</pub-id><?supplied-pmid 23471868?><pub-id pub-id-type="pmid">23471868</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref102">
      <label>102</label>
      <mixed-citation publication-type="journal"><name><surname>Urrutia</surname><given-names>E</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Maity</surname><given-names>A</given-names></name>, <name><surname>Zhao</surname><given-names>N</given-names></name>, <name><surname>Shen</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Rare variant testing across methods and thresholds using the multi-kernel sequence kernel association test (MK-SKAT).</article-title><source>Stat Interface</source>. <year>2015</year>;<volume>8</volume>(<issue>4</issue>):<fpage>495</fpage>–<lpage>505</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4310/SII.2015.v8.n4.a8</pub-id> PMC4698916. <?supplied-pmid 26740853?><pub-id pub-id-type="pmid">26740853</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref103">
      <label>103</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Xing</surname><given-names>EP</given-names></name>, <name><surname>Schaid</surname><given-names>DJ</given-names></name>. <article-title>Kernel methods for large-scale genomic data analysis</article-title>. <source>Brief Bioinform</source>. <year>2014</year>;<volume>16</volume>(<issue>2</issue>):<fpage>183</fpage>–<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bib/bbu024</pub-id><?supplied-pmid 25053743?><pub-id pub-id-type="pmid">25053743</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref104">
      <label>104</label>
      <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Cao</surname><given-names>H</given-names></name>, <name><surname>He</surname><given-names>T</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Cui</surname><given-names>Y</given-names></name>. <article-title>Multilevel heterogeneous omics data integration with kernel fusion</article-title>. <source>Brief Bioinform</source>. <year>2020</year>;<volume>21</volume>(<issue>1</issue>):<fpage>156</fpage>–<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bib/bby115</pub-id><?supplied-pmid 30496340?><pub-id pub-id-type="pmid">30496340</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref105">
      <label>105</label>
      <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Cao</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Cui</surname><given-names>Y</given-names></name>. <article-title>Predicting disease trait with genomic data: a composite kernel approach</article-title>. <source>Brief Bioinform</source>. <year>2016</year>;<volume>18</volume>(<issue>4</issue>):<fpage>591</fpage>–<lpage>601</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bib/bbw043</pub-id><?supplied-pmid 27255915?><pub-id pub-id-type="pmid">27255915</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref106">
      <label>106</label>
      <mixed-citation publication-type="journal"><name><surname>He</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Zhong</surname><given-names>P-S</given-names></name>, <name><surname>Cui</surname><given-names>Y</given-names></name>. <article-title>An optimal kernel-based U-statistic method for quantitative gene-set association analysis</article-title>. <source>Genet Epidemiol</source>. <year>2019</year>;<volume>43</volume>(<issue>2</issue>):<fpage>137</fpage>–<lpage>49</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/gepi.22170</pub-id><?supplied-pmid 30456931?><pub-id pub-id-type="pmid">30456931</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref107">
      <label>107</label>
      <mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Zhao</surname><given-names>W</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Kardia</surname><given-names>SLR</given-names></name>, <etal>et al</etal>. <article-title>Bayesian shrinkage estimation of high dimensional causal mediation effects in omics studies</article-title>. <source>Biometrics</source>. <year>2020</year>;<volume>76</volume>(<issue>3</issue>):<fpage>700</fpage>–<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/biom.13189</pub-id><?supplied-pmid 31733066?><pub-id pub-id-type="pmid">31733066</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref108">
      <label>108</label>
      <mixed-citation publication-type="journal"><name><surname>Ionita-Laza</surname><given-names>I</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Makarov</surname><given-names>V</given-names></name>, <name><surname>Buxbaum Joseph</surname><given-names>D</given-names></name>, <name><surname>Lin</surname><given-names>X</given-names></name>. <article-title>Sequence Kernel Association Tests for the Combined Effect of Rare and Common Variants</article-title>. <source>Am J Hum Genet</source>. <year>2013</year>;<volume>92</volume>(<issue>6</issue>):<fpage>841</fpage>–<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajhg.2013.04.015</pub-id><?supplied-pmid 23684009?><pub-id pub-id-type="pmid">23684009</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref109">
      <label>109</label>
      <mixed-citation publication-type="journal"><name><surname>VanderWeele</surname><given-names>TJ</given-names></name>. <article-title>Introduction to Statistical Mediation Analysis by MACKINNON</article-title>, <source>D. P. Biometrics</source>. <year>2009</year>;<volume>65</volume>(<issue>3</issue>):<fpage>998</fpage>–<lpage>1000</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1541-0420.2009.01315_12.x</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref110">
      <label>110</label>
      <mixed-citation publication-type="journal"><name><surname>Grambsch</surname><given-names>PM</given-names></name>, <name><surname>Therneau</surname><given-names>TM</given-names></name>. <article-title>Proportional hazards tests and diagnostics based on weighted residuals</article-title>. <source>Biometrika</source>. <year>1994</year>;<volume>81</volume>(<issue>3</issue>):<fpage>515</fpage>–<lpage>26</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/biomet/81.3.515</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref111">
      <label>111</label>
      <mixed-citation publication-type="journal"><name><surname>Qu</surname><given-names>L</given-names></name>, <name><surname>Guennel</surname><given-names>T</given-names></name>, <name><surname>Marshall Scott</surname><given-names>L</given-names></name>. <article-title>Linear score tests for variance components in linear mixed models and applications to genetic association studies</article-title>. <source>Biometrics</source>. <year>2013</year>;<volume>69</volume>(<issue>4</issue>):<fpage>883</fpage>–<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/biom.12095</pub-id><?supplied-pmid 24328714?><pub-id pub-id-type="pmid">24328714</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref112">
      <label>112</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>X</given-names></name>, <name><surname>Cai</surname><given-names>T</given-names></name>, <name><surname>Wu</surname><given-names>MC</given-names></name>, <name><surname>Zhou</surname><given-names>Q</given-names></name>, <name><surname>Liu</surname><given-names>G</given-names></name>, <name><surname>Christiani</surname><given-names>DC</given-names></name>, <etal>et al</etal>. <article-title>Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies</article-title>. <source>Genet Epidemiol</source>. <year>2011</year>;<volume>35</volume>(<issue>7</issue>):<fpage>620</fpage>–<lpage>31</lpage>. Epub 2011/08/04. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/gepi.20610</pub-id> .<?supplied-pmid 21818772?><pub-id pub-id-type="pmid">21818772</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref113">
      <label>113</label>
      <mixed-citation publication-type="journal"><name><surname>Duan</surname><given-names>Z</given-names></name>, <name><surname>Qiao</surname><given-names>Y</given-names></name>, <name><surname>Lu</surname><given-names>J</given-names></name>, <name><surname>Lu</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Yan</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>HUPAN: a pan-genome analysis pipeline for human genomes</article-title>. <source>Genome Biol</source>. <year>2019</year>;<volume>20</volume>(<issue>1</issue>):<fpage>149</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13059-019-1751-y</pub-id><?supplied-pmid 31366358?><pub-id pub-id-type="pmid">31366358</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref114">
      <label>114</label>
      <mixed-citation publication-type="journal"><name><surname>Goeman</surname><given-names>JJ</given-names></name>, <name><surname>van de Geer</surname><given-names>SA</given-names></name>, <name><surname>de Kort</surname><given-names>F</given-names></name>, <name><surname>van Houwelingen</surname><given-names>HC</given-names></name>. <article-title>A global test for groups of genes: testing association with a clinical outcome</article-title>. <source>Bioinformatics</source>. <year>2004</year>;<volume>20</volume>(<issue>1</issue>):<fpage>93</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btg382</pub-id><?supplied-pmid 14693814?><pub-id pub-id-type="pmid">14693814</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref115">
      <label>115</label>
      <mixed-citation publication-type="journal"><name><surname>Goeman</surname><given-names>JJ</given-names></name>, <name><surname>Van De Geer</surname><given-names>SA</given-names></name>, <name><surname>Van Houwelingen</surname><given-names>HC</given-names></name>. <article-title>Testing against a high dimensional alternative.</article-title><source>J R Stat Soc Ser B</source>. <year>2006</year>;<volume>68</volume>(<issue>3</issue>):<fpage>477</fpage>–<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1467-9868.2006.00551.x</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref116">
      <label>116</label>
      <mixed-citation publication-type="journal"><name><surname>Kwee</surname><given-names>LC</given-names></name>, <name><surname>Liu</surname><given-names>D</given-names></name>, <name><surname>Lin</surname><given-names>X</given-names></name>, <name><surname>Ghosh</surname><given-names>D</given-names></name>, <name><surname>Epstein</surname><given-names>MP</given-names></name>. <article-title>A Powerful and Flexible Multilocus Association Test for Quantitative Traits</article-title>. <source>Am J Hum Genet</source>. <year>2008</year>;<volume>82</volume>(<issue>2</issue>):<fpage>386</fpage>–<lpage>97</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajhg.2007.10.010</pub-id><?supplied-pmid 18252219?><pub-id pub-id-type="pmid">18252219</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref117">
      <label>117</label>
      <mixed-citation publication-type="journal"><name><surname>Crainiceanu</surname><given-names>CM</given-names></name>, <name><surname>Ruppert</surname><given-names>D</given-names></name>. <article-title>Likelihood ratio tests in linear mixed models with one variance component.</article-title><source>J R Stat Soc Ser B</source>. <year>2004</year>;<volume>66</volume>(<issue>1</issue>):<fpage>165</fpage>–<lpage>85</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1467-9868.2004.00438.x</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref118">
      <label>118</label>
      <mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>P</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Huang</surname><given-names>S</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>. <article-title>Rare Variants Detection with Kernel Machine Learning Based on Likelihood Ratio Test.</article-title><source>PLoS ONE.</source><year>2014</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e93355</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0093355</pub-id><?supplied-pmid 24675868?><pub-id pub-id-type="pmid">24675868</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref119">
      <label>119</label>
      <mixed-citation publication-type="journal"><name><surname>Davies</surname><given-names>RB</given-names></name>. <article-title>Algorithm AS 155: The Distribution of a Linear Combination of chi-2 Random Variables</article-title>. <source>Journal of the Royal Statistical Society: Series C (Applied Statistics).</source><year>1980</year>;<volume>29</volume>(<issue>3</issue>):<fpage>323</fpage>–<lpage>33</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2307/2346911</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref120">
      <label>120</label>
      <mixed-citation publication-type="other">Therneau TM. coxme: Mixed Effects Cox Models. R package version 2.2–14. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=coxme" ext-link-type="uri">https://CRAN.R-project.org/package=coxme</ext-link>. 2019.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref121">
      <label>121</label>
      <mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>AA</given-names></name>, <name><surname>Huang</surname><given-names>Y-T</given-names></name>, <name><surname>Eliot</surname><given-names>M</given-names></name>, <name><surname>Houseman</surname><given-names>EA</given-names></name>, <name><surname>Marsit</surname><given-names>CJ</given-names></name>, <name><surname>Wiencke</surname><given-names>JK</given-names></name>, <etal>et al</etal>. <article-title>A novel approach to the discovery of survival biomarkers in glioblastoma using a joint analysis of DNA methylation and gene expression</article-title>. <source>Epigenetics</source>. <year>2014</year>;<volume>9</volume>(<issue>6</issue>):<fpage>873</fpage>–<lpage>83</lpage>. Epub 2014/03/26. <comment>doi: </comment><pub-id pub-id-type="doi">10.4161/epi.28571</pub-id> .<?supplied-pmid 24670968?><pub-id pub-id-type="pmid">24670968</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref122">
      <label>122</label>
      <mixed-citation publication-type="journal"><name><surname>Teumer</surname><given-names>A</given-names></name>, <name><surname>Chaker</surname><given-names>L</given-names></name>, <name><surname>Groeneweg</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Di Munno</surname><given-names>C</given-names></name>, <name><surname>Barbieri</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>4455</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-018-06356-1</pub-id><?supplied-pmid 30367059?><pub-id pub-id-type="pmid">30367059</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref123">
      <label>123</label>
      <mixed-citation publication-type="journal"><name><surname>Sobel</surname><given-names>ME</given-names></name>. <article-title>Asymptotic Confidence Intervals for Indirect Effects in Structural Equation Models.</article-title><source>Sociological Methodology.</source><year>1982</year>;<volume>13</volume>:<fpage>290</fpage>–<lpage>312</lpage>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref124">
      <label>124</label>
      <mixed-citation publication-type="journal"><name><surname>Sobel</surname><given-names>ME</given-names></name>. <article-title>Some New Results on Indirect Effects and Their Standard Errors in Covariance Structure.</article-title><source>Sociological Methodology</source>. <year>1986</year>:<fpage>159</fpage>–<lpage>86</lpage>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref125">
      <label>125</label>
      <mixed-citation publication-type="journal"><name><surname>Mackinnon</surname><given-names>DP</given-names></name>, <name><surname>Warsi</surname><given-names>G</given-names></name>, <name><surname>Dwyer</surname><given-names>JH</given-names></name>. <article-title>A Simulation Study of Mediated Effect Measures.</article-title><source>Multivariate Behavioral Research.</source><year>1995</year>;<volume>30</volume>(<issue>1</issue>):<fpage>41</fpage>–. <comment>doi: </comment><pub-id pub-id-type="doi">10.1207/s15327906mbr3001_3</pub-id> .<?supplied-pmid 20157641?><pub-id pub-id-type="pmid">20157641</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref126">
      <label>126</label>
      <mixed-citation publication-type="journal"><name><surname>Langaas</surname><given-names>M</given-names></name>, <name><surname>Lindqvist</surname><given-names>BH</given-names></name>, <name><surname>Ferkingstad</surname><given-names>E</given-names></name>. <article-title>Estimating the proportion of true null hypotheses, with application to DNA microarray data</article-title>. <source>J R Stat Soc Ser B</source>. <year>2005</year>;<volume>67</volume>(<issue>4</issue>):<fpage>555</fpage>–<lpage>72</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1467-9868.2005.00515.x</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref127">
      <label>127</label>
      <mixed-citation publication-type="journal"><name><surname>Jin</surname><given-names>J</given-names></name>, <name><surname>Cai</surname><given-names>TT</given-names></name>. <article-title>Estimating the Null and the Proportion of Nonnull Effects in Large-Scale Multiple Comparisons</article-title>. <source>J Am Stat Assoc</source>. <year>2007</year>;<volume>102</volume>(<issue>478</issue>):<fpage>495</fpage>–<lpage>506</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1198/016214507000000167</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref128">
      <label>128</label>
      <mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>H</given-names></name>, <name><surname>Doerge</surname><given-names>RW</given-names></name>. <article-title>Estimating the proportion of true null hypotheses for multiple comparisons</article-title>. <source>Cancer Inform</source>. <year>2008</year>;<volume>6</volume>:<fpage>25</fpage>–<lpage>32</lpage>. <?supplied-pmid 19259400?><pub-id pub-id-type="pmid">19259400</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref129">
      <label>129</label>
      <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>Y-T</given-names></name>, <name><surname>Pan</surname><given-names>W-C</given-names></name>. <article-title>Hypothesis test of mediation effect in causal mediation model with high-dimensional continuous mediators</article-title>. <source>Biometrics</source>. <year>2016</year>;<volume>72</volume>(<issue>2</issue>):<fpage>402</fpage>–<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/biom.12421</pub-id><?supplied-pmid 26414245?><pub-id pub-id-type="pmid">26414245</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref130">
      <label>130</label>
      <mixed-citation publication-type="journal"><name><surname>Efron</surname><given-names>B</given-names></name>. <article-title>Size, power and false discovery rates.</article-title><source>Ann Stat</source>. <year>2007</year>;<volume>35</volume>(<issue>4</issue>):<fpage>1351</fpage>–<lpage>77</lpage>.</mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref131">
      <label>131</label>
      <mixed-citation publication-type="journal"><name><surname>Storey</surname><given-names>J.</given-names></name><article-title>The positive false discovery rate: a Bayesian interpretation and the q-value.</article-title><source>Ann Stat</source>. <year>2003</year>;<volume>31</volume>:<fpage>2013</fpage>–<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1214/aos/1074290335</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref132">
      <label>132</label>
      <mixed-citation publication-type="journal"><name><surname>Efron</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>NR</given-names></name>. <article-title>False discovery rates and copy number variation</article-title>. <source>Biometrika</source>. <year>2011</year>;<volume>98</volume>(<issue>2</issue>):<fpage>251</fpage>–<lpage>71</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/biomet/asr018</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref133">
      <label>133</label>
      <mixed-citation publication-type="journal"><name><surname>Storey</surname><given-names>J</given-names></name>, <name><surname>Tibshirani</surname><given-names>R</given-names></name>. <article-title>Statistical significance for genomewide studies</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2003</year>;<volume>100</volume>:<fpage>9440</fpage>–<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1530509100</pub-id><?supplied-pmid 12883005?><pub-id pub-id-type="pmid">12883005</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref134">
      <label>134</label>
      <mixed-citation publication-type="journal"><name><surname>Storey</surname><given-names>J.</given-names></name><article-title>Journal of the Royal Statistical Society: Series B (Statistical Methodology).</article-title><source>JR Stat Soc B.</source><year>2002</year>;<volume>64</volume>:<fpage>479</fpage>–<lpage>98</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/1467-9868.00346</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref135">
      <label>135</label>
      <mixed-citation publication-type="journal"><name><surname>Efron</surname><given-names>B</given-names></name>, <name><surname>Tibshirani</surname><given-names>R</given-names></name>. <article-title>Empirical bayes methods and false discovery rates for microarrays</article-title>. <source>Genet Epidemiol</source>. <year>2002</year>;<volume>23</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>86</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/gepi.1124</pub-id><?supplied-pmid 12112249?><pub-id pub-id-type="pmid">12112249</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref136">
      <label>136</label>
      <mixed-citation publication-type="journal"><name><surname>Bender</surname><given-names>R</given-names></name>, <name><surname>Augustin</surname><given-names>T</given-names></name>, <name><surname>Blettner</surname><given-names>M</given-names></name>. <article-title>Generating survival times to simulate Cox proportional hazards models.</article-title><source>Statistics in Medicine</source>. <year>2005</year>;<volume>24</volume>(<issue>11</issue>):<fpage>1713</fpage>–<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.2059</pub-id><?supplied-pmid 15724232?><pub-id pub-id-type="pmid">15724232</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref137">
      <label>137</label>
      <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Lemire</surname><given-names>M</given-names></name>, <name><surname>Choufani</surname><given-names>S</given-names></name>, <name><surname>Butcher</surname><given-names>D</given-names></name>, <name><surname>Grafodatskaya</surname><given-names>D</given-names></name>, <name><surname>Zanke</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray.</article-title><source>Epigenetics</source>. <year>2013</year>;<volume>8</volume>:<fpage>203</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4161/epi.23470</pub-id><?supplied-pmid 23314698?><pub-id pub-id-type="pmid">23314698</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref138">
      <label>138</label>
      <mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>P</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Huang</surname><given-names>C-C</given-names></name>, <name><surname>Jafari</surname><given-names>N</given-names></name>, <name><surname>Kibbe</surname><given-names>WA</given-names></name>, <name><surname>Hou</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis</article-title>. <source>BMC Bioinformatics</source>. <year>2010</year>;<volume>11</volume>(<issue>1</issue>):<fpage>587</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2105-11-587</pub-id><?supplied-pmid 21118553?><pub-id pub-id-type="pmid">21118553</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref139">
      <label>139</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Lu</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Zhao</surname><given-names>H</given-names></name>, <name><surname>Guan</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>How can gene expression information improve prognostic prediction in TCGA cancers: an empirical comparison study on regularization and mixed-effect survival models.</article-title><source>Frontiers in Genetics</source>. <year>2021</year>; <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fgene.2021.667877</pub-id><?supplied-pmid 34149809?><pub-id pub-id-type="pmid">34149809</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref140">
      <label>140</label>
      <mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>Q</given-names></name>, <name><surname>Shi</surname><given-names>X</given-names></name>, <name><surname>Xie</surname><given-names>Y</given-names></name>, <name><surname>Huang</surname><given-names>J</given-names></name>, <name><surname>Shia</surname><given-names>B</given-names></name>, <name><surname>Ma</surname><given-names>S</given-names></name>. <article-title>Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA</article-title>. <source>Brief Bioinform</source>. <year>2014</year>:<fpage>bbu003</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bib/bbu003</pub-id><?supplied-pmid 24632304?><pub-id pub-id-type="pmid">24632304</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref141">
      <label>141</label>
      <mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Shi</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>R</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Wei</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma</article-title>. <source>Clinical Epigenetics</source>. <year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>88</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13148-017-0392-9</pub-id><?supplied-pmid 28852427?><pub-id pub-id-type="pmid">28852427</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref142">
      <label>142</label>
      <mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>Y</given-names></name>, <name><surname>Liang</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>R</given-names></name>, <name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Shen</surname><given-names>S</given-names></name>, <name><surname>Su</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Epigenetic modifications in lysine demethylases associate with survival of early-stage NSCLC.</article-title><source>Clinical Epigenetics</source>. <year>2018</year>;<volume>10</volume>:<fpage>41</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13148-018-0474-3</pub-id>.<?supplied-pmid 29619118?><pub-id pub-id-type="pmid">29619118</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref143">
      <label>143</label>
      <mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>R</given-names></name>, <name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Loehrer</surname><given-names>E</given-names></name>, <name><surname>Wei</surname><given-names>Y</given-names></name>, <name><surname>Zhu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer</article-title>. <source>Mol Oncol</source>. <year>2018</year>;<volume>12</volume>(<issue>6</issue>):<fpage>913</fpage>–<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/1878-0261.12204</pub-id> .<?supplied-pmid 29656435?><pub-id pub-id-type="pmid">29656435</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1009250.ref144">
      <label>144</label>
      <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Lichtenberg</surname><given-names>T</given-names></name>, <name><surname>Hoadley</surname><given-names>KA</given-names></name>, <name><surname>Poisson</surname><given-names>LM</given-names></name>, <name><surname>Lazar</surname><given-names>AJ</given-names></name>, <name><surname>Cherniack</surname><given-names>AD</given-names></name>, <etal>et al</etal>. <article-title>An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics</article-title>. <source>Cell</source>. <year>2018</year>;<volume>173</volume>(<issue>2</issue>):<fpage>400</fpage>–<lpage>16</lpage>.e11. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id><?supplied-pmid 29625055?><pub-id pub-id-type="pmid">29625055</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pcbi.1009250.r001" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1009250.r001</article-id>
    <title-group>
      <article-title>Decision Letter 0</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Markowetz</surname>
          <given-names>Florian</given-names>
        </name>
        <role>Deputy Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rueda</surname>
          <given-names>Oscar</given-names>
        </name>
        <role>Guest Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2021 Markowetz, Rueda</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>Markowetz, Rueda</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1009250" id="rel-obj001" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <boxed-text id="pcbi-1009250-box001" position="float" specific-use="prior_peer_review_unavailable">
      <sec id="sec026">
        <title>Transfer Alert</title>
        <p>This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.</p>
      </sec>
    </boxed-text>
    <p>
      <named-content content-type="letter-date">16 Mar 2021</named-content>
    </p>
    <p>Dear Dr. Zeng,</p>
    <p>Thank you very much for submitting your manuscript "IUSMMT: survival mediation analysis of gene expression with multiple DNA methylation exposures and its application to cancers of TCGA" for consideration at PLOS Computational Biology.</p>
    <p>As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.</p>
    <p>We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.</p>
    <p>When you are ready to resubmit, please upload the following:</p>
    <p>[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p>
    <p>[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).</p>
    <p>Important additional instructions are given below your reviewer comments.</p>
    <p>Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.</p>
    <p>Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.</p>
    <p>Sincerely,</p>
    <p>Oscar Rueda</p>
    <p>Guest Editor</p>
    <p>PLOS Computational Biology</p>
    <p>Florian Markowetz</p>
    <p>Deputy Editor</p>
    <p>PLOS Computational Biology</p>
    <p>***********************</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <bold>Comments to the Authors:</bold>
    </p>
    <p>
      <bold>Please note here if the review is uploaded as an attachment.</bold>
    </p>
    <p>Reviewer #1: Review is uploaded as a .docx attachment.</p>
    <p>Reviewer #2: The authors claim that the found genes are causal. This is highly unlikely and should be noted. The authors should likely motivate these as informative tools for highlighting regions of interest as opposed to real causal signals.</p>
    <p>In addition, the required assumptions for a causal interpretation are not mentioned til the method (referencing to S1 text line 479), these should likely be mentioned much earlier in the paper perhaps in the introduction.</p>
    <p>If the proportional hazards assumption was violated, could standard approaches be used to correct for this?</p>
    <p>How were DNA methylation markers mapped to genes? Was it solely based on distance? If so what was the threshold?</p>
    <p>How was DNA methylation and gene expression standardized?</p>
    <p>Is the data already QCed to adjust for potential batch or technical effects? The authors mention they restrict to those people of European Ancestry, was this verified through self-report or SNP data? The number of potential mediation genes seems like there is likely some inflation or unmeasured confounder in the analysis. The supplement says quality control but no further details are given.</p>
    <p>Was cell type composition of the DNA methylation adjusted for? If not, it should be as it could be driving the associations.</p>
    <p>In SFig 6 a ch DNA methylation marker is listed. Were non-cg DNAm probes left in the analysis? These are typically removed.</p>
    <p>In the DNA methylation data, were DNAm sites that map to the sex chromosomes removed? Were cross reactive probes removed (PMCID: PMC3592906).</p>
    <p>In the supplement materials discussing the \\lambda values it reads as if it can be set above 1, “It needs to highlight that a value of λα or λβ that is much closer to one can lead to a higher confidence to guarantee the null of or . However, a larger λα or λβ”. Larger than 1? Or just lambda values close to 1.</p>
    <p>What is the practical guidance for researchers for \\lambda? Setting equal to 0.5?</p>
    <p>In the supplement figures, the authors typically show the qq-plot and then show the histogram plots for the real data application. Would be best to be consistent. Perhaps showing the qq-plot for Supplement Figure 5?</p>
    <p>How many genes are involved in Table 1</p>
    <p>For the power in Figure 3: How many genes was this examined over? Is the power defined as the number of times the 1% of potential genes was selected at the desired TIE?</p>
    <p>For the 6 different simulation scenarios: Is there a better way to display this information. At the current moment feels like a bit much and hard to take in.</p>
    <p>Can the authors provide some intuition on why the estimation of the composite components is so poor under the dense null case</p>
    <p>The authors discuss the power (S1 Fig) prior to the TIE (S2 Fig). While S1 appears motivated by the estimation of the parameters perhaps there is a way to discuss the TIE prior</p>
    <p>The discussion of \\gamma^{total} seems unnecessary and distracts from the focus of the analysis, the NIE. Why the decision to include?</p>
    <p>Is there any biological reasoning for why there are so many signals for KIRP and survival compared to the other cancers?</p>
    <p>Minor</p>
    <p>Line 175: typo “note”, think meant not?</p>
    <p>Line 357: DNA methylation impacting gene expression is not a novel result</p>
    <p>Figure 1: Perhaps better to have two DAGs? Reads almost like \\gamma^{total} is part of the same mechanism.</p>
    <p>“Methylations”-&gt; This is not typically how it is referred to as. It’s usually DNA methylation at a CpG site or methylation at probe.The authors claim that the found genes are causal. This is highly unlikely and should be noted. The authors should likely motivate these as informative tools for highlighting regions of interest as opposed to real causal signals.</p>
    <p>Reviewer #3: Uploaded as an attachment.</p>
    <p>**********</p>
    <p>
      <bold>Have all data underlying the figures and results presented in the manuscript been provided?</bold>
    </p>
    <p>Large-scale datasets should be made available via a public repository as described in the <italic toggle="yes">PLOS Computational Biology</italic>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.plos.org/ploscompbiol/s/data-availability" ext-link-type="uri">data availability policy</ext-link>, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.</p>
    <p>Reviewer #1: <bold>No: </bold>Data underlying tables from simulation studies and publically available TCGA data was not available for review.</p>
    <p>In the absence of providing the underlying data, depending on PLOS Computational Biology policy, could the code be included to generate the simulated datasets/ analysis, and also code that follows the application in TCGA from the publically available data to the plots/ tables?</p>
    <p>Reviewer #2: Yes</p>
    <p>Reviewer #3: Yes</p>
    <p>**********</p>
    <p>PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
    <p>Reviewer #1: <bold>Yes: </bold>Rajbir Nath Batra</p>
    <p>Reviewer #2: No</p>
    <p>Reviewer #3: <bold>Yes: </bold>Majed Mohamed Magzoub</p>
    <p>
      <underline>Figure Files:</underline>
    </p>
    <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com</ext-link></underline>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <underline><email>figures@plos.org</email></underline>.</p>
    <p>
      <underline>Data Requirements:</underline>
    </p>
    <p>Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5" ext-link-type="uri">http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5</ext-link>.</p>
    <p>
      <underline>Reproducibility:</underline>
    </p>
    <p>To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions, please see <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.plos.org/plospathogens/s/submission-guidelines" ext-link-type="uri">http://journals.plos.org/compbiol/s/submission-guidelines#loc-materials-and-methods</ext-link></underline></p>
    <supplementary-material id="pcbi.1009250.s019" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">PCOMPBIOL-D-21-00050_Review_RNB.docx</named-content></p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s019.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1009250.s020" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">review_PCOMPBIOL-D-21-00050.docx</named-content></p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s020.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="author-comment" id="pcbi.1009250.r002">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1009250.r002</article-id>
    <title-group>
      <article-title>Author response to Decision Letter 0</article-title>
    </title-group>
    <related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1009250" id="rel-obj002" related-article-type="editor-report"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="author-response-date">28 May 2021</named-content>
    </p>
    <supplementary-material id="pcbi.1009250.s021" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">2021-05-28 Comments and Responses.docx</named-content></p>
      </caption>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1009250.s021.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pcbi.1009250.r003" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1009250.r003</article-id>
    <title-group>
      <article-title>Decision Letter 1</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Markowetz</surname>
          <given-names>Florian</given-names>
        </name>
        <role>Deputy Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rueda</surname>
          <given-names>Oscar</given-names>
        </name>
        <role>Guest Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2021 Markowetz, Rueda</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>Markowetz, Rueda</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1009250" id="rel-obj003" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">6 Jul 2021</named-content>
    </p>
    <p>Dear Dr. Zeng,</p>
    <p>We are pleased to inform you that your manuscript 'IUSMMT: survival mediation analysis of gene expression with multiple DNA methylation exposures and its application to cancers of TCGA' has been provisionally accepted for publication in PLOS Computational Biology.</p>
    <p>Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.</p>
    <p>Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.</p>
    <p>IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.</p>
    <p>Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.</p>
    <p>Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. </p>
    <p>Best regards,</p>
    <p>Oscar Rueda</p>
    <p>Guest Editor</p>
    <p>PLOS Computational Biology</p>
    <p>Florian Markowetz</p>
    <p>Deputy Editor</p>
    <p>PLOS Computational Biology</p>
    <p>***********************************************************</p>
    <p>Note from the editor: I would try to address the minor comments made by the authors</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <bold>Comments to the Authors:</bold>
    </p>
    <p>
      <bold>Please note here if the review is uploaded as an attachment.</bold>
    </p>
    <p>Reviewer #1: The authors have provided a revised manuscript regarding their novel gene-centric approach called IUSMMT (Intersection-Union Survival Mixture-adjusted Mediation Test) to delineate causal genes that mediate the effect of DNA methylation on cancer-specific survival. The authors responded to each of the specific comments raised by the reviewers and revised the manuscript accordingly.</p>
    <p>In response to the reviewer’s comment regarding distinguishing passenger methylation events from mediation methylation events, the authors have performed an ad-hoc reverse analysis by regressing DNA methylations on expression for all the identified mediating genes based on a multivariate model. Could the authors include statistical details (with equations) of this additional analysis in the Methods section, as they have for the rest of the IUSMMT construction?</p>
    <p>The authors should ensure that the IUSMMT method is released as a publicly available package to enable application to other datasets. The computational code for the analysis should also be made readily available to the research community.</p>
    <p>My overall impression remains that the manuscript is a matter of interest since the new approach (IUSMMT) has potential utility in understanding the mechanism underlying the regulatory role of DNA methylation in cancer progression; and can aid in molecular classification as well as generate new insights into potential therapeutic targets. This paper will be a good addition to PLOS Computational Biology.</p>
    <p>Reviewer #3: The authors have adequately addressed the necessary changes suggested in previous major and minor concerns. The manuscripts quality and content merit publication.</p>
    <p>Reviewer #4: The authors proposed a novel method IUSMMT to link DNA methylation and survival via gene expression.</p>
    <p>The model and results looks pretty interesting.</p>
    <p>I am pleased to read the revision along with responses to all review comments. And I think the authors have addressed most of the concerns, and the current version is good to be accepted.</p>
    <p>However, I do have one major question and one minor comment.</p>
    <p>Major question: Per reviewer 1's Q3, the authors replied "However, these identified genes cannot include proliferation or cell cycle related genes. Following the suggestion, we now clearly pointed out this issue in lines 459-462 on page 22." I am super confused by what the sentence means here. Why cannot the identified genes include proliferation or cell cycle related genes? The statement does not make sense to me. Reading the version, I guess the authors meant that they are not sure whether the identified genes are cell cycle related genes, right? But the author could do a simple enrichment analysis on these genes using the GO cell cycle gene list.</p>
    <p>I also have a minor comment related to reviewer 2's major comment 6.</p>
    <p>Although I don't think the authors must consider cell type composition in their model as they have already done some extensive job, they should at least mention two points in discussion: 1) the DNAm levels are affected by cell type composition - cite Jaffe AE and Irizarry RA 2014 Genome Biology; 2) the cell type composition is an important factor for survival - see Figure 4 (Ratio of infiltrating PMNs to plasma cells is prognostic in diverse solid tumors) in Gentles AJ et al 2015 Nature Medicine. The lack of consideration in cell type composition is indeed the weak point of the current model and should be explored in future work.</p>
    <p>**********</p>
    <p>
      <bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
    </p>
    <p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.</p>
    <p>Reviewer #1: <bold>No: </bold></p>
    <p>Reviewer #3: Yes</p>
    <p>Reviewer #4: Yes</p>
    <p>**********</p>
    <p>PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
    <p>Reviewer #1: <bold>Yes: </bold>Rajbir Nath Batra</p>
    <p>Reviewer #3: <bold>Yes: </bold>Majed Mohamed Magzoub</p>
    <p>Reviewer #4: No</p>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pcbi.1009250.r004" specific-use="acceptance-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1009250.r004</article-id>
    <title-group>
      <article-title>Acceptance letter</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Markowetz</surname>
          <given-names>Florian</given-names>
        </name>
        <role>Deputy Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rueda</surname>
          <given-names>Oscar</given-names>
        </name>
        <role>Guest Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2021 Markowetz, Rueda</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>Markowetz, Rueda</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1009250" id="rel-obj004" related-article-type="reviewed-article"/>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">25 Aug 2021</named-content>
    </p>
    <p>PCOMPBIOL-D-21-00050R1 </p>
    <p>IUSMMT: survival mediation analysis of gene expression with multiple DNA methylation exposures and its application to cancers of TCGA</p>
    <p>Dear Dr Zeng,</p>
    <p>I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.</p>
    <p>The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. </p>
    <p>Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.</p>
    <p>Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work! </p>
    <p>With kind regards,</p>
    <p>Livia Horvath</p>
    <p>PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom <email>ploscompbiol@plos.org</email> | Phone +44 (0) 1223-442824 | <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ploscompbiol.org" ext-link-type="uri">ploscompbiol.org</ext-link> | @PLOSCompBiol</p>
  </body>
</sub-article>
